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A sociedade atual é profundamente afetada por diversas doenças, sendo o cancro uma das mais 
devastadoras. Apesar de toda a investigação desenvolvida em torno do cancro, as taxas de 
incidência e de mortalidade associadas a esta doença continuam muito elevadas. Esta realidade 
está em parte relacionada com as limitações dos tratamentos disponíveis para o cancro, que 
incluem cirurgia, quimioterapia e radioterapia. Estas terapias são caracterizadas por 
apresentarem uma baixa eficácia terapêutica e por causarem efeitos secundários nos pacientes. 
Para além disto, a eficácia destes tratamentos é ainda diminuída por mecanismos de resistência 
a fármacos/radiação desenvolvidos pelas células cancerígenas. Por outro lado, as novas terapias 
que estão a ser testadas em meio clínico (ex.: imunoterapia e quimioterapia direcionada) 
também são afetadas por mecanismos de resistência e acarretam custos superiores para o 
Serviço Nacional de Saúde. Desta forma, existe uma necessidade premente de desenvolver e 
implementar tratamentos inovadores para o cancro, que apresentem maior eficácia sem, no 
entanto, induzirem efeitos secundários significativos. 
De entre as numerosas abordagens terapêuticas em investigação, a terapia fototérmica (PTT) 
mediada por nanomateriais tem demonstrado resultados promissores nos ensaios pré-clínicos. 
Esta abordagem explora a utilização de nanomateriais, que devido às suas propriedades  
físico-químicas, conseguem acumular-se preferencialmente no local do tumor. Posteriormente, 
a zona do tumor é irradiada com um feixe de luz, e os nanomateriais acumulados nesta zona 
absorvem-na e convertem-na em calor, induzindo assim danos nas células cancerígenas.  
Na PTT mediada por nanomateriais é fundamental usar uma radiação com um comprimento de 
onda na região do infravermelho próximo (NIR; 750-1000 nm) uma vez que os principais 
componentes biológicos (ex.: água, hemoglobina, proteínas, melanina) têm uma absorção 
mínima ou insignificante nesta gama de comprimentos de onda. Devido a este facto, as 
nanoestruturas projetadas para utilização na PTT devem ter uma elevada absorção no NIR de 
modo a conseguirem produzir um efeito fototérmico, que induza citotoxicidade para as células 
cancerígenas. Assim, comparativamente com as terapias convencionais, a PTT mediada por 
nanomateriais pode induzir um efeito espácio-temporal controlado, permitindo-lhe atingir uma 
maior seletividade para a zona do tumor. 
De entre os diferentes nanomateriais responsivos à luz, o óxido de grafeno (GO) tem revelado 
propriedades promissoras para aplicação na PTT do cancro. O GO é um nanomaterial composto 
por uma matriz de grafite, que contém diversos tipos de grupos funcionais (carboxílico, 
hidroxilo e epóxi). Este nanomaterial absorve na região do NIR, apresentando uma capacidade 
fototérmica eficiente. Para além disto, os seus grupos aromáticos permitem o encapsulamento 
de diversas moléculas na sua estrutura através de interações não covalentes (interações 
 xx 
hidrofóbicas e empilhamento π-π). Assim, o GO tem um elevado potencial para aplicações 
fototérmicas e de entrega de fármacos. 
Porém, a aplicação direta do GO na terapia do cancro é severamente limitada pela sua baixa 
estabilidade coloidal, o que faz com que este nanomaterial precipite em soluções salinas e em 
fluídos biológicos. Este fator limita assim a sua administração intravenosa. Para além disto, a 
matriz aromática do GO pode adsorver moléculas do sistema complemento e este nanomaterial 
pode ser reconhecido por macrófagos. Estes eventos induzem a rápida eliminação do GO, 
diminuindo a probabilidade deste se acumular na zona do tumor. Finalmente, o GO não é 
seletivamente internalizado pelas células cancerígenas e, portanto, pode afetar as células 
saudáveis que se encontram no microambiente tumoral. As estratégias que permitam 
ultrapassar estas limitações irão certamente contribuir para incrementar a aplicabilidade e a 
capacidade terapêutica dos materiais à base de GO. 
Tendo em consideração as limitações do GO, o principal objetivo do plano de trabalhos 
desenvolvido nesta tese foi implementar novas estratégias para melhorar a PTT mediada por 
nanomateriais à base de GO. Para tal, procurou-se i) implementar revestimentos com 
capacidade de melhorar a performance biológica do GO, ii) explorar métodos de preparação 
capazes de aumentar a capacidade fototérmica do GO, e iii) encapsular combinações de 
fármacos com atividade anticancerígena sinérgica na matriz do GO. 
No primeiro estudo apresentado nesta tese, foi avaliada a capacidade terapêutica de materiais 
à base de GO funcionalizados com succinato de D-α-tocoferil polietilenoglicol 1000 (TPGS). 
Inicialmente, o óxido de grafite foi sintetizado usando uma versão modificada do método de 
Hummer’s melhorado. Seguidamente, este material sofreu um tratamento alcalino, com o 
intuito de remover os detritos da oxidação (o que pode melhorar a sua capacidade para adsorver 
moléculas), e foi posteriormente exfoliado de forma a obter o GO com dimensões nanométricas 
(bwGO). De seguida, foram exploradas duas abordagens diferentes para funcionalizar o bwGO 
com TPGS: um processo de sonicação simples (obtendo-se TPGS/bwGO) e um tratamento 
hidrotérmico (obtendo-se TPGS/htGO). Os resultados obtidos demonstraram que os 
nanomateriais revestidos com TPGS apresentam uma maior estabilidade coloidal. Em 
particular, o TPGS/htGO demonstrou possuir uma estabilidade coloidal superior e cerca de 1,9 
vezes maior absorção no NIR (a 808 nm), quando comparado com o TPGS/bwGO. Após a sua 
irradiação com luz NIR, o TPGS/htGO induziu uma variação de temperatura 1,4 a 1,6 vezes 
superior àquela que é induzida pelo TPGS/bwGO. Nos estudos in vitro, os nanomateriais 
funcionalizados com TPGS reduziram a viabilidade das células do cancro da mama, e não 
tiveram um efeito citotóxico considerável nas células saudáveis. Para além disto, a combinação 
da luz NIR com os derivados de GO funcionalizados com TPGS promoveu um efeito terapêutico 
ainda mais acentuado. Neste ensaio, o TPGS/htGO mediou uma fototerapia ligeiramente mais 
eficaz devido às suas propriedades óticas melhoradas.  
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No segundo estudo apresentado nesta tese, foi avaliado o potencial quimio-fototerapêutico do 
bwGO funcionalizado na sua superfície com um polímero anfifílico baseado em  
poli(2-etil-2-oxazolina) (bwGO POxilado) e que tinha incorporado na sua matriz a combinação 
de fármacos Doxorrubicina (DOX) e Succinato de D-α-tocoferol (TOS). Os resultados obtidos 
demonstraram que o bwGO POxilado apresenta propriedades físico-químicas, coloidais, óticas 
e biológicas adequadas para a sua aplicação na terapia do cancro. Para além disto, a análise da 
eficácia de diferentes combinações molares de DOX:TOS, de 5:1 a 1:5, revelou que o rácio 
molar 1:3 de DOX:TOS produz um efeito terapêutico sinérgico ótimo nas células do cancro da 
mama. Este rácio de fármacos demonstrou ainda um efeito cerca de 2 vezes inferior nas células 
saudáveis. Com base nestes resultados, a combinação molar 1:3 DOX:TOS foi selecionada para 
encapsulação no bwGO POxilado, com o objetivo de avaliar o potencial quimio-fototerapêutico 
deste. Nos estudos in vitro, a entrega de DOX:TOS pelo bwGO POxilado às células cancerígenas 
induziu um efeito terapêutico superior àquele que é obtido com a combinação dos fármacos na 
sua forma livre. Para além disto, a exposição do bwGO POxilado carregado com a combinação 
DOX:TOS à luz NIR induziu um maior efeito citotóxico nas células cancerígenas. 
Em suma, os resultados obtidos nestes estudos demonstraram que a aplicabilidade dos materiais 
à base de GO na terapia do cancro pode ser melhorada através da funcionalização deste com 
polímeros anfifílicos. Para além disto, o potencial terapêutico dos derivados de GO pode ser 
melhorado através do uso de revestimentos com atividade anticancerígena intrínseca, ou 
através da co-encapsulação de fármacos com um efeito citotóxico maior para as células 
cancerígenas. Estudos pré-clínicos mais aprofundados destes nanomateriais poderão conduzir à 




















Regardless of the advancements in medicine, there are diseases that have a tremendous impact 
on today’s society. In this context, cancer is probably the most devastating one. Despite all the 
intensive research on cancer, its incidence and mortality rates are still high. In fact, the 
classical cancer treatments (surgery, chemotherapy and radiotherapy) have a low therapeutic 
efficacy and induce side effects in patients that can pose a threat to their life. Furthermore, 
the low therapeutic index of the available treatments is further impaired by resistance 
mechanisms developed by cancer cells to drugs/radiation. On the other hand, the novel 
therapies that are under clinical investigation (e.g. targeted chemotherapy and 
immunotherapy) are also affected by resistance mechanisms and have an even higher cost to 
the health service providers. In this way, there is an urgent need to discover and implement 
innovative cancer treatments that possess a higher therapeutic efficacy and display fewer  
side-effects. 
Among the different therapeutic approaches under investigation, photothermal therapy (PTT) 
mediated by nanomaterials has been showing promising results both in in vitro and in vivo 
assays. This therapy employs nanomaterials that, due to their physicochemical properties, can 
accumulate preferentially in the tumor site. Afterwards, an external light is used to irradiate 
the tumor zone, and the nanostructures accumulated at the tumor site absorb the radiation 
energy and convert it into heat, inducing damage to the cells. In nanomaterials’ mediated PTT, 
it is crucial to use near infrared radiation (NIR; 750-1000 nm) since most of the biological 
components (e.g. water, hemoglobin, proteins, melanin) have a minimal or an insignificant 
absorption within this wavelength range. Consequently, nanostructures should have a high NIR 
absorption in order to produce an efficient photothermal effect, when they are exposed to NIR 
light. In this way, compared to conventional therapies, cancer PTT mediated by nanomaterials 
can induce a spatial-temporal controlled effect with a higher selectivity towards the tumor 
zone. 
Among the different light-responsive nanomaterials, graphene oxide (GO) reveals promising 
properties to be applied in cancer PTT. GO is a 2D nanomaterial composed by a graphitic lattice 
that contains several types of oxygen-functional groups (carboxyl, hydroxyl and epoxy). This 
nanomaterial absorbs in the NIR region, displaying an efficient photothermal capacity. 
Furthermore, the aromatic lattice of this nanomaterial allows the loading of different types of 
molecules through non-covalent interactions (hydrophobic-hydrophobic interactions and π-π 
stacking). In this way, GO has a tremendous potential for photothermal and drug delivery 
applications.  
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However, the direct use of GO in cancer therapy is severely limited by different factors. Firstly, 
GO has a weak colloidal stability – it precipitates in saline solutions and in biological fluids. This 
factor limits its intravenous administration. Furthermore, the aromatic lattice of GO can adsorb 
complement proteins, leading to its recognition by macrophages, and subsequent clearance 
from blood circulation. This removal avoids nanomaterials’ accumulation in the tumor zone. 
Additionally, GO is not selectively internalized by cancer cells, and thus can mediate a 
therapeutic effect that also affects the healthy cells found within the tumor microenvironment.  
The main objective of this thesis’ work plan was to address the limitations associated to  
GO-based materials and implement novel strategies to improve the PTT mediated by these 
materials. Such was pursued by i) employing coatings that can improve the biological 
performance of GO-based materials, ii) exploring preparation methods that can enhance GO 
photothermal capacity, and iii) encapsulating drug combinations with optimal synergistic 
anticancer activity on GO. 
In the first study, the anticancer capacity of D-α-tocopheryl polyethylene glycol 1000 succinate 
(TPGS) functionalized GO-based materials was evaluated. Initially, graphite oxide was 
synthesized through a modified version of the improved Hummer’s method. This material was 
then base-washed to remove the oxidation debris from its structure, which can improve its 
ability to adsorb molecules. Then, the material was exfoliated, yielding nanosized  
base-washed GO (bwGO). Afterwards, TPGS was explored for the functionalization of bwGO 
through two different approaches: a simple sonication method (yielding TPGS/bwGO) and a 
one-pot hydrothermal treatment (yielding TPGS/htGO). The results revelated that the TPGS 
coating successfully improved the stability of the GO derivatives. In particular, the TPGS/htGO 
displayed a greater colloidal stability and a 1.9-times higher NIR absorption (at 808 nm) in 
comparison to TPGS/bwGO. In in vitro studies, the TPGS/GO derivatives reduced the viability 
of breast cancer cells and had an insignificant effect on healthy cells. Furthermore, the 
combined application of TPGS/GO derivatives and NIR light induced an improved therapeutic 
effect. Particularly, the enhanced optical properties of TPGS/htGO enabled it to mediate a 
slightly more efficient phototherapy. 
In the second part of this thesis, the chemo-phototherapeutic potential of bwGO functionalized 
with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) (POxylated bwGO) and loaded 
with Doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) was assessed. The results revealed 
that the POxylated bwGO presents suitable physicochemical, colloidal, optical and biological 
properties for application in cancer therapy. In addition, the screening of different DOX:TOS 
molar combination ratios, ranging from 5:1 to 1:5, disclosed that the 1:3 DOX:TOS molar ratio 
produces an optimal synergistic therapeutic effect towards breast cancer cells (combination 
index of about 0.56). Furthermore, this drug ratio had a 2-times weaker effect on normal cells. 
POxylated bwGO was then loaded with the 1:3 DOX:TOS combination in order to evaluate its 
chemo-phototherapeutic potential. In in vitro studies, the delivery of DOX:TOS by POxylated 
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bwGO to cancer cells induced a stronger therapeutic effect than that attained with the free 
drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved 
by exposing DOX:TOS loaded POxylated bwGO to NIR radiation. 
Overall, the obtained results demonstrate that the applicability of GO-based materials in 
cancer therapy can be improved by performing their functionalization with amphiphilic 
polymers. Furthermore, the therapeutic potential of GO derivatives can be enhanced by using 
coatings with intrinsic anticancer activity or by encapsulating drugs that display a higher effect 
on cancer cells. These novel strategies will further contribute for the translation of GO-based 




















This Doctoral thesis is organized in 6 chapters. 
The first chapter comprises the general and specific aims established for the work plan of this 
PhD thesis. 
The second and third chapters enclose the introductory section. Chapter 2 gives an overview 
on the cancer PTT mediated by nanomaterials, reviewing the different strategies applied so far 
to improve its therapeutic outcome. Chapter 3 analyses the state-of-the-art of the 
functionalizations used in the design of GO-based materials aimed for application in cancer 
therapy, disclosing their role on surpassing the critical issues related to this nanomaterial. 
The fourth and fifth chapters present the results of the research works developed during this 
PhD thesis: 
 -Research Work 1: D-α-Tocopheryl polyethylene glycol 1000 succinate functionalized 
nanographene oxide for cancer therapy (Chapter 4)  
 -Research Work 2: POxylated Graphene Oxide Nanomaterials for Combination  
Chemo-Phototherapy of Breast Cancer Cells (Chapter 5) 
Finally, the sixth chapter contains the concluding remarks, discussing the results obtained 
during this PhD thesis in the light of the state-of-the-art, and provides future directions 
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GO-based materials encompass an extraordinary potential for cancer therapy due to their 
excellent photothermal and drug delivery capabilities. However, the intrinsic limitations of GO 
derivatives hinder their direct use in cancer therapy. Taking this into account, the main 
objective of this PhD thesis was to implement novel strategies to improve cancer PTT mediated 
by GO-based materials, while simultaneously addressing the core problems associated with 
these nanomaterials. In this way, the specific aims of this thesis were: 
- Assess the suitability of the novel coatings in the improvement of the biological performance 
of GO-based materials; 
- Evaluate formulation methods that yield GO-based materials with an improved photothermal 
capacity; 















Introduction (part. A) 
 
Strategies to Improve Cancer Photothermal 








This chapter is based on the publication entitled: Strategies to Improve Cancer Photothermal 
Therapy Mediated by Nanomaterials, Advanced Healthcare Materials, 2017, 





2.1. Abstract  
The deployment of hyperthermia-based treatments for cancer therapy has captured the 
attention of different researchers worldwide. In particular, the application of light-responsive 
nanomaterials to mediate hyperthermia has revealed promising results in several pre-clinical 
assays. Unlike conventional therapies, these nanostructures can display a preferential tumor 
accumulation and thus mediate, upon irradiation with near-infrared light, a selective 
hyperthermic effect with temporal resolution. Different types of nanomaterials such as those 
based on gold, carbon, copper, molybdenum, tungsten, iron, palladium and conjugated 
polymers have been used for this photothermal modality. This chapter summarizes the different 
strategies that have been applied so far for increasing the efficacy of the photothermal 
therapeutic effect mediated by nanomaterials, namely those that improve the accumulation of 
nanomaterials in tumors (e.g. by changing the corona composition or through the 
functionalization with targeting ligands), increase nanomaterials’ intrinsic capacity to generate 
photoinduced heat (e.g. by synthesizing new nanomaterials or assembling nanostructures) or 
by optimizing the parameters related to the laser light used in the irradiation process (e.g. by 
modulating the radiation wavelength). Overall, the development of new strategies or the 
optimization and combination of the existing ones will surely give a major contribution for the 
application of nanomaterials in cancer PTT. 
 
Keywords: cancer treatment; hyperthermia; inorganic nanostructures; light‐responsive 




Cancer is a highly complex disease and it is responsible for an overwhelming number of deaths 
worldwide [1]. In the clinic, the mainstream therapeutic options for this disease include surgical 
resection of the tumor, radiotherapy, chemotherapy, or their combined application. However, 
in many cases, these treatment regimens are not effective and have associated notorious side 
effects.  
Nowadays, different therapeutic modalities are under clinical evaluation to further improve 
the effectiveness of cancer treatment. In particular, hyperthermia-based treatments that 
involve a localized or an unrestricted increase of body temperature have captured the attention 
of clinicians [2]. However, depending on the area under treatment, the maximum temperature 
and the duration used vary [3]. Hyperthermia at mid-temperatures (41.8-45 °C) is capable of 
exerting a therapeutic effect on malignant cells in hypoxic environments, while eliciting a 
minimum damage on the surrounding healthy tissues (reviewed in detail in [3]). Additionally, it 
can also be used to improve the therapeutic outcome of radio- and chemotherapy [3]. On the 
other hand, hyperthermia at high-temperatures (45-90 °C) can affect both cancer and normal 
cells, inducing cellular changes (e.g. enzymatic and mitochondrial dysfunctions) and ultimately 
necrosis (reviewed in detail in [3, 4]). However, the equipment and techniques currently 
available to perform such types of hyperthermia-based treatments present some limitations 
and need further improvements for attaining a higher selectivity, tissue penetration, and 
effectiveness [5]. To accomplish that, researchers are currently developing new responsive 
nanomaterials that due to their small size (usually < 200 nm), can accumulate preferably in 
tumor and induce on-demand hyperthermia, after being subjected to an external stimulus  
(e.g. magnetic field or light), with a high efficacy and safety [6, 7-10]. Among the different 
nanomaterials explored, until now, to induce hyperthermia, some can mediate this effect by 
absorbing light, generated by a laser, and releasing its energy as heat (nanomaterials’ mediated 
photothermal therapy (PTT)). This feature has been displayed by several types of 
nanostructures produced with gold, carbon, copper, molybdenum, tungsten, iron, palladium or 
conjugated polymers [7, 11-18]. Moreover, different strategies are currently being explored to 
further enhance the photothermal potential of these nanostructures. Compared to  
laser-induced interstitial thermotherapy (a therapeutic modality that only employs laser light 
to thermally ablate tumors), nanomaterials’ mediated PTT is less invasive, demands radiation 
with a lower intensity and its therapeutic outcome is less dependent on the characteristics of 
the irradiated tissue (e.g. water or hemoglobin content) [19]. In addition, PTT mediated by 
nanomaterials can potentially achieve a higher selectivity towards cancer cells through the use 
of precisely engineered nanostructures that are specifically internalized by diseased cells [20-
22]. Still, it should be noted that the clinical translation of these photothermal agents is 
challenging since only recently the clinical safety profile of AuroLase® therapy (PTT using 
AuroShell® - poly(ethylene glycol) (PEG) functionalized gold nanoshells), whose initial  
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pre-clinical studies started in the 1990’s, was published and the clinical efficacy of this therapy 
is yet to be disclosed (ClinicalTrials.gov Identifier: NCT02680535, NCT00848042, NCT01679470) 
[23]. 
In the following sub-sections, the different strategies described in the literature to improve 
nanomaterials’ mediated cancer PTT are highlighted. In section 2.3, an overview of the key 
parameters that dictate the success of PTT is given. In section 2.4, the approaches used to 
enhance nanomaterials tumor accumulation are described. The improvement of nanomaterials’ 
intrinsic capacity to generate photoinduced heat and the optimization of the parameters 
related to the laser light are other types of procedures assessed in sections 2.5 and 2.6, 
respectively. Finally, an outlook about the state of the art of nanomaterials’ mediated PTT will 
be presented (section 2.7). For the sake of simplicity, this chapter will not cover improvements 
based on the inclusion of other therapeutics in the nanomaterials (e.g. chemotherapeutic 
drugs), nor on the utilization of hybrid nanostructures to externally promote tumor 
accumulation (e.g. by applying magnetic fields). 
 
2.3. Cancer photothermal therapy mediated by 
nanomaterials 
Cancer PTT mediated by nanomaterials involves the application of nano-sized structures and 
laser light to irradiate the tumor zone (or metastatic sites) for inducing hyperthermia. 
Generally, this therapeutic approach starts with the intravenous administration of the 
nanomaterials, which can become accumulated within the tumor through the enhanced 
permeability and retention (EPR) effect, by taking advantage of the 3D architecture of blood 
vessels that supply the tumor, which are characterized by having fenestrae of variable sizes 
(ranging from 200 to 1200 nm; Figure 2.1) [24]. Moreover, the impaired lymphatic drainage 
prevents nanomaterials removal, leading to their retention within the tumor microenvironment 
[25]. Simultaneously, the accumulation of nanomaterials in off-target organs or their rapid 
elimination from the body (e.g. by renal filtration or through the reticuloendothelial system 
(RES)) must be avoided.  
Once inside the tumor tissue, nanomaterials must be capable of migrating and also be 
homogeneously internalized by cancer cells [26]. However, such internalization may be 
hampered by tumor’s high interstitial fluid pressure that results from a defective lymphatic 
drainage [27]. 
After nanomaterials successful accumulation within tumor tissue, the PTT is performed by 
irradiating the tumor zone with a laser light (Figure 2.1). The effectiveness of this therapeutic 
 10 
modality is dependent on the capacity of nanomaterials to absorb radiation emitted by the 
laser. A significant or negligible interaction may occur between radiation and biological 
components like proteins, melanin, hemoglobin, collagen and water [28]. All these biological 
components have a low or residual absorption within the 750-1000 nm wavelength range (near 
infrared (NIR)) [28]. Therefore, the use of NIR light in cancer PTT is crucial since this radiation 
displays low off-target interactions and high penetration depth (up to 1-2 cm, that is dependent 
on the type of tissue under irradiation, the wavelength and the power density of the laser light 
used) [29]. The knowledge of the laser light properties is fundamental to maximize  
light-nanomaterials interactions in order to guarantee a selective and effective hyperthermia, 
that produces irreversible damages on cancer cells leading to their death by necrosis (such 
effect is usually attained for temperatures above 50 °C) [4]. Moreover, the laser beam is 
directed to the tumor zone, thus preventing any side effects resulting from nanomaterials that 
were accumulated in off-target organs [8, 30]. Exceptionally, nanomaterials accumulated in 
skin can cause off-target hyperthermia and, consequently, origin an undesired outcome since 
this organ is inevitably irradiated during the PTT [12].  
 
 
Figure 2.1. Representation of the several events that occur during the PTT mediated by nanomaterials. 
First nanomaterials are administered and can accumulate in the tumor through the so-called EPR effect. 
Afterward, the tumor zone is irradiated and nanomaterials induce hyperthermia with high  
spatial-temporal resolution. Finally, the therapeutic effect is monitored and may have as outcome mice’s 
survival due to tumor elimination. 
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To date, different types of nanomaterials (both organic and inorganic) have been studied for 
cancer PTT. Among the inorganic nanomaterials, gold-based nanostructures like gold 
nanocages, nanohexapods, nanorods (GNR), nanoshells and nanostars have been deeply 
investigated for this biomedical application [31, 32, 33, 34]. More recently, researchers also 
began investigating the applicability of gold nanobipyramids for cancer PTT [35]. Furthermore, 
carbon-based nanostructures such as carbon nanotubes (CNT) and nanographene oxide (nGO) 
have also been explored as PTT agents [12, 13]. Currently, other inorganic nanostructures based 
on copper (Cu), molybdenum (Mo), tungsten (W), iron (Fe) and palladium (Pd) are being studied 
for tumor photoablation [7, 14-17]. The Cu-based nanostructures include copper sulfides  
(e.g. Cu2-xS nanodots, Cu7.2S4 nanocrystals or CuS nanoparticles), selenides (e.g. Cu2-xSe 
nanocrystals) and bismuth sulfides (e.g. Cu3BiS3 hollow nanospheres) [10, 36-39]. Regarding Mo 
and W-based nanomaterials, their oxides (e.g. MoO3-x hollow nanospheres, WO3 nanoparticles) 
and disulfides (MoS2 and WS2 nanosheets) have been the most selected for this particular 
biomedical application [9, 15, 26, 40]. Fe-based nanomaterials such iron oxides (e.g. Fe3O4 
nanoparticles), sulfides (FeS nanoplates), diselenides (FeSe2 nanoparticles) and prussian blue 
nanostructures (Fe4[Fe(CN)6]3; PB) have also revealed suitable properties to act as PTT agents 
[17, 41-43]. Regarding Pd-based nanomaterials, researchers have been mainly focused on the 
applicability of Pd nanosheets for PTT [7, 44]. On the other hand, the application of organic 
nanomaterials for cancer PTT is not so developed as for inorganic materials. In literature, 
polyaniline (PANI), polypyrrole (PPy), poly(3,4-ethylenedioxythiophene) (PEDOT) and other 
polymeric materials have been used for cancer PTT [8, 18, 45-47]. 
Overall, several approaches have been followed to further improve the PTT capacity of these 
nanostructures (both organic and inorganic). Researchers used different strategies to  
(i) improve nanomaterials accumulation in tumor, (ii) augment nanomaterials’ intrinsic capacity 
to produce photoinduced heat or (iii) optimize the parameters related to the laser light. A 
detailed description of the in vivo therapeutic outcome attained so far by adopting such 
strategies is summarized in Table S.2.1 (supplementary information). 
 
2.4. Approaches used to improve nanomaterials 
accumulation in tumors 
In order to mediate an effective and selective hyperthermia upon laser irradiation, 
nanomaterials must be accumulated in the tumor tissue and also be internalized by cancer 
cells. The fulfillment of these milestones is affected by nanomaterials’ size, shape, surface 
charge, and corona composition, as well as by the presence of targeting ligands on their surface 
(Figure 2.2). Therefore, the modulation of these features is currently being explored to improve 




Figure 2.2. Schematic illustration of the parameters of the nanomaterials that influence their blood 
circulation, accumulation and penetration in the tumor, and internalization by cancer cells. The key 




The blood clearance or off-target accumulation in RES organs (liver and spleen) of 
nanomaterials are size dependent. In literature, it is described that nanostructures with a size 
bellow 3-5 nm tend to be rapidly cleared through renal filtration, which constitutes a drawback 
for their accumulation in the tumor tissue [48]. Moreover, nanostructures with a diameter lower 
than 50 nm tend to be off-target accumulated in the liver, whereas those larger than 200 nm 
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are more likely to become accumulated in spleen and in liver [25, 27, 49]. By taking such 
restrictions into account, nanomaterials aimed to be accumulated within the tumor through 
the EPR effect must have an appropriate size in the range between 100 and 200 nm [25]. Still, 
these are general considerations and the optimization of nanomaterials’ size must be 
performed for each type of photothermal agent in order to attain a proper distribution in the 
body and therapeutic performance. In this context, Tang and co-workers observed that by 
reducing the Pd-poly(vinylpyrrolidone) (PVP) nanosheets’ size from 41 to 4.4 nm, their liver 
uptake decreases from ≈ 45 to ≈ 35 % of the total injected dose per gram of tissue (ID g-1) [7]. 
In another study, Akhavan and Ghaderi demonstrated that PEGylated graphene oxide (GO) 
derivatives with a size of ≈ 61 nm were more effective in cancer PTT than their ≈ 2 µm sized 
equivalents, since the smaller nanomaterials have a higher tumor-homing capacity (≈ 8.9 vs.  
≈ 7.3 % ID g-1) and their uptake by liver (≈ 17 vs. ≈ 26 % ID g-1) and spleen (≈ 12 vs.  
≈ 22 % ID g-1) is lower [50]. 
In addition to the influence of nanomaterials’ size in tumor accumulation, this parameter also 
has a direct impact on nanomaterials tumor penetration and cellular internalization [51]. Once 
again, the optimization of the size is decisive for improving nanomaterials therapeutic efficacy. 
In this context, Wang and co-workers substantiated that PEGylated gold-based capsules with a 
size of 207 x 105 nm can penetrate and achieve a wide distribution within the tumor mass, 
while those with a size of 125 x 95 nm are mainly accumulated in the tumor periphery [52]. 
Due to this fact, the 207 x 105 nm sized nanocapsules were able to mediate a stronger 
photothermal effect in vivo. In another work, Wang and co-workers observed that 80 and  
100 nm sized PEGylated MoS2 nanosheets are better internalized by cancer cells than those with 
300 nm, rendering them as the most suitable for being applied in cancer PTT [15]. In a recent 
study, Zhang et al. adjusted the size of GO to improve its uptake by cancer cells and their 
results revealed that the smallest nanosheets (< 50 nm) achieve an higher internalization [53]. 
 
2.4.2. Shape 
The nanomaterial’s shape is another feature that has a huge impact on its blood circulation 
time, tumor uptake, and cellular internalization [54]. Although the shape contribution on these 
bioprocesses tends to be different for each type of nanostructure, the modulation of this 
property can be explored for improving nanomaterials’ mediated PTT. Tang and co-workers 
verified that by coating Pd-PVP nanosheets with silica (transition from a 2D material to a 
nanosphere), their uptake by cancer cells is increased by ≈ 4.7-fold, leading to an enhanced 
photothermal effect [55]. Moreover, Wang et al. reported that PEGylated gold nanohexapods 
display a 1.2- and 3.2-fold higher internalization by cancer cells than PEGylated gold nanocages 
and PEGylated GNR, respectively [31]. In contrast, under in vivo conditions, PEGylated gold 
nanocages displayed a low blood circulation time and a high liver uptake (≈ 62 % ID g-1), which 
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resulted in a low tumor accumulation (≈ 2.6 % ID g-1). On the other hand, PEGylated GNR and 
gold nanohexapods had superior blood circulation times, that led to a greater tumor 
accumulation (GNR: ≈ 8.4 % ID g-1; nanohexapods: ≈ 7.2 % ID g-1). Based on these remarks, the 
application of PEGylated gold nanohexapods in cancer PTT seems to be a promising strategy 
due to their improved tumor accumulation and cellular uptake. 
 
2.4.3. Surface charge 
The surface charge exhibited by nanomaterials is another parameter that has to be taken into 
account when an augmented cellular internalization is aimed. In general, positively charged 
nanostructures tend to be better internalized by normal and cancer cells since these materials 
are able to interact with the negatively charged components of cells’ membrane [56]. In 
particular, cancer cells have on their plasma membrane a higher number of negatively charged 
components (e.g. phosphatidylserine or sialic acid), which further promote the uptake of 
positively charged nanomaterials [57]. In this context, Tang and co-workers functionalized  
Pd-PVP nanosheets with poly(ethyleneimine) (PEI; polycation) and confirmed that this 
modification increases their cellular internalization by ≈ 1.9-fold [55]. Moreover, the 
functionalization of silica coated Pd-PVP nanosheets with amine groups also revealed an 
improved uptake (2.75-fold increase), which is crucial for attaining a heightened photothermal 
effect [55].  
Nevertheless, the surface charge of nanomaterials must be properly tuned since it also 
mediates nanodevices interaction with RES, blood components and elements of the 
extracellular matrix of the tumor. Nanomaterials with a highly charged surface (positively or 
negatively) have a greater uptake by RES cells and liver, which has a direct impact on their 
capacity to reach the tumor tissue [58]. Furthermore, serum proteins can also be adsorbed on 
nanomaterials’ charged surface, which may lead to the opsonization and clearance of these 
materials [59]. Moreover, nanomaterials’ surface charge can impair their tumor penetration 
capacity by favoring interactions with the components of the extracellular matrix of the tumor, 
such as hyaluronic acid (HA; for positively charged nanomaterials) or collagen (for negatively 
charged nanomaterials) [27]. Owing to these facts, the so-called neutral nanomaterials, which 
have a zeta potential (ζ) between -10 and +10 mV, are considered the most appealing for 
cancer-related applications [27].  
As discussed above, positively charged nanomaterials may display a higher internalization by 
cancer cells but an excessive surface charge can also impair nanomaterials accumulation in 
tumors. To circumvent this pitfall, Wang et al. prepared PEGylated gold nanostars whose charge 
changes according to the pH of the extracellular environment [34]. Such feature was achieved 
by controlling the content of amine and carboxyl groups on the surface of the nanostars. In 
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their study, the nanostars with a ratio of four amines to one carboxyl group showed a high 
differential uptake by cancer cells, i.e., these presented a low internalization at pH 7.4 and an 
enhanced internalization at pH 6.4. These results may be explained by the surface charge of 
the nanostars since these are slightly negative at physiological pH (ζ ≈ -14 mV) and become 
neutral (ζ ≈ - 6 mV) at the pH characteristic of the tumor microenvironment. In vivo, these 
carboxyl/amine functionalized nanostars demonstrated a high tumor uptake (≈ 10 % ID g-1), 
which was sufficient to allow tumors elimination under NIR laser irradiation. In stark contrast, 
nanostars functionalized only with carboxyl (ζ ≈ - 27 mV) or amine (ζ ≈ + 13 mV) groups 
presented a tumor accumulation of ≈ 4 and ≈ 2 % ID g-1, respectively. Therefore, the PTT 
mediated by these nanomaterials only caused a reduction of the tumor growth. In particular, 
the majority of the amine functionalized nanostars became accumulated in  
liver (> 120 % ID g-1), thus leading to a lower tumor uptake. 
 
2.4.4. Corona composition 
Nanomaterials’ corona composition is another important factor that influences their biological 
fate. The functionalization of nanomaterials’ surface with PEG is known for improving 
nanodevices hydrophilicity and biocompatibility, features that are fundamental for their 
successful biological application [60]. Moreover, PEG functionalization can increase 
nanomaterials’ blood circulation time and also reduces their opsonization and recognition by 
the RES, thus leading to their improved accumulation in the tumors [12, 44, 61]. Therefore, the 
appropriate PEGylation of the different types of nanomaterials has been pursued in order to 
improve their potential for cancer PTT. Zhou et al. verified that PEGylated CuS nanoparticles 
have a higher blood residence than citrate coated CuS nanoparticles and almost 3-fold higher 
tumor accumulation (7.6 % ID g-1) [37]. Compared to the PEGylated nanoparticles, the citrate 
coated nanomaterials displayed a higher uptake by the liver (≈ 44 vs. ≈ 23 % ID g-1) and spleen 
(≈ 34 vs. ≈ 9 % ID g-1), resulting in a lower tumor uptake (2.6 % ID g-1). Choi et al. encapsulated 
GNR in photocrosslinked chitosan-Pluronic® F-68 conjugates and verified that this modification 
increases nanomaterials tumor accumulation from ≈ 12 to ≈ 117 % ID g-1 [11]. Due to their 
superior tumor-homing capacity, the PTT mediated by these nanodevices resulted in tumor 
eradication while when non-coated GNR were used only a slight decrease in the rate of tumor 
growth was noticed.  
On the other hand, CNT coated with PEGylated poly(maleic anhydride-alt-1-octadecene)  
(C18-PMH-mPEG) showed a blood circulation half-life (t1/2) of ≈ 30.8 h and a tumor accumulation 
of ≈ 30 % ID g-1 [62]. In contrast, the CNT coated with 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-(methoxy PEG) (DSPE-mPEG) had a lower tumor accumulation  
(4 % ID g-1), resulting from their lower blood circulation time (t1/2 ≈ 3.5 h) and higher liver 
uptake (≈ 69 vs. ≈ 28 % ID g-1) [62]. In other studies, C18-PMH-mPEG was also successfully used 
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to coat reduced nGO and Mo oxide nanosheets, conferring these nanomaterials a tumor-homing 
capacity that granted tumors eradication upon laser irradiation [63, 64]. PEGylation of W, Fe, 
Pd and conjugated polymer-based nanostructures also allowed the production of materials with 
a high tumor-homing capacity and that were efficiently applied for cancer PTT [8, 17, 26, 44, 
65].  
However, the PEGylation of nanomaterials to enhance their biologic properties is not always a 
straightforward process since the molecular weight and the density of the PEG immobilized on 
the surface of the nanostructures can affect their biodistribution [12, 66]. In this regard, Liu et 
al. thoroughly investigated the coating of CNT with C18-PMH-mPEG with different PEG lengths 
(2 and 5 kDa) and densities (5 to 100 %) [12]. The results revealed that by increasing the PEG 
length and density, the CNT blood circulation time is extended, which in turn boosts their 
accumulation in the tumor and skin (CNT accumulation in the skin can induce an off-target 
heating and simultaneously decrease the amount of radiation that reaches the tumor during 
PTT). Furthermore, an opposite trend was noticed for CNT accumulation in RES organs. 
Therefore, the CNT coated with C18-PMH-mPEG with a PEG density of 10 % and a molecular 
weight of 5 kDa were considered the most appealing for cancer PTT, since these displayed a 
suitable blood circulation time (t1/2 = 12.8 h), high tumor accumulation (≈ 15 % ID g
-1) and scarce 
uptake by skin (≈ 3 % ID g-1). Shi and co-workers noticed that PEGylated Pd nanosheets prepared 
using a thiolated mPEG to Pd-PVP nanosheet mass ratio of 1 to 1 are optimal since the 
incorporation of a higher PEG mass did not significantly improve the blood circulation time of 
the nanosheets (t1/2 ≈ 30 h) [44]. However, the tumor accumulation of these nanosheets was 
further increased from ≈ 8 to ≈ 12 % ID g-1 by increasing the PEG molecular weight from 5 to  
10 kDa, thus allowing tumor eradication upon NIR laser irradiation using a low power density. 
To further improve nanomaterials accumulation in tumors, other coatings are currently being 
investigated. A variety of hydrophilic polymers such as poly(carboxybetaine), poly(glycerol), 
poly(2-ethyl-2-oxazoline), PVP and poly(N-(2-hydroxypropyl) methacrylamide) have been used 
for such purpose [67]. Zhou et al., observed that PVP coated CuS nanodots display a higher 
resistance to protein adsorption than those prepared with mPEG, which is fundamental for their 
efficient tumor accumulation (≈ 3.6 % ID g-1) and low uptake by RES organs (≈ 4.3 % ID g-1 of 
liver; ≈ 1 % ID g-1 of spleen) [14].  
Moreover, coatings produced with red blood cells’ (RBC) and macrophages’ membranes have 
been added to nanomaterials’ surface as an alternative to polymeric-based coatings since these 
coatings exhibit long-blood circulation times [33, 68, 69]. Piao and co-workers reported that 
the incorporation of PVP coated gold nanocages within vesicles derived from RBC ghosts 
amplifies their t1/2 from 1 to 9.5 h [68]. Accordingly, the RBC coating was also responsible for 
enhancing the tumor accumulation of the nanocages from 4.37 to 8.34 % ID g-1 and subsequently, 
an improved PTT was attained. Recently, Xu et al. demonstrated that by coating gold nanoshells 
with macrophages’ membranes, their blood circulation time is extended and tumor 
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accumulation is amended from ≈ 1.6 to ≈ 7.5 % ID g-1 [33]. Additionally, the modification of the 
nanoshells’ surface also reduced their accumulation in liver and spleen, from about 27 and 14 
to 14 and 9 % ID g-1, respectively. In vivo, the PTT mediated by non-coated gold nanoshells only 
produced a reduction of the tumor growth, while when macrophage-based coated 
nanomaterials were used a potent tumor regression was obtained. 
 
2.4.5. Targeting ligands 
Nanomaterials’ surface can be further tailored with targeting moieties in order to raise their 
specificity towards cancer cells. As previously substantiated for CNT, nGO, gold, Cu, W, Fe and 
PANI-based nanomaterials, the outcome of the PTT mediated by these nanostructures can be 
improved by targeting receptors overexpressed on the surface of cancer cells [9, 30, 70-74]. 
Liang et al. verified that by grafting anti-CD44 antibodies on PEGylated gold nanostars, their 
accumulation in tumor is enhanced by more than 2-fold and, simultaneously, their uptake by 
RES organs is reduced [72]. Due to these features, the CD44 targeted nanostars produced a 
greater therapeutic effect upon laser irradiation than their non-targeted equivalents [72]. 
Nanomaterials surface can also be simultaneously functionalized with more than one targeting 
ligand to further increase the therapeutic outcome achieved with the PTT [75, 76]. Jang et al. 
demonstrated that the dual functionalization of nGO with Pluronic® F-127-Folic acid (FA) and  
Pluronic® F-127-(arginine-glycine-aspartic acid) (RGD) conjugates (25 % density for each ligand) 
heightens the tumor accumulation of this nanomaterial, leading to tumor eradication upon NIR 
laser irradiation [76]. In contrast, nGO functionalized only with RGD (density of 25 %) or  
FA (density of 25%)-based conjugates promoted a similar reduction of the tumor growth, 
however this effect was smaller than that reached by the dual-functionalized nGO.  
The targeting of the endothelial cells present in tumor vasculature has also been explored for 
ameliorating the accumulation of nanomaterials in the tumor zone [77]. Neves et al. 
functionalized CNT with DSPE-PEG-Annexin V to target the phosphatidylserine residues 
available on the membranes of tumor cells and endothelial cells found in the tumor vasculature 
[70]. Such approach allowed CNT to be almost 7-times more accumulated in tumor  
(≈ 5 % ID g-1) [70]. Additionally, the targeting of angiogenic biomarkers present on tumor 
vasculature has also been exploited to grant nanomaterials accumulation in metastases. To 
accomplish that, Yang and co-workers functionalized PEGylated nGO with an anti-follicle 
stimulating hormone receptor (FSHR) antibody and noticed that this functionalization is able to 
rise the accumulation of nanomaterials in breast cancer lung metastasis from about 5 to  
19.7 % ID g-1 [78]. 
Yet, the functionalization of nanomaterials is still regarded as a complex and a delicate process. 
In some cases, the complete functionalization of nanomaterials’ surface does not guarantees 
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an improvement of nanomaterials accumulation in tumors [71, 79]. In fact, targeted 
nanomaterials demand an appropriate ligand density for accomplishing such purpose.  
Lee et al. verified that nGO coated with Pluronic® F-127-FA conjugates with FA densities of 50 
and 100 % display a similar tumor-homing capacity [71]. In contrast, nanomaterials 
functionalized with lower FA densities (10 and 25 %) exhibited a tumor accumulation 
comparable to that of non-FA functionalized nGO, and, therefore, mediated a weaker 
photothermal effect. Furthermore, the selectivity of targeted nanostructures can also be 
hampered by the formation of a protein corona on their surface [80]. To circumvent this 
possibility some nanomaterials are engineered to only expose their targeting moieties upon 
reaching the tumor microenvironment [81]. Alternatively, the immobilization of targeting 
ligands in PEG segments with higher lengths while leaving shorter PEG segments  
non-functionalized can attenuate the loss of selectivity mediated by the adsorption of serum 
proteins on the surface of nanomaterials [82]. In addition, the length of the spacer-arm to 
which the targeting ligand binds is also a decisive parameter for governing the biodistribution 
of these nanomaterials. To address this issue, Liu and co-workers coated CNT with  
DSPE-PEG-RGD conjugates containing different PEG lengths (2000 or 5400 Da). Their results 
revealed that CNT coated with DSPE-PEG5400-RGD show a superior tumor accumulation  
(≈ 13 % ID g-1) and lower uptake by liver (≈ 20 % ID g-1) than the DSPE-PEG2000-RGD coated CNT 
(≈ 5 % ID g-1 of tumor; ≈ 30 % ID g-1 of liver) [83]. Interestingly, CNT coated with  
DSPE-PEG2000-RGD had only a slightly higher tumor accumulation than those coated with  
DSPE-PEG5400 (≈ 4 % ID g
-1). Such may be attributed to the higher resistance to protein adsorption 
displayed by the CNT coated with DSPE-PEG5400. This fact may also be the reason for the higher 
blood circulation time (t1/2 ≈ 2 h) and lower liver accumulation displayed by CNT functionalized 
with DSPE-PEG5400 derivatives, thus emphasizing the importance of the PEG length on the 
biodistribution of targeted nanomaterials. 
 
2.5. Strategies used to augment nanomaterials’ 
capacity to produce photoinduced heat 
The application of nanomaterials with a high NIR absorption and good photothermal conversion 
efficiency for cancer PTT is highly desirable since these can produce a larger temperature 
variation upon NIR irradiation (Figure 2.3). Therefore, researchers are currently using a variety 
of strategies to obtain nanomaterials with these desired properties (see Table 2.2 for further 





Figure 2.3. Schematic representation of the key parameters that influence nanomaterials’ capacity to 
generate heat upon interaction with NIR light. 
 
2.5.1. Production of new nanomaterials 
Nanomaterials’ capacity to produce heat under NIR laser irradiation has been enhanced through 
the synthesis of new materials with a higher photothermal conversion efficiency and NIR 
absorption [9, 40, 43, 84]. Copper sulfide nanostructures have been produced with different Cu 
to S stoichiometric ratios in order to obtain more efficient photothermal agents. In recent 
studies, nanocrystals based on Cu9S5 showed a photothermal conversion efficiency of ≈ 26 %, 
while those composed of Cu7.2S4 had a photothermal conversion efficiency ≈ 57 % (at 980 nm) 
[10, 85].  
Regarding Pd and gold-based nanostructures, their photothermal capacity is influenced by their 
shape and this parameter has been optimized during nanostructures synthesis to obtain agents 
with an improved PTT capacity [31, 86]. Xiao et al. prepared porous Pd nanoparticles that have 
a higher NIR absorption than that displayed by Pd nanocubes, non-porous Pd nanoparticles, and 
Pd polyhedrons [86]. Such feature makes their application in cancer PTT more advantageous 
[86]. In addition, the photothermal conversion efficiency of gold nanomatryoshkas, nanocages, 
bellflowers, nanobipyramids and nanorods can be superior to 60 %, which makes them one of 
the most promising gold-based photothermal agents (Table 2.2) [87-91]. 
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Moreover, nanomaterials based on Mo, W, Fe, and conjugated polymers with an upgraded 
photothermal capacity have also been produced for application in cancer PTT [42, 92-95]. Yang 
et al. prepared PEGylated FeS nanoplates with a ≈ 17 times higher NIR absorption than that 
displayed by Fe3O4 nanoparticles [42]. Consequently, the FeS nanoplates were able to mediate 
the production of a photoinduced heat to about 70 °C while, in the same conditions, the Fe3O4 
nanoparticles only increased the temperature to ≈ 45 °C. In another work, Kim and co-workers 
synthesized poly(3,4-propylenedioxyselenophene) (PProDOS) nanoparticles that had a slightly 
superior NIR absorption than PEDOT nanoparticles and, consequently, produced a higher 
photoinduced heat (ΔT ≈ 10 °C vs. ΔT = 6 °C) [95]. 
Another strategy used to improve nanomaterials’ mediated PTT comprises the synthesis of 
materials that are responsive to the pH or oxygen gradient of the tumor microenvironment. 
PANI-based nanoparticles in acidic media (≈ pH 3), in contact with hydroxyl radicals or in the 
presence of bio-dopants, change from the emeraldine base (EB) to the emeraldine salt (ES) 
form, that displays an augmented NIR absorption [18, 96]. Recently, Ju and co-workers 
polymerized a PANI shell at the surface of gold nanoparticles, enabling a heightened NIR 
absorption at the range of pH values found in tumor microenvironment [97]. In particular,  
PANI-based nanoparticles with a 16 nm gold core displayed the lowest NIR absorption at pH 7.4 
while at pH 6.5 these had a high absorption. This difference led to a temperature increase 
under NIR laser irradiation to ≈ 40 °C and ≈ 53 °C, at pH 7.4 and 6.5, respectively. A similar 
responsiveness to the tumor microenvironment was also demonstrated for Mo oxide nanosheets 
and WO3-x nanodots [64, 98]. 
The production of hybrid nanostructures composed by different types of photothermal agents 
has also been pursued to obtain materials with an improved photothermal capacity. These 
structures are usually obtained by combining photothermal agents with gold, PPy or 
polydopamine due to the ability of the latter be grown or polymerized on the surface of 
nanomaterials [99-104]. In this regard, Li et al. verified that by coating PEI-gold nanostars with 
polydopamine, their photothermal conversion efficiency is improved from 36.1 to 49.9 % (at 
808 nm) [104]. In other works, PEGylated gold-silver star- and urchin-shaped hybrid 
nanostructures demonstrated a photothermal conversion efficiency of 79.01 and 80.4 %  
(at 808 nm), respectively, which are one of the highest efficiencies reported so far (see Table 
2.2 for further details) [99, 100]. 
 
2.5.2. Optimization of nanomaterials’ size 
Upon irradiation, nanomaterials can scatter and absorb light, being this latter phenomenon 
responsible for the heat generation [105]. Smaller nanomaterials scatter less light and can 
display a faster heat transfer to the surrounding environment due to their large surface 
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area/volume ratio [106, 107]. In this way, nanomaterials with an improved photothermal 
capacity can be obtained by selecting nanostructures based on their size [7, 15, 107, 108]. 
Wang et al. verified that despite 100 nm sized MoS2 nanosheets exhibiting a higher NIR 
absorption than their 80 nm equivalents, the latter are capable of producing a greater 
temperature variation under laser irradiation due to their improved photothermal efficiency 
(ΔT ≈ 4.5 °C vs. ΔT ≈ 6 °C) [15]. Tang et al. prepared 41 and 4.4 nm sized Pd-PVP nanosheets 
and verified that the smallest nanomaterials show the highest photothermal conversion 
efficiency (52 vs. 27.6 % at 808 nm) [7]. Accordingly, the 4.4 nm nanosheets were able to raise 
the temperature to ≈ 50 °C under NIR laser irradiation, while the 41 nm nanomaterials only 
elevated it to ≈ 37.5 °C. 
On the other hand, the absorption spectrum of some nanomaterials can be fine-tuned towards 
the NIR region by increasing nanomaterials’ size. Peng et al. observed that by augmenting the 
size of citrate and PEG functionalized Fe3O4 nanoparticles from 120 to 380 nm, a red-shift in 
their absorption spectrum is attained [109]. Due to this phenomenon, the 380 nm sized Fe3O4 
nanoparticles exhibited an improved NIR absorption and mediated the highest temperature 
increase under NIR laser irradiation when compared to their equivalents with smaller 
dimensions (120, 240 and 300 nm). Ye et al. verified that by increasing the length of gold 
nanotubes from 300 to 530 nm, a shift in their absorption towards the NIR region is also observed 
[110]. In this case, the gold nanotubes with a length of approximately 370 nm were considered 
optimal systems since these showed the highest absorption at 800 nm. 
 
2.5.3. Chemical treatment of nanomaterials 
The reduction of nGO is the most employed strategy to enhance its NIR absorption by restoring 
the aromatic lattice of this nanomaterial [50, 63]. Yang et al. demonstrated that the reduction 
of GO derivatives with hydrazine hydrate produces reduced GO (rGO)-based nanomaterials that 
have a 3-4 times higher NIR absorption than nGO, leading to the production of a higher 
photoinduced heat (≈ 58 °C vs. ≈ 44 °C) [63]. Akhavan and Ghaderi reported that the 
photodegradation and subsequent reduction of nGO yields reduced graphene oxide nanomesh 
(rGONM) with a NIR absorption ≈ 4.2 times higher than that of reduced nGO [50]. In this way, 
the rGONM induced, under NIR laser irradiation, an increase in temperature up to ≈ 57 °C, while 
in the same conditions the reduced nGO only elevated the temperature to ≈ 42 °C.  
The photothermal capacity of PB nanostructures has been improved by doping these materials 
with Mn2+and Gd3+ [111, 112]. PEGylated PB nanocubes doped with 15% Mn2+ displayed an almost 
2-fold increased NIR absorption that lead to an improved temperature variation (ΔT ≈ 10 °C), 
upon material irradiation [111].  
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2.5.4. Assembling of nanostructures 
In some cases, the assembly of nanostructures into clusters or vesicles can be used to provoke 
a red-shift in their absorption profile towards the NIR region and, consequently, enhance their 
photothermal capacity [41, 113, 114]. Shen et al. prepared clusters of Fe3O4 nanoparticles that 
display a ≈ 3.6-fold higher NIR absorption than the individual Fe3O4 nanoparticles [41]. The 
clustered Fe3O4 nanoparticles elicited the highest hyperthermia (≈ 56 °C vs. ≈ 50 °C) and the 
most potent antitumoral effect upon NIR laser irradiation due to their superior NIR absorption. 
In another work, Huang et al. synthesized PEG-poly(caprolactone) functionalized gold 
nanoparticles, which did not display any NIR absorption, and assembled them into gold-based 
nanovesicles [113]. The assembled nanovesicles presented a high NIR absorption and a 
photothermal conversion efficiency of 37 %, which was higher than that of GNR (22 % at  
808 nm). Owing to their superior photothermal efficiency, the assembled nanovesicles 
increased the temperature of the tumors by ≈ 18 °C and mediated their eradication under NIR 
laser irradiation. In the same conditions, the GNR were only able to induce a hyperthermia of  
≈ 10 °C and a reduction of the tumor growth, thus revealing the advantage of the assembly of 
nanovesicles for the desired biomedical application. 
 
2.5.5. Sorting of nanomaterials 
The commonly available methods to produce CNT (e.g. high-pressure carbon monoxide 
conversion) yield a mixture of nanostructures with different chiralities, some of which have a 
low NIR absorption. For this reason, sorting CNT with defined chirality is a successful strategy 
for improving the photothermal performance of these materials [115, 116]. Antaris and  
co-workers demonstrated that PEGylated chirality sorted (6,5) CNT have a higher NIR absorption 
than non-sorted CNT [116]. Consequently, the sorted CNT were able to mediate under NIR laser 
irradiation a hyperthermia to ≈ 51 °C and tumor eradication for 3 in 4 mice. For mice treated 
with non-sorted CNT, tumor growth inhibition was not observed since these nanomaterials only 
induced a hyperthermia to ≈ 44 °C due to their inferior optical properties.  
 
2.6. Optimization of the parameters related to the 
laser light for improving the PTT mediated by 
nanomaterials 
The wavelength, power density and onset of the irradiation are important players in 
nanomaterials’ mediated PTT since their correct modulation is crucial for avoiding off-target 
heating of healthy tissues and also to ensure that an appropriate hyperthermia is achieved 
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during the therapeutic procedure [93, 117]. Therefore, various strategies have been applied to 
improve the outcome of this therapeutic modality by performing the adjustment of these laser 
light related parameters (Figure 2.4). The exposition of multiple sites to NIR light and 
application of multiple irradiation sessions are other strategies that have been explored to 
improve nanomaterials’ mediated PTT (summarized in Table 2.3; presented after the 
conclusion section). 
 
Figure 2.4. Schematic representation of the parameters related to the laser light that influence the PTT 
mediated by nanomaterials. In the wavelength panel, the bars represent the absorption of different  
bio-components and the color intensity is proportional to their absorption at that specific wavelength. 
The data from the wavelength panel were extrapolated from Vogel et al.[28]. 
 
2.6.1. Wavelength 
As discussed in section 2.3, the application of NIR light is crucial in cancer PTT. However, the 
absorption displayed by water at wavelengths above 900 nm demands additional precautions 
when tissues are exposed to radiation with a wavelength superior to 900 nm in order to avoid 
off-target heating [28, 118, 119]. 
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In this way, the selection of the appropriate wavelength of the NIR radiation can be pursued to 
improve nanomaterials’ mediated PTT. Xu et al. verified that despite PEGylated CsxWO3 
nanorods having a higher absorbance at 980 nm than at 915 nm, nanostructures irradiation at 
915 nm is advantageous over their irradiation at a higher wavelength, since a higher penetration 
and lower off-target heating are reached [119]. Tian and co-workers observed that although 
PVP coated Rb0.27WO3 nanorods display a higher absorption at 980 nm than at 808 nm, the 
irradiation of the nanorods with the lower wavelength light can produce a higher temperature 
variation, since the 980 nm light has a lower depth penetration [120].  
 
2.6.2. Power density 
The power density (total energy per second delivered into a specific area) of the NIR irradiation 
can be adjusted to improve the outcome of the PTT. Yang et al. assessed in vivo the PTT 
capacity of poly(vinyl alcohol) (PVA) coated PPy nanoparticles using different power densities 
[117]. When nanoparticles were irradiated at a power density of 0.1 W cm-2, these mediated a 
hyperthermia to ≈ 42 °C that led to tumor growth reduction. In contrast, when a power density 
of 0.25 and 0.5 W cm-2 was used, a hyperthermia to about 55 and 60 °C was attained, leading 
to the elimination of mice’s tumors. Guo et al. verified that (NH4)xWO3 nanocubes mediate an 
increment of ≈ 45 °C in tumor’s temperature when these are irradiated at a power density of 
1 W cm-2 [93]. This hyperthermic effect was responsible for a reduction in the volume of the 
tumors and also for the inhibition of lung metastases. On the other hand, when PTT was 
performed at a power density of 0.5 W cm-2, a weaker therapeutic effect was obtained, which 
is consistent with the lower hyperthermia attained (ΔT ≈ 33 °C). 
 
2.6.3. Irradiation onset 
The therapeutic effect achieved through nanomaterials’ mediated PTT depends on the ON/OFF 
cycles of the radiation [9, 10]. Thereby, the hyperthermia and the therapeutic outcome can be 
maximized by synchronizing the onset of the laser irradiation with the maximum accumulation 
of the nanomaterials within the tumor. This strategy was explored by Sharker et al., which 
verified that WO3 nanoparticles functionalized with HA display a high tumor accumulation at  
8 h post-injection (p.i.) [9]. Accordingly, these researchers noticed that the highest 
hyperthermia (50 °C) is obtained when the onset of the NIR laser irradiation starts on this time 
point (at 8 h p.i.). In another work, Zhou et al. verified that PVP coated CuS nanodots hit their 
maximum tumor accumulation (≈ 3.6 % ID g-1) at 2 h p.i. and PTT performed at this time point 




2.6.4. Irradiated site 
The therapeutic effect mediated by nanomaterials can also be improved by exposing 
simultaneously the tumor zone and metastatic sites to NIR light. This strategy was explored by 
Liang et al., who verified that intratumorally injected PEGylated CNT remain in the tumor 
tissue and also become accumulated in the tumor-adjacent lymph node [121]. These zones 
were then exposed to NIR light and nanomaterials increased the temperature of the tumor and 
the lymph node to about 55 and 47 °C, respectively. Such effect was responsible for tumor 
eradication in 6 out of 7 mice [121]. In stark contrast, mice irradiated only in the tumor had a 
poor survival rate, since multiple metastases were observed in the lungs. Furthermore, it should 
also be highlighted that to compensate for the lower accumulation of the CNT in the lymph 
node (and also due to its deeper localization), this site was irradiated at a higher power density 
(0.8 W cm-2 for lymph node vs. 0.5 W cm-2 for tumor). Thus, the optimization of the irradiation 
site and the power density are fundamental to achieve an appropriate hyperthermia at the 
target sites in order for an improved photothermal effect be attained.  
 
2.6.5. Number of irradiation sessions 
The application of multiple irradiation sessions is another approach that has been used for 
achieving better photothermal effects. Choi and co-workers observed that chitosan-Pluronic®  
F-68 conjugates encapsulating GNR are able to mediate tumor eradication with two laser 
irradiation sessions (at 24 and 48 h p.i.) while the application of one irradiation session  
(at 24 h p.i.) only resulted in a reduction of the tumor growth [11]. In another work, Zhou and 
co-workers noticed that PEGylated WO2.9 nanorods could mediate the elimination of mice’s 
tumors by using a low power density (0.35 W cm-2) through the application of multiple 
irradiation sessions (every two days during 14 days) [16]. Recently, Zhang et al. performed 
multiple irradiation sessions after administration of DSPE-PEG coated CNT (at 10 min and on 
day 3, 6 and 9 p.i.), and they verified that the application of NIR radiation at 10 min p.i. 
improves nanomaterials’ tumor accumulation by about 2.6-fold, presumably due to an 
enhanced tumor vasculature perfusion and permeability that is promoted by the hyperthermia 
attained (hyperthermia enhanced EPR effect) [122]. In the same study, authors also explored 
DSPE-PEG-(Cys-Arg-Glu-Lys-Ala) (CREKA) functionalized CNT, which bind to fibrin, and they 
perceived that after administration of the targeted CNT and application of the first irradiation 
session (at 10 min p.i.), the hyperthermia produced greatly increases the amount of fibrin 
deposited in the tumor zone and such is responsible for a ≈ 3.8-fold increase in the tumor 
accumulation of the functionalized CNT. 
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2.7. Conclusion and outlook 
In this chapter, the recent strategies, reported in the literature, used for improving the 
therapeutic outcome of the PTT mediated by gold, carbon, copper, molybdenum, tungsten, 
iron, palladium and conjugated polymers based nanomaterials were covered. 
The application of PEG-based coatings and the inclusion of targeting ligands on nanomaterials’ 
surface improved their tumor-homing capacity and hence their PTT capacity. Such data 
emphasizes the importance of pursuing the appropriate surface composition for each type of 
photothermal agent through the optimization of the PEG corona composition, targeting ligand 
density and spacer-arm length, or through the application of alternative coatings, such as those 
based on PVP or RCB/macrophages’ membranes. Moreover, reports describing the application 
of targeted Mo, Pd, PPy and PEDOT based nanomaterials in cancer PTT were not found, which 
should motivate the development of functionalization strategies for these types of 
nanostructures. Nanomaterials’ size, shape, and charge were not systematically optimized for 
each type of photothermal agent. In the particular case of the size and shape, such could be 
attributed to the fact that variations in these characteristics have a direct impact on 
nanomaterials’ photothermal efficiency. Regarding nanomaterials’ charge, the utilization of 
zwitterionic-based approaches should be further explored since it holds a great potential for 
improving the biodistribution of the nanostructures.  
So far, several strategies have also been applied to augment the capacity of nanomaterials to 
generate heat under NIR laser irradiation and thus enhance their PTT potential. To accomplish 
that, new nanomaterials have been produced, being this the most straightforward strategy. 
Other approaches are currently under investigation, comprising the optimization of 
nanostructures’ size, chemical treatment, sorting and assembling of nanostructures. However, 
in some of the reports describing these strategies, the photothermal efficacy of the 
nanostructures was only assessed in vitro or in vivo after intratumoral injection, which should 
motivate researchers to evaluate nanomaterials’ photoablation capacity after systemic 
administration (e.g. intravenous administration) in future works. Moreover, some of these 
nanomaterials were not engineered to present colloidal stability, tumor-homing capacity or 
resistance to protein adsorption and thus, the improvement of these attributes will surely 
augment their PTT potential. 
The optimization of the parameters related to the laser light can also improve the outcome of 
nanomaterials’ mediated PTT. The strategies applied, until now, have been focused on the 
adjustment of the wavelength, power density, irradiated sites, number of irradiation sessions 
and on the optimization of the irradiation onset. However, these strategies were not frequently 
explored in the literature and were mostly applied for W-based nanostructures and to a lesser 
extent to others such as CNT or gold-based nanomaterials. Moreover, this type of laser-sided 
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optimizations does not imply modifications in the attributes of the nanomaterials and, for this 
reason, its implementation should be simple and further explored in cancer PTT. 
Finally, excluding the influence of the differences between the tumor models (e.g. type and 
size of tumor) of the reports herein analyzed (Table S.2.1), it seems that for the bulk part of 
the cases and independently of the type of strategy applied to improve the PTT mediated by 
nanomaterials, achieving a hyperthermia to 57 °C ensures the photoablation of the tumors. 
Hence, the development of new strategies that endow nanomaterials with this capability or the 
optimization and combination of the existing ones will surely give a major contribution for their 




Table 2.1. Strategies used to improve nanomaterials’ accumulation in the tumor. 
Nanomaterial Optimization Result Ref. 
PEGylated rod-like gold nanoshell 
capsules 
Size PEGylated gold-based capsules with a size of 385 x 155 nm become less accumulated in the tumor zone when 
compared to their 125 x 95 nm and 207 x 105 nm sized equivalents; 
PEGylated gold-based capsules with a size of 207 x 105 nm can penetrate and achieve a wide distribution in 
the tumor mass, while those with a size of 125 x 95 nm become accumulated mostly in tumor periphery. 
[52] 
GO Size Small GO sheets (< 50 nm) achieve the highest internalization by cancer cells. [53] 
PEGylated MoS2 nanosheets Size PEGylated MoS2 nanosheets with a size of 80 and 100 nm are better internalized by cancer cells than those 
with 300 nm. 
[15] 
Pd-PVP nanosheets Size Pd-PVP nanosheets with a size of 4.4 nm have a lower uptake by the liver (≈ 35 % ID g-1) than their 41 nm 
sized equivalents (≈ 45 % ID g-1). 
[7] 
PEGylated GO Size PEGylated GO derivatives with a size of 27 nm have a lower uptake by the liver (≈ 11 % ID g-1) and spleen  
(≈ 7 % ID g-1) than their 65 nm sized equivalents (≈ 25 % ID g-1 of liver; ≈ 25 % ID g-1 of spleen). 
[63] 
PEGylated GO Size PEGylated GO derivatives with a size of ≈ 61 nm have a higher tumor-homing capacity (≈ 8.9 % ID g-1) and 
lower uptake by the liver (≈ 17 % ID g-1) and spleen (≈ 12 % ID g-1) than ≈ 2 µm sized PEGylated nanomaterials 
(≈ 7.3 % ID g-1 of tumor; ≈ 26 % ID g-1 of liver; ≈ 22 % ID g-1 of spleen). 
[50] 
PEGylated gold nanocages, 
nanohexapods and nanorods 
Shape PEGylated gold nanohexapods display 1.2- and 3.2-fold higher internalization by cancer cells than PEGylated 
gold nanocages and nanorods, respectively; 
PEGylated GNR (≈ 8.4 % ID g-1) and nanohexapods (≈ 7.2 % ID g-1) have a higher tumor-homing capacity than 
nanocages (≈ 2.6 % ID g-1). 
[31] 
Silica coated Pd-PVP nanosheets Shape Coating of Pd-PVP nanosheets with silica results in a ≈ 4.7-fold increase in their uptake by cancer cells. [55] 
Pd-PVP nanosheets immobilized in 
silica nanoparticles 
Shape Electrostatic immobilization of Pd-PVP nanosheets in amine-terminated silica nanoparticles improves their 
cellular uptake by ≈ 11-fold. 
[123] 
PEI coated Pd-PVP nanosheets Charge Modification of Pd-PVP nanosheets with PEI increases their cellular internalization by ≈ 1.9-fold. [55] 
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Amine-terminated silica coated  
Pd-PVP nanosheets 




PEGylated gold nanostars 
Charge Amine/carboxyl-terminated nanostars have a low and enhanced internalization by cancer cells at pH 7.4 
and 6.4, respectively; 
Amine/carboxyl-terminated nanostars display a higher tumor accumulation (≈ 10 % ID g-1) than nanostars 
terminated with only carboxyl (≈ 4 % ID g-1) or amine groups (≈ 2 % ID g-1); 
Amine-terminated nanostars have a high liver uptake (> 120 % ID g-1). 
[34] 
Chitosan-Pluronic® F-68 conjugates 
encapsulating GNR 
Corona Chitosan-Pluronic® F-68 conjugates encapsulating GNR have a superior tumor accumulation when compared 
to non-modified GNR (≈ 117 vs. ≈ 12 % ID g-1). 
[11] 
RBC membrane coated PVP-gold 
nanocages  
Corona Incorporation of PVP-gold nanocages within vesicles derived from RBC membranes improves their t1/2 from 
1 to 9.5 h; 
RBC coating also improves the tumor accumulation of nanomaterials from 4.37 to 8.34 % ID g-1. 
[68] 
Macrophage cell membrane coated 
gold nanoshells 
Corona Coating of Au nanoshells with macrophage cell membrane extends their blood circulation time and improves 
their tumor accumulation from ≈ 1.6 to ≈ 7.5 % ID g-1; 
The coating also reduces the liver and spleen accumulations from about 27 and 14 to about 14 and  
9 % ID g-1, respectively. 
[33] 
C18-PMH-mPEG and DSPE-mPEG 
coated CNT 
Corona C18-PMH-mPEG coated CNT have a higher blood circulation time (t1/2 ≈ 30.8 h) and tumor accumulation  
(≈ 30 % ID g-1) than DSPE-mPEG coated CNT (t1/2 ≈ 3.5 h; 4 % ID g-1); 
C18-PMH-mPEG coated CNT have a lower liver uptake than DSPE-mPEG coated CNT (≈ 28 vs. ≈ 69 % ID g-1). 
[62] 
C18-PMH-mPEG coated CNT Corona Increasing the PEG length and density of C18-PMH-mPEG coated CNT enhances their blood circulation time, 
augments tumor and skin accumulations, and reduces uptake by RES organs; 
CNT coated with C18-PMH-mPEG with a PEG density and molecular weight of 10 % and 5 kDa are considered 
optimal due to their good circulation time (t1/2 = 12.8 h), high tumor accumulation (≈ 15 % ID g-1) and low 
uptake by skin (≈ 3 % ID g-1). 
[12] 
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PEGylated rGO and reduced nGO Corona The blood circulation time of C18-PMH-mPEG coated rGO (t’1/2a) ≈ 17.5) and C18-PMH-mPEG coated reduced 
nGO (t’1/2 ≈ 16.7 h) is superior to that of PEGylated (6-arm branched) nGO (t’1/2 ≈ 5.8 h); 
The tumor accumulation of C18-PMH-mPEG coated nanomaterials (≈ 5-6 % ID g-1) is 7-8 times higher than that 
of PEGylated nGO. 
[63] 
Double PEGylated reduced nGO Corona Conjugation of amine-terminated C18-PMH-PEG5000 coated reduced nGO with a PEG5000 derivative (double 
PEGylation) improves its blood circulation time from t’1/2 = 18.8 h (t1/2 = 0.19 h) to t’1/2 = 27.7 h  
(t1/2 = 0.35 h); 
The tumor accumulation is also augmented from 8.8 to 15.5 % ID g-1. 
[124] 
Citrate and mPEG coated CuS 
nanoparticles 
Corona mPEG coated CuS nanoparticles have a higher blood residence and almost 3-fold greater tumor accumulation 
(7.6 % ID g-1) than citrate-CuS nanoparticles; 
mPEG coated CuS nanoparticles have a lower uptake by the liver (≈ 23 % ID g-1) and spleen (≈ 9 % ID g-1) than 
citrate coated nanomaterials (≈ 44 % ID g-1 of liver; ≈ 34 % ID g-1 of spleen). 
[37] 
Citrate, mPEG, and PVP coated CuS 
nanodots 
Corona PVP coated CuS nanodots display the highest resistance to protein adsorption, followed by mPEG coated 
nanodots and then by citrate coated nanodots. 
[14] 
PEGylated Cu2-xSe nanoparticles Corona PEGylated Cu2-xSe nanoparticles display a blood circulation time of t’1/2 = 8.14 h (t1/2 = 0.73 h) and a tumor 
accumulation of 4.4 % ID g-1; 
Nanoparticles also have a low uptake by the liver (≈ 9 % ID g-1) and spleen (≈ 8 % ID g-1). 
[84] 
PTMP-PMAAb) coated WO3-x nanodots Corona PTMP-PMAA coated WO3-x nanodots have a tumor accumulation of ≈ 5 % ID g-1 and low uptake by the liver  
(≈ 15 % ID g-1) and spleen (≈ 13 % ID g-1). 
[98] 
PEGylated WS2 nanosheets Corona PEGylated WS2 nanosheets possess a high tumor-homing capacity (13 % ID g-1) that allows tumor eradication 




C18-PMH-PEG coated WS2 nanoflakes Corona C18-PMH-PEG coated WS2 nanoflakes possess a high tumor-homing capacity (≈ 10 % ID g-1). The liver and 
spleen accumulations are ≈ 34 and ≈ 19 % ID g-1, respectively. 
[125] 
PEGylated PB hollow nanocubes Corona Coating of hollow PB nanocubes with PEG improves their t1/2 from 5.6 to 8.7 h. 
 
[73] 
RBC-derived membrane coated 
Fe3O4 nanoclusters 
Corona RBC coated Fe3O4 nanoclusters have about 2.3-fold lower uptake by macrophages than their non-coated 
equivalents; 
RBC coated Fe3O4 nanoclusters have a higher blood retention than their non-coated equivalents and achieve 
a superior tumor accumulation (≈ 4.9 vs. ≈ 1.3 % ID g-1) and lower uptake by the liver (≈ 18 vs.  
≈ 32 % ID g-1). 
[69] 
GSHc) modified Pd-PVP nanosheets Corona Functionalization of Pd-PVP nanosheets with GSH increases their blood circulation (t1/2 = 1.25 h) and tumor 
accumulation to ≈ 4.5 % ID g-1; 
GSH functionalization reduces the uptake of the nanosheets by the liver (from ≈ 35 to ≈ 8 % ID g-1) and spleen 
(from ≈ 12 to ≈ 2 % ID g-1). 
[7] 
PEGylated Pd-PVP nanosheets Corona PEGylated Pd-PVP nanosheets have a high blood circulation time (t1/2 ≈ 30 h), good tumor accumulation  
(≈ 8 % ID g-1) and low accumulation in RES organs (≈ 11 % ID g-1 of liver; ≈ 15 % ID g-1 of spleen); 
PEGylation using a mPEG-SH:Pd-PVP mass ratio of 1:1 is optimal for the nanosheets; 
Increasing the PEG molecular weight from 5 to 10 kDa improves the tumor accumulation of the nanosheets 
from ≈ 8 to ≈ 12 % ID g-1. 
[44] 
PVP-PPy based nanoparticles Corona PVP-PPy based nanoparticles have a low blood circulation time (t1/2 ≈ 12 min) and high uptake by the liver 
(≈ 49 % ID g-1) but achieve a tumor accumulation of ≈ 4 % ID g-1. 
[45] 
PEGylated PPy-based nanoparticles Corona Nanoparticles prepared with a Py:Py-COOHd) molar feed ratio of 7:3 are considered as optimal since these 
display a good compromise between NIR absorption and carboxyl groups for PEG conjugation (inclusion of 
Py-COOH decreases NIR absorption); 
PEGylated nanoparticles have a good blood circulation time (t1/2 ≈ 12.5 h), achieve high tumor accumulation 





Corona PEGylated PEDOT:PSS nanoparticles possess a high tumor-homing capacity (≈ 28 % ID g-1). The liver and 
spleen accumulations are ≈ 32 and ≈ 17 % ID g-1, respectively. 
[8] 
PEGylated gold-Pd nanoplates Corona PEGylated gold-Pd nanoplates display a blood circulation time of t1/2 = 8 h and a tumor accumulation of  
≈ 79 % ID g-1; 
Nanoplates have a low uptake by the liver (≈ 17 % ID g-1) but display a high accumulation in the spleen  
(≈ 33 % ID g-1) and skin (≈ 16 % ID g-1). 
[126] 
A10 and DUP-1 dual-functionalized 
PEGylated gold nanostars 
Targeting Dual aptamer functionalized PEGylated gold nanostars mediate a photothermal effect selective for prostate 
cancer cells. 
[75] 
CD44 targeted PEGylated gold 
nanostars 
Targeting Conjugation of anti-CD44 antibodies to PEGylated gold nanostars increases their tumor accumulation by 
more than 2-fold and reduces their uptake by RES organs. 
[72] 
DSPE-PEG-RGD coated CNT Targeting DSPE-PEG5400-RGD coated CNT have a superior tumor accumulation (≈ 13 % ID g-1) and lower liver uptake  
(≈ 20 % ID g-1) than their equivalents coated with DSPE-PEG2000-RGD (≈ 5 % ID g-1 of tumor; ≈ 30 % ID g-1  
of liver); 
DSPE-PEG2000-RGD and DSPE-PEG5400 coated CNT have similar tumor accumulations (≈ 5 vs. ≈ 4 % ID g-1). 
[83] 
DSPE-PEG-Annexin V coated CNT Targeting Annexin V functionalization improves the tumor accumulation of CNT by almost 7-fold (≈ 5 % ID g-1). [70] 
HA functionalized nGO Targeting HA-nGO mediates a superior PTT when compared to non-functionalized nGO. [127] 
Pluronic® F-127-FA conjugates 
coated nGO 
Targeting nGO functionalized with FA densities of 50 and 100% have a similar tumor accumulation; 
nGO with FA densities of 10 and 25 % have a tumor accumulation similar to that of non-functionalized  
nGO. 
[71] 
Pluronic® F-127-FA and Pluronic®  
F-127-RGD conjugates coated nGO 
Targeting Dual-targeted nGO has a higher tumor-homing capacity than single-ligand functionalized (FA or RGD) nGO. [76] 
DSPE-PEG-RGD coated rGONM and 
rGO 
Targeting rGONM and rGO functionalized with DSPE-PEG-RGD have a better blood circulation profile than their 




RGD functionalization improves the tumor accumulation of PEGylated rGO and rGONM from ≈ 7.3 and ≈ 8.9 
to ≈ 22.7 and ≈ 31 % ID g-1, respectively; 
RGD functionalization also reduces the uptake of these nanomaterials by the liver (values in % ID g-1: ≈ 26 
for rGO-PEG; ≈ 7 for rGO-PEG-RGD; ≈ 17 for rGONM-PEG; ≈ 5 for rGONM-PEG-RGD) and spleen (values in % 
ID g-1: ≈ 22 for rGO-PEG; ≈ 6 for rGO-PEG-RGD; ≈ 12 for rGONM-PEG; ≈ 3 for rGONM-PEG-RGD). 
Anti-FSHR antibody functionalized 
PEGylated nGO 
Targeting Functionalization of PEGylated nGO with anti-FSHR antibody improves the accumulation of these 
nanomaterials in breast cancer lung metastasis from about 5 to 19.7 % ID g-1. 
[78] 
FA and PEG coated CuS 
nanoparticles 
Targeting FA coated CuS nanoparticles are rapidly cleared from circulation and have high liver uptake  
(≈ 35 % ID g-1); 
FA coated CuS nanoparticles have a higher tumor-homing capacity than PEGylated CuS nanoparticles  
(≈ 9.7 vs. ≈ 6.4 % ID g-1). 
[30] 
Anti-HER-2 antibody functionalized 
poly(acrylic acid)-W18O49 
nanoparticles 
Targeting HER-2 targeted W18O49 nanoparticles accumulate in HER-2 positive lymphatic metastases and mediate their 
elimination under NIR laser irradiation. 
[20] 
HA functionalized WO3 
nanoparticles 
Targeting HA functionalization improves the tumor accumulation of the WO3 nanoparticles from ≈ 5 % to 34 % ID. [9] 
HER-2 affinity protein 
functionalized DSPE-PEG Fe5C2 
nanoparticles 
Targeting HER-2 targeting functionalization improves the tumor accumulation of Fe5C2 nanoparticles, which then 
mediate the elimination of mice’s tumors with only 3 minutes of laser irradiation. 
[128] 
HA-g-PEG coated PB hollow 
nanocubes 
Targeting HA-g-PEG coated PB nanocubes mediate a higher hyperthermia under NIR laser irradiation than PEGylated 
nanocubes (53 °C vs. 43 °C) due to their superior tumor accumulation. 
[73] 





Targeting Cetuximab conjugation increases the tumor accumulation of PANI-based nanoparticles from ≈ 1.7 to  
≈ 7.1 % ID g-1. 
[74] 
Anti-CD44 antibody functionalized 
PPDSf) nanoparticles 
Targeting PPDS nanoparticles electrostatically complexed with anti-CD44 antibodies mediate a photothermal effect 
selective for cancer cells overexpressing CD44 receptors. 
[22] 
a) second phase blood circulation half-life (t’1/2); b) pentaerythritol tetrakis (3-mercaptopropionate)-terminated poly(methacrylic acid) (PTMP-PMAA); c) reduced glutathione 
(GSH); d) pyrrole:pyrrole-1-propanoic acid (Py:Py-COOH); e) PEDOT:poly(styrenesulfonate) (PEDOT:PSS); f) poly(sodium3-((3-methyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepin-
3-yl)methoxy)propane-1-sulfonate) (PPDS).  
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Table 2.2. Strategies used to improve nanomaterials’ capacity to produce photoinduced heat. 
Nanomaterial Optimization Result Ref. 
Urchinlike gold nanoparticles New material Photothermal conversion efficiency of 11 % (at 808 nm). [101] 
Gold nanohexapods New material Photothermal conversion efficiency of 29.6 % (at 808 nm). [88] 
Gold/SiO2 nanoshells New material Photothermal transduction efficiency of ≈ 34 % (at 815 nm). [90] 
Gold nanoshells New material Photothermal transduction efficiency of 39 % (at 810 nm). [87] 
Nanoporous gold disks New material Photothermal conversion efficiency of ≈ 56 % (at 700-900 nm). [129] 
Gold nanomatryoshkas New material Photothermal transduction efficiency of 63 % (at 810 nm). [87] 
Gold nanocages New material Photothermal conversion efficiency of 63.6 % (at 808 nm). [88] 
Gold bellflowers New material Photothermal conversion efficiency of 74 % (at 808 nm). [89] 
Gold nanobipyramids New material Photothermal conversion efficiency depends on the radius of the nanostructures  
(51-≈ 90 %, at 809 nm). 
[91] 




Gold nanocages, nanohexapods, and 
nanorods 
New material Gold nanocages generate a photoinduced heat similar to that of GNR and nanohexapods, but 
at a ≈ 3-fold lower concentration. 
[31] 
PEGylated Cu nanowires New material Photothermal conversion efficiency of 12.5 % (at 808 nm). [131] 
Cu2-xSe nanocrystals coated with 
hydrolyzed poly(isobutylene-alt-maleic 
anhydride)-oleylamine conjugates 
New material Photothermal transduction efficiency of 22 % (at 800 nm). [38] 
Cu9S5 nanocrystals modified with 
aminocaproic acid 
New material Photothermal conversion efficiency of 25.7 % (at 980 nm). [85] 
PEGylated Cu3BiS3 hollow nanospheres New material Photothermal conversion efficiency of 27.5 % (at 980 nm). [39] 
BSA-Gd:CuS nanoparticles New material Photothermal conversion efficiency of 32.3 % (at 980 nm). [132] 
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Ferritin-CuS New material Photothermal conversion efficiency of ≈ 47 % (at 808 nm). [133] 
Silica coated Cu1.75S nanoparticles New material Photothermal conversion efficiency of 54.13 % (at 808 nm). [134] 
Cu7.2S4 nanocrystals coated with a 
hydrolyzed poly(maleic anhydride)-
oleylamine based amphiphile 
New material Photothermal conversion efficiency of 56.7 % (at 980 nm). [10] 
PEGylated Cu2-xSe nanoparticles New material Photothermal conversion efficiency of 64.8 % (at 808 nm). [84] 
PEGylated Mo oxide nanospheres and 
nanoribbons 
New material Mo oxide nanorods (synthesized in the absence of PEG) have a weak NIR absorption, while 
Mo oxide nanospheres and nanoribbons (synthesized in the presence of PEG) have high NIR 
absorption. 
[135] 
PEGylated MoO3-x hollow nanospheres New material MoO3-x hollow nanospheres prepared in the presence of PEG have an enhanced NIR absorption 
and a photothermal conversion efficiency of 22.64 % (at 808 nm). 
[40] 
Chitosan functionalized MoS2 nanosheets New material Photothermal conversion efficiency of 24.37 % (at 808 nm). [136] 
PEGylated MoS2 nanoflakes New material Photothermal conversion efficiency of 27.6 % (at 808 nm). [92] 
Layered MoS2 hollow spheres New material Layered MoS2 hollow spheres have a higher NIR absorption than MoS2 nanosheets and a 
photothermal conversion efficiency of 34.46 % (at 808 nm). 
[137] 
Pluronic® F-127 coated MoSe2 nanodots New material Photothermal conversion efficiency of 46.5 % (at 785 nm). [138] 
Radar-like MoS2 nanoparticles New material Radar-like MoS2 nanoparticles have a higher photothermal conversion efficiency (53.3 %) than 
MoS2 nanoflowers (18.2 %) and MoS2 microspheres (15.2 %, at 808 nm). 
[139] 
PVP coated MoSe2 nanosheets New material Photothermal conversion efficiency of 57.9 % (at 808 nm). [140] 
PEGylated Mo oxide nanosheets New material Mo oxide nanosheets display a pH dependent NIR absorption that is governed by their 
degradation. In healthy tissues, the nanosheets have a fast degradation rate. In the tumor 
microenvironment (slightly acidic) the nanosheets degrade slowly, thereby retaining their 
NIR absorption. 
[141] 
HA functionalized WO3 nanoparticles New material Photothermal conversion efficiency of 11.78 % (at 808 nm). [9] 
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PVP coated Rb0.27WO3 nanorods New material Photothermal conversion efficiency of 17.8 % (at 808 nm). [120] 
(NH4)xWO3 nanocubes New material Photothermal conversion efficiency of 39.4 % (at 1064 nm). [93] 
WO3 nanoparticles New material Photothermal conversion efficiency of 41.96 % (at 808 nm). [9] 
PTMP-PMAA coated WO3-x nanodots New material WO3-x nanodots NIR absorption is enhanced in acidic and in hypoxic environments. [98] 
Fe3O4 nanoparticles New material Photothermal conversion efficiency of 6.4 % (at 808 nm). [103] 
Fe3O4 nanoparticles New material Fe3O4 nanoparticles functionalized with PEG produce a higher photoinduced heat than Fe3O4 
nanoparticles stabilized with PVP, PVA, polyglutamic acid, xalic acid, citrate, glutamic acid, 
and diethylene glycol. 
[109] 
PEGylated FeS nanoplates New material PEGylated FeS nanoplates have ≈ 17 times higher NIR absorption than Fe3O4 nanoparticles, 
thus producing a superior photoinduced heat (≈ 70 °C vs. ≈ 45 °C). 
[42] 
PEGylated FeSe2 New material PEGylated FeSe2 nanoparticles have ≈ 9 times higher NIR absorption than Fe3O4-based 
nanoparticles, thus generating a superior photoinduced heat (≈ 65 °C vs. ≈ 31 °C). 
[43] 
Denatured BSA coated Mn2+ doped iron 
oxide nanoparticles 
New material Photothermal conversion efficiency of 26.9 % (at 808 nm). [142] 
Fe(III)-gallic acid nanoparticles New material Photothermal conversion efficiency of 66.8 % (at 808 nm). [143] 
Pd nanocubes, nanoparticles, porous 
nanoparticles, and polyhedrons 
New material Porous Pd nanoparticles have a higher NIR absorption than Pd nanocubes, Pd nanoparticles, 
and Pd polyhedrons. 
[86] 
PEG coated gold-PANI nanoparticles New material PANI-based nanoparticles with a 16 nm gold core display the lowest NIR absorption at 
physiological pH (7.4) and high NIR absorption at acidic pH (6.5). Thereby, at pH 7.4 these 
generate a photoinduced heat to ≈ 40 °C while at pH 6.5 the temperature reaches ≈ 53 °C. 
[97] 
PVP coated PPy nanoparticles New material Photothermal conversion efficiency of 44.7 % (at 808 nm). [45] 
Tosylate doped poly(2TMOI-OEGMA)a)-PPy 
nanoparticles 
New material Photothermal transduction efficiency of 46.9 % (at 808 nm). [94] 
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PEDOT nanotubes and PEDOT:PSS 
nanoparticles 
New material PEDOT nanotubes have almost a 2-fold higher NIR absorption than PEDOT:PSS nanoparticles 
and thus generate a superior photoinduced heat (ΔT ≈ 16 °C vs. ΔT ≈ 8 °C). 
[144] 
PProDOS nanoparticles New material PProDOS nanoparticles have a slightly superior NIR absorption than PEDOT nanoparticles, 
thus producing a higher photoinduced heat (ΔT ≈ 10 °C vs. ΔT = 6 °C). 
[95] 
PCPDTBTb) and PCPDTBSec) nanoparticles New material PCPDTBT nanoparticles produce a slightly higher photoinduced heat than PCPDTBSe 
nanoparticles (ΔT ≈ 35 °C vs. ΔT ≈ 30 °C). 
[145] 
Pluronic® F-127 coated PCPDTBSe 
nanoparticles 
New material Pluronic® F-127 coated PCPDTBSe nanoparticles mediate a higher photoinduced heat  
(ΔT = 47 °C) than Pluronic® F-127 coated PCPDTBSe nanofibers (ΔT ≈ 35 °C) and PCPDTBSe 
nanoparticles (ΔT ≈ 35 °C). 
[47] 
PPDS nanoparticles  New material Photothermal conversion efficiency of 31.4 % (at 808 nm). [22] 
Gold nanopopcorn conjugated CNT New material The NIR absorption of the hybrid nanostructures is enhanced by increasing the content of 
gold nanopopcorn immobilized on CNT. 
[146] 
PEG-GO/CuS nanocomposites New material PEG-GO/CuS nanocomposites produce a higher photoinduced heat (ΔT = 24.9 °C) than GO 
(ΔT = 14 °C) due to their superior NIR absorption. 
[147] 
Polydopamine coated Fe3O4 nanoparticles New material Increasing the thickness of the polydopamine shell improves the NIR absorption of the hybrid 
nanostructures. 
Photothermal conversion efficiency of 13.1 % (at 808 nm). 
[103] 
PEGylated Fe-Fe3O4 nanoparticles New material Photothermal conversion efficiency of 20.3 % (at 808 nm). [148] 
PPy coated GNR incorporating Fe3O4 
nanoparticles 
New material Photothermal conversion efficiency of 23.9 % (at 808 nm). [149] 
PPy coated urchinlike gold nanoparticles New material Increasing the thickness of the PPy shell from 3.5 to 15.3 nm improves the photothermal 
conversion efficiency of the hybrid nanostructures from 18.6 to 27.5 % (at 808 nm). 
[101] 
PEGylated gold-Pd nanoplates New material Photothermal conversion efficiency of 28.6 % (at 808 nm). [126] 
Fe3O4 coated PPy nanoparticles New material Photothermal conversion efficiency of 39.15 % (at 808 nm). [150] 
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PPy coated Fe3O4 superstructures New material Increasing the thickness of the PPy shell improves the NIR absorption of the hybrid 
nanostructures; 
Nanostructures with a 16 nm thick PPy shell display the highest photothermal transduction 
efficiency (49 % at 808 nm). 
[102] 
Polydopamine coated PEI-gold nanostars New material Polydopamine coating improves the photothermal conversion efficiency of the PEI-gold 
nanostars from 36.1 to 49.9 % (at 808 nm). 
[104] 
Gold/Au2S nanoshells New material Photothermal transduction efficiency of ≈ 58 % (at 815 nm). [90] 
Gold nanopopcorn-iron oxide cluster 
nanoparticles 
New material Photothermal conversion efficiency of 61 % (at 808 nm). [151] 
PEGylated gold-silver nanostars New material Photothermal conversion efficiency of 79.01 % (at 808 nm). [99] 
PEGylated hollow gold-silver alloy  
urchin-shaped nanostructures 
New material Photothermal conversion efficiency of 80.4 % (at 808 nm). [100] 
PVA coated PPy nanoparticles Size 50 nm PVA coated PPy nanoparticles produce a higher photoinduced heat (ΔT = 29.4 °C) than 
their 75 nm equivalents (ΔT = 26.2 °C). 
[107] 
PEGylated MoS2 nanosheets Size 80 nm MoS2 nanosheets produce a higher photoinduced heat (ΔT ≈ 6 °C) than their 100 nm 
equivalents (ΔT ≈ 4.5 °C). 
[15] 
PEGylated WS2 quantum dots Size Reduction of WS2 particles’ size increases their NIR absorption and thus improves the 
photoinduced heat mediated by these nanostructures; 
WS2 quantum dots (3 nm) have a slightly higher photothermal conversion efficiency  
(44.3 %) than ≈ 28 nm WS2 nanosheets (40.6 %, at 808 nm), and thus generate a superior 
photoinduced heat (ΔT = 20 °C vs. ΔT ≈ 12 °C). 
[108] 
Pd-PVP nanosheets Size 4.4 nm Pd-PVP nanosheets have a higher photothermal conversion efficiency than 41 nm 
nanosheets (52 vs. 27.6 %, at 808 nm), thus producing a superior photoinduced heat  
(≈ 50 °C vs. ≈ 37.5 °C). 
[7] 
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PEGylated hollow gold-silver alloy  
urchin-shaped nanostructures 
Size Reduction of the hybrid structures’ size from 200 to 80 nm shifts their NIR absorption peak 
from 950 to 772 nm, thereby improving the photoinduced heat generated by these structures 
under 808 nm laser radiation. 
[100] 
Citrate and PEGylated Fe3O4 nanoparticles Size Increasing the size of citrate and PEG functionalized Fe3O4 nanoparticles from 120 to 380 nm 
produces a red-shift in their absorption and thus improves the photoinduced heat mediated 
by these materials. 
 
[109] 
Gold nanotubes Size Increasing the length of gold nanotubes from 300 to 530 nm produces a red-shift in their 
absorption; 
Gold nanotubes with a length of ≈ 370 nm display the highest absorption at 800 nm and thus 
were selected for cancer PTT using 800 nm radiation. 
[110] 
PEGylated rGO derivatives Chemical 
treatment 
rGO derivatives have about 3-4 times higher NIR absorption than non-reduced nGO and 
thereby generate a superior photoinduced heat (≈ 58 °C vs. ≈ 44 °C). 
[63] 
PEGylated rGONM Chemical 
treatment 
rGONM has about 4.2 times higher NIR absorption than reduced nGO, thus producing a 
superior photoinduced heat (≈ 57 °C vs. ≈ 42 °C). 
[50] 
Mn2+ doped PEGylated PB nanocubes Chemical 
treatment 
Mn2+ doping increases the NIR absorption of PEGylated PB nanocubes; 
Mn2+ doping of 15 % produces the highest increment in the NIR absorption of the PB nanocubes 
(≈ 2-fold at 808 nm). 
[111] 




Incorporation of Gd3+ in PB nanoparticles produces a red-shift in their absorption towards 
the NIR region. 
[112] 
Clustered Fe3O4 nanoparticles Assembling of 
nanostructures 
Clustered Fe3O4 nanoparticles have ≈ 3.6-fold higher NIR absorption than individual Fe3O4 









Self-assembled gold-based nanovesicles have a higher photothermal conversion efficiency 
than GNR (37 % vs. 22 %, at 808 nm), thus producing a superior photoinduced heat  
(ΔT ≈ 41 °C vs. ΔT = 24 °C). 
[113] 
Gold‒attapulgite nanocomposites Assembling of 
nanostructures 
Electrostatic assembly of gold nanospheres on the surface of attapulgite yields a composite 
with a photothermal conversion efficiency of 25.6 % (at 808 nm). 
[114] 
PEGylated chirality sorted (6,5) CNT Sorting of 
nanomaterials 
Chirality sorted (6,5) CNT have an enhanced NIR absorption, thus producing a higher 
photoinduced heat than non-sorted CNT (≈ 53 °C vs. ≈ 44 °C). 
[116] 
a) poly(2-(methacryloyloxy)ethylaminocarboxymethyl)thiophene-stat-oligo(ethylene glycol) methacrylate) (poly(2TMOI-OEGMA)); b) poly[4,4-bis(2-ethylhexyl)-cyclopenta[2,1-




Table 2.3. Strategies based on the optimization of the parameters related to the laser light. 
Nanomaterial Optimization Result Ref. 
PEGylated CsxWO3 nanorods Wavelength Even though PEGylated CsxWO3 nanorods have a higher absorbance at 980 nm than at 915 nm,  
the use of 915 nm light is beneficial since the 980 nm radiation has less penetration and induces a higher  
off-target heating. 
[119] 
PVP coated Rb0.27WO3 
nanorods 
 
Wavelength Even though PVP coated Rb0.27WO3 nanorods have a higher absorption at 980 nm than at 808 nm, the application 
of 808 nm light to irradiate the nanorods can produce a higher temperature variation than 980 nm radiation due 
to its higher penetration. 
[120] 
PVA coated PPy nanoparticles Power density Nanomaterials’ mediated PTT at a power density of 0.25 and 0.5 W cm-2 produces a hyperthermia to about 55 
and 60 °C, resulting in the elimination of mice’s tumors; 
PTT at a power density of 0.1 W cm-2 mediates a hyperthermia to ≈ 42 °C, leading to a reduction of the tumor 
growth. 
[117] 




Nanomaterials’ mediated PTT at a power density of 1 W cm-2 (every three days during 9 days) mediates a higher 
hyperthermia (ΔT ≈ 45 °C) and a better therapeutic outcome than PTT at 0.5 W cm-2 (ΔT ≈ 33 °C). 
[93] 
C18-PMH-mPEG coated CNT Power density 
 
Irradiation sites 
Irradiation of tumor zone and tumor-adjacent lymph node results in an improved therapeutic effect; 
The lymph node was irradiated at a higher power density due to its deeper location and due to CNT lower 
accumulation at this site (lymph node: 0.8 W cm-2; tumor: 0.5 W cm-2). 
[121] 
Chitosan-Pluronic® F-68 
conjugates encapsulating GNR 
Irradiation 
sessions 
Irradiation of the tumor zone at 24 and 48 h p.i. of nanoparticles leads to tumor eradication. [11] 




Laser irradiation once a day during 19 days elicits a potent therapeutic effect. [68] 
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Laser irradiation every two days during 14 days elicits a potent therapeutic effect. [72] 
PEGylated WO2.9 nanorods Irradiation 
sessions 





Irradiation of the tumor zone at 10 min after administration of DSPE-PEG-CREKA coated CNT (fibrin targeted 
CNT) enhances their tumor accumulation by about 3.8-fold; 
Irradiation of the tumor zone at 10 min after administration of DSPE-PEG coated CNT improves their tumor 
accumulation by about 2.6-fold; 
Mice administered with these materials were irradiated multiple times (at 10 min and on day 3, 6 and 9 p.i.) to 
take advantage of these phenomena. 
[122] 




Irradiation of the tumor zone at 8 h p.i. of HA-WO3 nanoparticles produces the highest hyperthermia (50 °C). [9] 
PVP coated CuS nanodots Irradiation 
onset 
PVP coated CuS nanodots achieve their maximum tumor accumulation (≈ 3.6 % ID g-1) at 2 h p.i. and PTT at this 
time point leads to tumor eradication with only 2 minutes of NIR laser irradiation. 
[14] 




HA-g-PEG coated PB hollow nanocubes achieve their maximum tumor accumulation at 24 h p.i. and PTT at this 






PEGylated Cu2-xSe nanoparticles achieve their maximum tumor accumulation (4.4 % ID g-1) at 12 h p.i. and PTT 
at this time point leads to tumor eradication. 
[84] 




GSH functionalized MoS2 nanodots achieve their maximum tumor accumulation (≈ 5 % ID g-1) at 4 h p.i. and PTT 
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2.9. Supplementary Information 
Table S.2.1. In vivo assays data of some nanomaterials used in cancer PTT. 
Type of nanomaterial Tumor model Administration 
route 





PEGylated GNR MDA-MB-435 
tumor-bearing 
mice 
i.v. 20 mg kg-1 810 nm, 2 W cm-2,  
5 min 
≈ 70 °C Tumor 
eradication 
[1] 





i.v. 10 mg kg-1 800 nm, 0.4 W cm-2,  
3 min 
N.A. Tumor growth 
reduced 
[2] 
PEGylated gold nanohexapods MDA-MB-435 
tumor-bearing 
mice 
i.v. 800 µg 808 nm, 1.2 W cm-2,  
10 min 
≈ 56 °C Tumor 
eradication 
[3] 




i.v. 300 µg 808 nm, 2 W cm-2,  
5 min 
ΔT ≈ 34 °C Tumor 
eradication 
(for 5 in 6 mice) 
[4] 
PEGylated gold bellflowers 4T1 
tumor-bearing 
mice 
i.t. 20 µg 808 nm, 0.5 W cm-2,  
5 min 
≈ 52 °C Tumor 
eradication 
[5] 





i.v. 75 µg 808 nm, 1.6 W cm-2,  
5 min 





Chitosan-Pluronic® F-68 conjugates 




i.v. 100 µg 808 nm, 4 W cm-2,  










i.v. 250 µg 850 nm, 1 W cm-2,  
10 min, once a day 
during 19 days 
≈ 47 °C Tumor 
regression 
[8] 










Nanovesicles assembled using PEG-PCL 




i.t. 20 µg 808 nm, 0.5 W cm-2,  
5 min 
ΔT ≈ 18 °C Tumor 
eradication 
[10] 
Au‒attapulgite nanocomposites A549 
tumor-bearing 
mice 
i.t. 100 µg 808 nm, 0.5 W cm-2,  
15 min 
≈ 48 °C Tumor 
regression 
[11] 
PEGylated gold nanostars functionalized 





i.v. 130 µg 790 nm, 0.8 W cm-2,  
5 min, every two days 
during 14 days 








i.v. ≈ 2×10–7 M 
(100 µL) 
808 nm, 1 W cm-2,  
5 min 
≈ 56 °C Tumor 
eradication 
[13] 




i.v. 100 µg 808 nm, 1 W cm-2,  
5 min 




DSPE-PEG-Annexin V functionalized CNT 4T1 
tumor-bearing 
mice 
i.v. ≈ 16.35 µg 
0.8 mg kg-1 




(for 4 in 6 mice) 
[15] 




i.v. 4 mg kg-1 808 nm, 3.5 W cm-2,  
90 sec, on day 0, 3, 6 
and 9 
 
≈ 55 °C Tumor 
regression 
[16] 
C18-PMH-mPEG coated CNT 4T1 
tumor-bearing 
mice 
i.t. 4.25 µg 
0.2 mg kg-1 
Tumor: 
808 nm, 0.5 W cm-2,  
10 min 
Lymph node: 
808 nm, 0.8 W cm-2,  
10 min 
Tumor: 
≈ 55 °C 
Lymph node: 
≈ 47 °C 
Tumor 
eradication 
(for 6 in 7 mice) 
[17] 
C18-PMH-mPEG coated (6,5) CNT 4T1 
tumor-bearing 
mice 
i.v. ≈ 4 µg 
0.254 mg kg-1 
980 nm, 0.6 W cm-2,  
5 min 
≈ 51 °C Tumor 
eradication 
(for 3 in 4 mice) 
[18] 
PEGylated nGO 4T1 
tumor-bearing 
mice 
i.v. 400 µg 
20 mg kg-1 
808 nm, 2 W cm-2,  
5 min 
≈ 50 °C Tumor 
eradication 
[19] 
C18-PMH-mPEG coated reduced nGO 4T1 
tumor-bearing 
mice 
i.v. 400 µg 
20 mg kg-1 
808 nm, 0.15 W cm-2,  
5 min 
≈ 48 °C Tumor 
eradication 
[20] 
HA conjugated nGO B16F1 
tumor-bearing 
mice 







Pluronic® F-127-FA coated nGO KB 
tumor-bearing 
mice 
i.v. 10 mg kg-1 808 nm, 2 W cm-2,  
10 min 
≈ 60 °C Tumor 
eradication 
(for 2 in 3 mice) 
[22] 
Pluronic® F-127-FA and Pluronic®  




i.v. 7.5 mg kg-1 808 nm, 2 W cm-2,  
10 min 
≈ 57 °C Tumor 
eradication 
[23] 









DSPE-PEG coated Cu2-xS nanodots HeLa 
tumor-bearing 
mice 
i.v. ≈ 200 µg 
10 mg kg-1 
980 nm, 1.41 W cm-2,  
5 min 
≈ 69 °C Tumor 
eradication 
[25] 
Silica coated Cu1.75S 4T1 
tumor-bearing 
mice 
i.t. 1.1 mg 808 nm, 1 W cm-2,  
10 min 









i.t. 40 ppm 
(100 µL) 
980 nm, 0.72 W cm-2,  
7 min 
≈ 46 °C N.A. [27] 
PVP coated CuS nanodots 4T1 
tumor-bearing 
mice 
i.v. 100 µg 
4 mg kg-1 
808 nm, 2 W cm-2,  
2 min 
≈ 46 °C Tumor 
eradication 
[28] 
FA coated CuS nanoaparticles KB 
tumor-bearing 
mice 
i.v. 40 µg 808 nm, 1.5 W cm-2,  
2 min 
≈ 57 °C N.A. [29] 
 60 
Ferritin-CuS nanocages U87MG 
tumor-bearing 
mice 
i.v. N.A. 808 nm, 0.8 W cm-2,  
5 min 
≈ 65 °C Tumor 
eradication 
[30] 
PEGylated Cu nanowires CT26 
tumor-bearing 
mice 
i.t. 125 – 150 µg 808 nm, 1.5 W cm-2,  
6 min 
≈ 56 °C Tumor growth 
reduced 
[31] 
PEGylated Cu2-xSe nanoparticles 4T1 
tumor-bearing 
mice 
i.v. 100 µg 808 nm, 1.5 W cm-2,  
6 min 
≈ 58 °C Tumor 
eradication 
[32] 




i.v. 10 mg kg-1 980 nm, 0.8 W cm-2,  
5 min 
≈ 51 °C Tumor 
eradication 
[33] 
PEGylated MoS2 nanosheets 4T1 
tumor-bearing 
mice 
i.v. 200 µg 808 nm, 1 W cm-2,  
5 min 
N.A. Tumor growth 
inhibition 
[34] 
PEGylated MoO3-x hollow nanospheres PANC-1 
tumor-bearing 
mice 
i.v. 10 mg kg-1 808 nm, 1 W cm-2,  
10 min 
≈ 48 °C Tumor 
regression 
[35] 





i.t. 2 mg kg-1 808 nm, 0.9 W cm-2,  
7 min 













1.25 mg kg-1 
 
i.v.: 
20 mg kg-1 
808 nm, 0.7 W cm-2,  
10 min 










1 mg kg-1 808 nm, 1 W cm-2,  
3 min 
≈ 55 °C Tumor 
eradication 
[38] 
Radar-like MoS2 nanoparticles 4T1 
tumor-bearing 
mice 
i.t. 100 ppm 
(100 µL) 
808 nm, 0.5 W cm-2,  
10 min 
N.A. Tumor growth 
reduced 
[39] 
GSH functionalized MoS2 nanodots 4T1 
tumor-bearing 
mice 
i.v. ≈ 100 µg 808 nm, 1 W cm-2,  
5 min 
≈ 52 °C Tumor 
eradication 
[40] 
(NH4)xWO3 nanocubes 4T1 
tumor-bearing 
mice 
i.t. ≈ 500 µg 
5 mg kg-1 
1064 nm, 1 W cm-2,  
2 min, every three days 
during 9 days 
ΔT ≈ 45 °C Tumor 
regression 
[41] 
PEGylated WO2.9 nanorods HeLa 
tumor-bearing 
mice 
i.t. 20 mg kg-1 980 nm, 0.35 W cm-2,  
5 min, every two days 
during 14 days 
ΔT = 20 °C Tumor 
eradication 
[42] 




i.t. 25 µg 915 nm, 0.72 W cm-2,  
10 min 
≈ 48 °C N.A. [43] 
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15 mg 1064 nm, 0.75 W cm-2,  
10 min 









i.v. ≈ 750 µg 
30 mg kg-1 
808 nm, 2 W cm-2,  
5 min 
50 °C Tumor 
regression 
[45] 







2 mg kg-1 
i.v.:  
400 µg, 
20 mg kg-1 
808 nm, 0.8 W cm-2,  
5 min 
≈ 65 °C 




C18-PMH-PEG coated WS2 nanoflakes 4T1 
tumor-bearing 
mice 
i.v. 20 mg kg-1 808 nm, ≈ 0.3 W cm-2,  
20 min 
≈ 45 °C Tumor growth 
reduced 
[47] 
PVP-coated Rb0.27WO3 nanorods PANC-1 
tumor-bearing 
mice 
i.t. N.A. 808 nm, 1 W cm-2,  
10 min 
≈ 50 °C Tumor growth 
reduced 
[48] 
PTMP-PMAA coated WO3-x nanodots 4T1 
tumor-bearing 
mice 
i.v. 400 µg 808 nm, 0.75 W cm-2,  
10 min 
ΔT = 25 °C Tumor growth 
reduced 
[49] 
PEGylated WS2 quantum dots BEL-7402 
tumor-bearing 
mice 
i.t. 40 µg 808 nm, 1 W cm-2,  
10 min 





Mn2+ doped PEGylated PB nanocubes 4T1 
tumor-bearing 
mice 
i.v. 20 mg kg-1 808 nm, 0.8 W cm-2,  
5 min 
≈ 55 °C Tumor 
eradication 
[51] 





i.t. 50 ppm 
(30 µL) 
808 nm, 0.58 W cm-2,  
10 min 
ΔT ≈ 16 °C Tumor 
eradication 
[52] 
PEGylated PB nanocubes 4T1 
tumor-bearing 
mice 
i.v. 200 µg 
10 mg kg-1 
808 nm, 0.8 W cm-2,  
5 min 
≈ 62 °C Tumor 
eradication 
[53] 





i.v. 10 mg kg-1 808 nm, 1 W cm-2,  
10 min 
≈ 53 °Cb) Tumor growth 
inhibition 
[54] 
Clustered Fe3O4 nanoparticles A549 
tumor-bearing 
mice 
i.t. 50 µg 808 nm, 5 W cm-2,  
3 min 
≈ 56 °C Tumor growth 
reduced 
[55] 





i.v. 2.5 mg kg-1 808 nm, 5 W cm-2,  
5 min 
≈ 53 °C Tumor 
regression 
[56] 
PEGylated Fe-Fe3O4 nanoparticles HeLa 
tumor-bearing 
mice 
i.v. 1.46 g kg-1 808 nm, 0.31 W cm-2,  
10 min, once a day 
during 14 days 
ΔT ≈ 7 °C Tumor growth 
reduced 
[57] 





i.t. 40 mg kg-1 808 nm, 1.5 W cm-2,  
5 min 




Fe(III)-gallic acid nanoparticles 4T1 
tumor-bearing 
mice 
i.v. 4 x 10-3 M 
(200 µL) 
808 nm, 1 W cm-2,  
10 min 
ΔT ≈ 20 °C Tumor 
eradication 
[59] 
PEGylated FeS nanoplates 4T1 
tumor-bearing 
mice 
i.v. 20 mg kg-1 808 nm, 1 W cm-2,  
5 min 
≈ 60 °C Tumor 
eradication 
[60] 
PEGylated FeSe2 nanoparticles 4T1 
tumor-bearing 
mice 
i.t. 80 µg 
4 mg kg-1 
808 nm, 0.8 W cm-2,  
5 min 
≈ 63 °C Tumor 
eradication 
[61] 





i.v. 18 mg kg-1 808 nm, 2 W cm-2,  
3 min 
≈ 47 °C Tumor 
eradication 
[62] 
GSH functionalized Pd nanosheets 4T1 
tumor-bearing 
mice 
i.v. 400 µg 808 nm, 1 W cm-2,  
5 min 
≈ 56 °C Tumor 
eradication 
[63] 
PEG-SH functionalized Pd nanosheets S180 
tumor-bearing 
mice 
i.v. 300 µg 808 nm, 0.4 W cm-2,  
5 min 
≈ 52 °C Tumor 
eradication 
[64] 
PEG coated gold-PANI nanoparticles H22 
tumor-bearing 
mice 
i.t. 100 μg mL-1 808 nm, 2 W cm-2,  
5 min 
















HA-PANI nanoparticles HeLa 
tumor-bearing 
mice 









i.v. 200 µg 
10 mg kg-1 
808 nm, 1 W cm-2,  
5 min 
≈ 65 °C Tumor 
eradication 
[68] 
PVA-PPy nanoparticles 4T1 
tumor-bearing 
mice 
i.t. 40 µg 
2 mg kg-1 
808 nm, 0.25 W cm-2,  
5 min 
≈ 55 °C Tumor 
eradication 
[69] 









808 nm, 1.5 W cm-2,  
10 min 
i.t.: ≈ 55 °C 




PEGylated PEDOT:PSS nanoparticles 4T1 
tumor-bearing 
mice 
i.v. 200 μg 
10 mg kg-1 
808 nm, 0.5 W cm-2,  
5 min 
≈ 51 °C Tumor 
eradication 
[71] 
DSPE-mPEG coated PFTTQ nanoparticles HeLa 
tumor-bearing 
mice 
i.t. 40 μg 808 nm, 0.75 W cm-2,  
10 min 
≈ 45 °C Tumor 
eradication 
[72] 




i.v. 15 mg kg-1 808 nm, 0.5 W cm-2,  
4 min 




a) laser parameters were different for this assay (790 nm, 1.5 W cm-2, 3 min). b) laser parameters were different for this assay (808 nm, 0.8 W cm-2, 10 min). 
Intratumoral injection (i.t.); intravenous injection (i.v.); not available (N.A.). 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy PEG) (DSPE-mPEG); PEGylated poly(maleic anhydride-alt-1-octadecene) (C18-PMH-mPEG); pentaerythritol 
tetrakis (3-mercaptopropionate)-terminated poly(methacrylic acid) (PTMP-PMAA); poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS); poly(9,9-bis(4-(2-
ethylhexyl)phenyl)fluorene-alt-co-6,7-bis(4-(hexyloxy)phenyl)-4,9-di(thiophen-2-yl)-thiadiazoloquinoxaline) (PFTTQ); poly(acrylic acid) (PAA); polyaniline (PANI); 
poly(caprolactone) (PCL); poly(ethyleneimine) (PEI); poly(ethylene glycol) (PEG); polypyrrole (PPy); poly(vinyl alcohol) (PVA); poly(vinylpyrrolidone) (PVP); red blood cell 
(RBC); reduced glutathione (GSH).  
PEG-GO/CuS nanocomposites HeLa 
tumor-bearing 
mice 
i.t. 50 μg 980 nm, 1 W cm-2,  
10 min 
N.A. Tumor growth 
reduced 
[74] 
Polydopamine coated Fe3O4 nanoparticles A549 
tumor-bearing 
mice 
i.t. 50 μg 808 nm, 6.6 W cm-2,  
3 min 
≈ 60 °C Tumor 
regression 
[75] 
Fe3O4 coated PPy nanoparticles SW-1990 
tumor-bearing 
mice 
i.t. 25 μg 808 nm, 0.25 W cm-2,  
5 min 
≈ 49 °C N.A. [76] 





i.t. 3 μg 808 nm, 1 W cm-2,  
5 min 
≈ 70 °C Tumor 
eradication 
[77] 
Polydopamine coated PEI-gold nanostars HeLa 
tumor-bearing 
mice 
i.t. 5.6 mM 
(100 μL) 
808 nm, 1.3 W cm-2,  
10 min 
≈ 59 °C Tumor 
eradication 
[78] 
PEGylated gold-silver nanostars MCF-7 
tumor-bearing 
mice 
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3.1. Abstract  
Graphene family nanomaterials’ (GFN) ability to interact with near-infrared light has propelled 
their application in cancer PTT. Furthermore, the graphitic lattice of GFN can adsorb different 
types of molecules, which has motivated their use in cancer drug delivery. However, the direct 
application of GFN in cancer therapy is severely hindered by their poor colloidal stability,  
sub-optimal safety, inefficient tumor uptake and non-selectivity towards cancer cells. To 
overcome these limitations, GFN have been functionalized with different types of materials. 
This chapter is focused on the different functionalizations used in the design of GFN aimed for 
cancer therapy, disclosing their role on surpassing the critical issues related to GFN-based 
therapies. 
 




GFN have been receiving a growing attention in various fields, including cancer therapy [1-6]. 
In this context, GFN have been mostly explored as photothermal agents due to their NIR 
absorption and as delivery vehicles due to their ability to adsorb drugs (and other molecules) 
on their surface [7, 8]. 
Despite the enormous potential of GFN, the poor water solubility and weak stability of these 
materials limit their use in cancer therapy [9, 10]. Moreover, as-synthesized GFN are not suited 
to become passively accumulated in the tumor site nor tailored to be selectively internalized 
by cancer cells [11-14]. Furthermore, depending on the surface chemistry, size or impurities 
content, some GFN have shown to be cytotoxic [15-18]. To overcome these limitations, 
researchers have been modifying the surface of GFN with a variety of materials. 
In the following sub-sections, the different functionalizations performed to allow an efficient 
application of GFN in cancer therapy and enhance their therapeutic performance and safety 
are discussed. Firstly, the physicochemical properties of GFN as well as the most convenient 
routes for functionalizing these materials are analyzed (section 3.3). Afterward, the 
functionalization of GFN for application in cancer therapy and its implications are discussed 
(section 3.4). The functionalizations performed to improve GFN hydrophilicity and colloidal 
stability are discussed in section 3.4.1., and those that aim to improve their biocompatibility 
and hemocompatibility are analyzed in section 3.4.2. The approaches employed to enhance the 
blood circulation time and tumor uptake of GFN are reviewed in section 3.4.3. The 
functionalizations that improve GFN cellular uptake and selectivity towards cancer cells are 
discussed in section 3.4.4. Finally, an overview about the future directions are presented in 
section 3.5. For the sake of brevity, this chapter does not cover modifications that aim to 
improve GFN tumor accumulation by means of external forces (e.g. by using magnetic fields), 
nor those that enhance GFN therapeutic performance through the incorporation of other 
nanostructures (e.g. gold nanostructures).  
 
3.3. GFN: physicochemical properties and 
functionalization routes  
GO is probably the most applied GFN for cancer therapy and it is also used as the precursor for 
the synthesis of other graphene-based nanomaterials. GO is composed by a monolayer of 
graphite containing several types of oxygen functional groups such as carboxyl, hydroxyl or 
epoxy groups (Figure 3.1). This material is generally produced through the chemical oxidation 
of graphite and exfoliation of the resulting material (graphite oxide), into a single layer 
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material (GO). Over the years, several methods have been developed to synthesize GO, being 
the Hummer’s and the improved Hummer’s (also known as Tour method) methods the most 
commonly employed [19, 20]. 
 
  
Figure 3.1. Schematic representation of the synthesis of GO and rGO. The reduction of GO provokes 
alterations on physicochemical properties of the materials, which impact on their application in cancer 
therapy. The most commonly used routes for functionalizing GO and rGO are also represented.  
N-Hydroxysuccinimide (NHS). 
 
GO aromatic lattice can adsorb several types of molecules through hydrophobic interactions or 
π-π stacking. A variety of cancer-relevant molecules such as chemotherapeutic drugs or 
proteins can be loaded on GO by exploring these non-covalent interactions [7]. Although 
therapeutic agents may also be conjugated to the carboxyl-groups of GO, such approach is not 
usually pursued since these groups may be required for the functionalization of GO. 
Furthermore, the NIR absorption of GO also allows its application as a photothermal agent or 
as a light-responsive delivery vehicle in cancer therapy [21, 22]. 
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However, the direct applicability of GO in cancer therapy is limited by its poor colloidal stability 
since it promptly precipitates in biological fluids [9]. Moreover, GO has a sub-optimal 
biocompatibility and hemocompatibility, as well as inefficient tumor uptake and non-selectivity 
towards cancer cells (discussed in detail in section 3.4). These limitations can be surpassed by 
functionalizing GO with different types of materials (discussed in section 3.4). Based on its 
structure, GO is generally functionalized through the formation of amide bonds established 
between the carboxyl groups of GO and primary amines of other materials using  
1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC; a water soluble carbodiimide 
crosslinker) chemistry [23]. These oxygen functional groups may also be conjugated with 
polymerization initiators, allowing the direct growth of polymers on GO surface [24, 25]. 
Alternatively, the aromatic lattice of GO allows its functionalization with amphiphilic materials 
by exploring hydrophobic interactions or π-π stacking [26].  
GO derivatives such as base treated GO and carboxylated GO (GO-COOH) have also been 
explored in cancer therapy due to their improved properties [27-29]. Base treated GO is 
obtained by washing GO with sodium hydroxide, a process that removes the oxidation debris 
from GO lattice, improving its loading capacity [30, 31]. GO-COOH is produced by reacting GO 
with chloroacetic acid or sodium chloroacetate [32-34]. This modification introduces additional 
carboxyl groups for chemical conjugation and improves GO NIR absorption [32-34]. However, 
these GO derivatives suffer from the same stability, biocompatibility, tumor uptake and 
selectivity problems that affect GO, which impose their functionalization. 
rGO is another GFN applied in cancer therapy. rGO is generally obtained by treating GO with 
reducing agents such as hydrazine hydrate (for the sake of clarity, rGO will refer to rGO attained 
using hydrazine hydrate) [10, 35]. Other reducing agents such as ascorbic acid or dopamine 
have also been successfully applied in the reduction of GO [12, 36-38]. The reduction of GO 
aims to restore its graphitic lattice by removing the oxygen functional groups, and such 
procedure drastically changes the properties of the materials (Figure 3.1). In fact, when 
compared to GO and its derivatives, rGO displays a higher NIR absorption and loading capacity, 
conferring an improved photothermal and drug delivery potential to this material [10, 39]. 
However, rGO has a weak water solubility (and stability) and its application in cancer therapy 
is also hindered by the same factors that affect GO, thus demanding its functionalization 
(discussed in detail in section 3.4). As rGO has limited (or close to none) oxygen functional 
groups available for conjugation, this material is generally functionalized with amphiphilic 
polymers through non-covalent interactions (hydrophobic interactions or π-π stacking) [23, 40-
42]. Exceptionally, GO reduced by dopamine can be covalently functionalized with materials 
containing amine or thiol groups through catechol chemistry (reaction of the oxidized catechol 
groups with amine/thiol groups through Michael addition or Schiff base reactions) [37, 43]. 
Graphene oxide nanoribbons (GONR) and reduced graphene oxide nanoribbons (rGONR) are 
other GFN explored in cancer therapy. GONR are obtained by unzipping multiwall carbon 
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nanotubes (MWCNT) through means of oxidation and can be functionalized by the same 
procedures described for GO [44]. GONR can also be reduced to rGONR, a modification that 
also improves their NIR absorption and photothermal capacity but reduces their solubility [45]. 
Similar to rGO, rGONR are also usually functionalized with amphiphilic materials [45]. 
Overall, these functionalization routes are widely applied when preparing GFN aimed for cancer 
therapy due to their simplicity, ability to be performed in aqueous solutions and compatibility 
with the compounds to be bonded to GFN. Other functionalization approaches that are not 
within the scope of this chapter are thoroughly described elsewhere [46-48]. 
 
3.4. Functionalization of GFN for application in 
cancer therapy 
The functionalization of GFN enables a safer administration of these nanomaterials and ensures 
that these are able to overcome the different biological barriers required for an efficient and 
selective accumulation in the tumor cells (Figure 3.2). The different functionalizations 
performed to improve GFN properties and their implications are reviewed in the next  
sub-sections.  
 
3.4.1. Functionalizations used to improve the hydrophilicity and 
colloidal stability of GFN 
GFN should be soluble in aqueous solutions and must remain stable (i.e. preserve their 
physicochemical properties) in the medium used for their administration (usually phosphate 
buffered saline (PBS) or NaCl solutions) and in biological fluids (usually simulated using fetal 
bovine serum (FBS) supplemented cell culture medium) - Figure 3.2. Although GO has adequate 
solubility in water (due to its oxygen-functional groups), it precipitates in saline solutions and 
in physiological media [9]. To overcome this limitation, GO is usually covalently functionalized 
with hydrophilic polymers containing amine groups through the formation of amide bonds. In 
this regard, branched amine terminated PEG or amine terminated Dextran have been widely 
explored by researchers since these polymers are capable of entailing onto GO materials a 
lasting stability across several fluids [9, 10, 23]. Alternatively, amphiphilic PEGylated polymers 
such as Pluronic® F-127, Poloxamer 188 (Pluronic® F-68) or D-α-Tocopheryl polyethylene glycol 
1000 succinate (TPGS) can also be used for improving the colloidal stability of GO derivatives 
[26, 28, 49]. Other materials capable of improving the stability of GO-based nanomaterials are 
described in Table 3.1 (presented after the conclusion section). 
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Figure 3.2. Schematic representation of the different barriers that functionalized GFN must overcome in 
order to become accumulated in the tumor and internalized by cancer cells. 
 
The reduced forms of GO-based materials have a poor solubility in aqueous solutions [10]. 
Similar to GO, rGO derivatives also precipitate in saline and physiological media [10]. To address 
these limitations, rGO has been non-covalently functionalized with PEG-based amphiphilic 
polymers such as C18-PMH-PEG and with amphiphilic polymers based on Dextran and HA [23, 40-
42]. rGO coated with bovine serum albumin (BSA) also displays an improved solubility and 
colloidal stability [23, 50]. Alternatively, some synthetic routes allow the simultaneous 
reduction and functionalization of GO derivatives with hydrophilic polymers, which is a 
convenient approach to produce functionalized rGO-based materials with aqueous solubility 
and improved colloidal stability [28, 51-53]. Other types of coatings used for improving the 
solubility and colloidal stability of rGO-based nanostructures are also described in Table 3.1.  
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3.4.2. Functionalizations used to improve the biocompatibility 
and hemocompatibility of GFN 
The biocompatibility of GFN is a topic under intense investigation, since it is affected by the 
intrinsic properties of the materials (e.g. surface chemistry, size, stability, purity/impurities) 
and by factors related to the assays conditions (e.g. culture conditions/presence of serum, cell 
line, type of assay used to evaluate the cytotoxicity) - extensively reviewed elsewhere [15-18, 
54]. In general, GO-based nanomaterials tend to display a better cytocompatibility than their 
reduced equivalents [37, 52]. Part of the cytotoxicity induced by rGO derivatives can be 
explained by the poor solubility of rGO and by the high toxicity of hydrazine hydrate, which is 
used in the majority of the reduction processes [37, 52]. For instance, GO reduced by hydrazine 
hydrate and GO reduced by hydrothermal treatment with glucose have very distinct effects on 
cells, being the latter less cytotoxic [52]. 
To diminish the safety issues associated with the use of GFN, these materials have been 
functionalized with different types of hydrophilic and biocompatible materials (please see 
Table 3.2 for further details; presented after the conclusion section). For instance, the coating 
of GO and rGO with BSA or PEG (branched amine terminated PEG for GO; C18-PMH-PEG for rGO) 
greatly improves the cytocompatibility of these materials towards macrophage, fibroblast and 
liver cell lines [23]. In in vivo studies, the administration of GO conjugated with branched amine 
terminated PEG by intravenous (i.v.; 20 mg kg-1) and intraperitoneal (i.p.; 50 mg kg-1) injections 
did not induce toxicity, even after 90 days of p.i. [55, 56]. An excellent in vivo biocompatibility 
was also reported for rGO coated with C18-PMH-PEG [40, 56]. BSA coated rGO and GO conjugated 
with amine modified Dextran did also not elicit any noticeable alterations on mice organs [50, 
57]. 
Despite the excellent in vivo biocompatibility displayed by some functionalized GFN, their  
long-term toxicity is a major concern since these materials are regarded as non-biodegradable. 
Zhuang Liu group unveiled that GO conjugated with PEG-SS-NH2 can suffer  
oxidative-biodegradation catalyzed by peroxidases after the removal of the detachable PEG 
coating under reductive conditions (like those found intracellularly), leading to their fast 
clearance from mice body [23]. In contrast, authors found that GO and rGO functionalized with 
non-detachable PEG- and BSA-based coatings did not suffer oxidative-biodegradation 
presumably due to the inability of the enzymes to reach GFN surface [23].  
On the other hand, in recent studies it was demonstrated that PEGylated GFN can induce 
immunologic reactions [58, 59]. Im et al. reported that rGO coated with a C18-PMH-PEG based 
polymer suffers fast blood clearance at the time of its re-injection [58]. This phenomenon is 
known as accelerated blood clearance, and it has been associated to several PEGylated 
materials [60]. In this case, authors verified that the production of anti-PEG IgM by mice at the 
time of the first injection of the PEG coated rGO mediated the clearance of the materials in 
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the subsequent injections [58]. In another study, GO conjugated with amine terminated 
methoxy-PEG (mPEG) induced cytokine secretion by macrophages despite not being 
internalized by these cells [59]. Recently, it was unveiled that poly(acrylic acid) (PAA) 
functionalized GO displays a superior biocompatibility under in vivo conditions in comparison 
to PEGylated GO, which should motivate the continuous pursuit for the optimal surface coatings 
for GFN [11]. 
Although the hemolytic potential of GFN depends on multiple factors (e.g. materials size, 
oxygen content, surface charge), both GO and rGO based materials can induce the lysis of RBC 
[16]. In this regard, GO is generally a stronger inducer of RBC hemolysis than rGO [61]. For 
instance, a concentration as low as 12.5 µg mL-1 of GO can induce a hemolysis of  12 %, while 
100 µg mL-1 of rGO induces  13 % of hemolysis [61]. On the other hand, rGO may also induce 
blood clumping due to its poor solubility [16]. In this way, the functionalization of GFN surface 
is also crucial to address their blood compatibility problems. In this regard, the modification of 
GO surface with heparin or bovine α-lactalbumin can suppress in vitro the hemolysis of RBC 
(see Table 3.2 for further details) [62, 63]. Regarding rGO based materials, their 
functionalization with PVA, BSA or heparin also reduces the in vitro hemolytic potential of these 
materials [37, 62, 64]. The good in vivo biocompatibility displayed by GFN coated with PAA 
[11], PEG [55, 56], and Dextran [65] based materials further confirms that these materials can 
mitigate the blood compatibility problems associated with GFN, as attested by hematological 
analysis (Table 3.2). 
 
3.4.3. Functionalizations used to improve the blood circulation 
time and tumor accumulation of GFN 
GFN are not suited to overcome the biological barriers required to achieve a suitable tumor 
accumulation. Upon introduction in the blood stream, GFN adsorb proteins (including opsonins) 
[11] and suffer internalization by macrophages [12], leading to their clearance. In this regard, 
the functionalization of GFN with non-fouling and stealth materials such as Dextran [66], PEG 
[11, 59], PVP [12], or PAA [11] can greatly reduce these interactions, and thus may improve 
materials’ blood circulation time.  
During circulation, nanomaterials may extravasate through the 200-1200 nm fenestrae present 
on the tumor vasculature and may become retained at the tumor site due to the ineffective 
lymphatic drainage present on this zone [8, 67, 68]. This process is known as tumor 
accumulation through the EPR effect and it is often regarded as a process that is strongly 
influenced by nanomaterials’ size [8, 68]. Besides the extravasation through the static pores 
present on the tumor vasculature, recently it was unveiled that nanomaterials may reach the 
tumor zone by taking advantage from the dynamic and short-lived bursts (also termed 
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eruptions) that occur in tumor-associated vessels, which drive the blood flow into the tumor 
interstitial space [69] – Figure 3.2. Thus, the functionalization of GFN surface to achieve higher 
blood circulation times can lead to an improved tumor accumulation since it will increase the 
likelihood of the materials to benefit from the EPR effect and from the dynamic vents that may 
occur on tumor vasculature. In this regard, the functionalization of GFN with PEG based coatings 
can greatly improve their blood circulation time and thus their tumor accumulation (Table 3.3; 
presented after the conclusion section). Yang et al. observed that GO covalently functionalized 
with branched amine terminated PEG displays a t1/2 of  1.5 h, being able to achieve a high 
tumor uptake [21]. Due to its good tumor-homing capacity, the PTT mediated by PEGylated GO 
led to the eradication of mice’s tumor (20 mg kg-1, 808 nm, 2 W cm-2, 5 min) [21].  
In a subsequent work, authors investigated the biodistribution in tumor bearing mice of 
PEGylated GO (covalently functionalized with branched amine terminated PEG) and  
C18-PMH-PEG coated rGO [10]. In this case, PEGylated GO demonstrated a second phase blood 
circulation half-life (t’1/2) of about 5.8 h (t1/2  0.29 h), resulting in a tumor accumulation lower 
than 1 % ID g-1 [10]. In contrast, C18-PMH-PEG coated rGO displayed a up to  2.9-fold longer 
blood circulation time (t’1/2  16.7 h; t1/2  0.51 h), leading to a tumor accumulation of  
≈ 6 % ID g-1, a profile that may be attributed to a denser surface functionalization conferred by 
the C18-PMH-PEG coating [10]. Due to its higher tumor accumulation and superior photothermal 
capacity, C18-PMH-PEG coated rGO was able to induce tumor eradication at a power density of 
only 0.15 W cm-2 (808 nm, 5 min, 20 mg kg-1), while PEGylated GO only mediated a slight 
reduction of the tumor growth (808 nm, 0.15 W cm-2, 5 min, 20 mg kg-1) [10]. Later, Xu et al. 
conjugated an additional PEG segment to C18-PMH-PEG coated rGO (double PEGylation), which 
increased the blood circulation time of this nanomaterial from t1/2 = 0.19 h (t’1/2 = 18.8 h) to 
t1/2 = 0.35 h (t’1/2 = 27.7 h) [70]. This improvement on nanomaterials’ blood circulation time 
led to a  1.8-fold increase on their tumor-homing capacity (C18-PMH-PEG coated rGO: 8.8 % ID 
g-1; C18-PMH-PEG-PEG coated rGO: 15.5 % ID g
-1) [70]. These results are in line with other 
literature reports that highlight that the optimization of the PEG density and PEG molecular 
weight present on nanomaterials’ surface is crucial to achieve an enhanced tumor accumulation 
[71, 72]. 
The ability of functionalized GFN to become accumulated in the tumor zone can also be 
explored to improve the accumulation of therapeutics (e.g. drugs) in the tumor mass, through 
their loading on the aromatic matrix of GFN or covalent conjugation to the nanomaterials [22, 
27]. For instance, the delivery of a platinum-based drug by branched PEG-Platin-GO conjugates 
results in a  2.4-fold higher platinum tumor uptake than that achieved through the 
administration of cisplatin ( 9.6 vs. 4 µg g-1) [22]. In another work, the accumulation of 
Photochlor® in 4T1 tumors was also enhanced when delivered by linear PEG-GO  
( 1.3 vs. 3.1 % ID g-1) [27]. Furthermore, drug-loaded functionalized GFN can display a lower 
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accumulation in off-target organs (e.g. liver or spleen) than free drugs, and thus reduce drugs’ 
side-effects [22, 27] (Table 3.3). 
 
3.4.4. Functionalizations used to improve the cellular uptake and 
selectivity of GFN 
After reaching the tumor site, GFN must be internalized by cancer cells (Figure 3.2). In this 
regard, the functionalization of GFN can improve their cellular internalization, leading to an 
improved therapeutic effect. For instance, the delivery of therapeutics to cancer cells by PEG 
or Dextran functionalized GFN can be more efficient than that mediated by non-functionalized 
GFN or attained through the diffusion of free drugs (please see Table 3.4 for more details; 
presented after the conclusion section) [22, 27, 41, 73].  
Furthermore, GFN can also be decorated with ligands that are recognized by the overexpressed 
receptors available on cancer cells’ membranes, thus enhancing their tumor uptake and 
selectivity towards cancer cells, while reducing their off-target accumulation. In this regard, 
GFN have been mostly decorated with FA (folate receptor targeted) [13], RGD peptide  
(integrin αvβ3 targeted) [74], transferrin (transferrin receptor targeted) [75] and HA (CD44 
receptor targeted) [29]. For this purpose, targeted GO based materials can be prepared by 
covalent interactions (Table 3.4). Jung et al. covalently functionalized GO-COOH with 
hexamethylenediamine-HA (HMDA-HA; amine terminated HA), and they noticed that the 
photothermal effect mediated by HA-GO leads to the eradication of mice’s melanoma tumors 
due to the ability of these nanostructures to reach the tumor mass upon topical administration 
[29]. The attachment of thiol terminated antibodies to GO covalently functionalized with 
branched amine and maleimide (thiol reactive) terminated PEG can also be explored to prepare 
targeted PEGylated GO materials with a higher tumor-homing capacity than their non-targeted 
equivalents [76, 77]. 
To prepare targeted rGO-based nanostructures, this material is generally functionalized with 
amphiphilic polymers containing the targeting ligands (please note that this approach may also 
be applied to produce targeted GO derivatives) (Table 3.4). In this regard, Akhavan and Ghaderi 
compared the biodistribution of rGO nanomesh coated with 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-PEG (DSPE-PEG) and DSPE-PEG-RGD amphiphilic polymers, verifying 
that the RGD functionalization improved the nanomaterials’ tumor uptake from about 8.9 to  
31 % ID g-1 [74]. The RGD functionalization also reduced the nanomaterials’ liver and spleen 
accumulations from about 17 and 12 to 5 and 3 % ID g-1, respectively [74]. Due to its remarkably 
high tumor uptake, the photothermal effect mediated by DSPE-PEG-RGD coated rGO nanomesh 
induced the eradication of mice’s tumors using a low injected dose and at a very low power 
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density (2 µg, 808 nm, 0.1 W cm-2, 7 min) [74]. Other routes to prepare targeted rGO-based 
materials are summarized in Table 3.4. 
Furthermore, the decoration of GFN with more than one targeting ligand is also a promising 
approach to improve their tumor-homing capacity and therapeutic capacity [78, 79]. Jang and 
co-workers observed that GO dual-functionalized with cyclic RGD (cRGD) and FA (using 
Pluronic® F-127-cRGD and Pluronic® F-127-FA conjugates) has a tumor accumulation superior to 
that of their equivalents only decorated with one targeting ligand (cRGD or FA) [78]. In vivo, 
the photothermal effect mediated by the dual-ligand functionalized GO induced tumor 
eradication, while that mediated by single-ligand functionalized GO only promoted a reduction 
of the tumor growth (7.5 mg kg-1, 808 nm, 2 W cm-2, 10 min) [78].  
Still, the therapeutic capacity of targeted GFN is also influenced by the density of the ligand 
immobilized on the materials’ surface [80]. In this regard, Lee et al. prepared GO coated with 
Pluronic® F-127-FA conjugates with different FA densities [80]. In vitro, authors verified that 
increasing the FA density on GO surface augments the internalization of these materials by 
cancer cells [80]. However, in vivo, GO decorated with FA densities of 0, 10 and 25 % had a 
similar tumor accumulation [80]. In contrast, GO functionalized with FA densities of 50 and  
100 % had a similar performance, displaying the highest tumor uptake [80]. In agreement with 
these findings, the photothermal effect (10 mg kg-1, 808 nm, 2 W cm-2, 10 min) mediated by 
GO with 50 % FA decoration produced a hyperthermia to 60 °C and tumor eradication in 2 mice 
(out of 3) [80]. On the other hand, GO with 0 and 25 % FA densities only caused a reduction of 
the tumors’ growth upon irradiation, since these only produced hyperthermia to 47 and 50 °C, 
respectively [80]. 
 
3.5. Conclusion and outlook 
In this chapter, the different strategies used to functionalize GFN aimed for application in 
cancer therapy have been presented, disclosing their impact on overcoming the limitations 
associated with GFN based therapies. 
GFN are promising materials for application in cancer therapy due to their photothermal and 
drug delivery capabilities. However, the direct application of these materials for cancer 
therapy is severely limited by their poor colloidal stability, sub-optimal safety, inefficient 
tumor uptake and non-selectivity towards cancer cells. These critical limitations have been 
surpassed through the functionalization of GFN with different materials. In particular, GO 
derivatives were mostly functionalized by conjugating them with amine terminated polymers 
while rGO-based materials were largely non-covalently modified with amphiphilic polymers.  
 86 
In general, the passivation of GFN surface with PEG-based materials was the most explored 
approach by researchers. In fact, PEGylated GFN demonstrated an excellent colloidal stability 
and biocompatibility both in vitro and in vivo. PEG coatings also improved the blood circulation 
time of GFN. In some cases, the high tumor uptake of PEGylated GFN enabled the eradication 
of mice’s tumors upon NIR laser irradiation. Moreover, the decoration of GFN with targeting 
ligands could further improve their tumor-homing capacity and selectivity towards cancer cells, 
which permitted the complete photoablation of tumors, using a low injected dose of 
nanostructures and power density, as well as a reduction in the off-target toxicity of the 
delivered drugs. 
The therapeutic potential of passive and active-targeted PEGylated GFN is only challenged by 
the recent reports that disclose the immunogenicity of some PEG-based coatings. Considering 
the vast research on the immunogenicity of PEGylated liposomes, the PEGylated GFN-immune 
system interactions are likely to be influenced by multiple factors and thus further research is 
needed on this topic. Moreover, this phenomenon should motivate researchers to investigate 
alternative coatings that i) have a good safety profile, ii) are able to functionalize both GO and 
rGO derivatives, iii) display long blood circulation times, to promote a higher tumor uptake, 
and iv) offer versatility to be conjugated with targeting ligands, allowing a cancer-cell selective 
therapy. Moreover, coatings that detach from GFN surface in response to  
tumor-microenvironment or intracellular stimuli should be further investigated due to their 
possible impact on the clearance of GFN. 
Overall, the continuous interdisciplinary efforts for developing new routes or materials to 





Table 3.1. Different functionalizations used to improve the hydrophilicity and colloidal stability of GFN. 
GFN Material Type of 
functionalization 
Observations Ref. 
GO Branched amine terminated PEG Covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium (for at least 7 days) 
[23] 
GO Branched amine terminated PEG Covalent Stable in water, 9 % NaCl and FBS [10] 
GO Amine terminated mPEG with a bio-reducible linkage Covalent Stable in water and PBS [23] 
GO Amine terminated Dextran Covalent Stable in water, PBS and 20 % BSA solution  
(up to 1 month) 
[81] 
GO Amine modified Dextran Covalent Stable in water, 9 % NaCl, serum and cell culture 
medium 
[57] 
GO Chitosan Covalent Stable in water and cell culture medium (for at least  
48 h) 
[82] 
GO HA-ADH Covalent Stable in water, PBS and cell culture medium [83] 
GO Branched PEI Covalent Stable in water and saline solution [84] 
GO Heparin modified with dopamine Covalent Stable in water and PBS (for at least 1 month) [62] 
GO Branched amine terminated PEG, Branched PEI Covalent Stable in water, saline and FBS supplemented cell 
culture medium 
[84] 
GO Branched amine terminated PEG, PAH Covalent Stable in water and 10 % FBS supplemented cell culture 
medium (for at least 12 h) 
[73] 
GO Amine terminated branched PEG, PAH modified with 
Succinic anhydride or 2,3-Dimethylmaleic anhydride 
Covalent Stable in water and 10 % FBS supplemented cell culture 
medium (for at least 12 h) 
[73] 
GO PEGylated alginate with a bio-reducible linkage 
containing amine groups  
Covalent Stable in water and PBS (for at least 48 h) [85] 
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GO Amine terminated PEG (conjugation), 
PMAA (polymerization), Crosslinked with cystamine 
Covalent Stable in water and PBS (for at least 24 h) [86] 
GO Amine terminated PEG (conjugation), or PAA 
(polymerization) or PAM (polymerization) 
Covalent Stable in water, PBS and FBS supplemented cell culture 
medium (for at least 24 h) 
[11] 
GO BSA Non-covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium (for at least 7 days) 
[23] 
GO Pluronic® F-127 Non-covalent Stable in water, 75 mM NaCl, PBS, 10 % FBS 
supplemented cell culture medium and FBS  
(for at least 24 h) 
[26] 
GO Poloxamer 188 Non-covalent Stable in water, PBS and cell culture medium [49] 
GO (base treated) Amine terminated mPEG  Covalent Stable in water, PBS, FBS and cell culture medium  
(for at least 24 h) 
[27] 
GO (base treated) Branched amine terminated PEG Covalent Stable in water, PBS, cell culture medium and serum [9] 
GO (base treated) TPGS Non-covalent Stable in NaCl (during 12 h) and water and 10 % FBS 
supplemented cell culture medium (for at least 5 days) 
[28] 
GO-COOH Amine terminated PEG with a bio-reducible linkage Covalent Stable in water, PBS and cell culture medium [87] 
GO-COOH FA-PEG-NH2 Covalent Stable in PBS (for at least 48 h) [88] 
GO-COOH HMDA-HA Covalent Stable in water and 100 mM NaCl [29] 
GO-COOH FA Covalent Stable in water and D-Hanks buffer (for at least 24 h) [34] 
GO-COOH Octaarginine Covalent Stable in water and 10 % FBS supplemented cell culture 
medium (for at least 2 days) 
[89] 
GO-COOH Amine terminated mPEG, amine terminated PEG-FA 
conjugate 
Covalent Stable in cell culture medium [90] 
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GO (modified with 
amines)  
HA Covalent Stable in water and saline [91] 
rGO Glucose Covalent Stable in FBS and 10 % FBS supplemented cell culture 
medium (for at least 1 month) 
[53] 
rGO Heparin modified with dopamine Covalent Stable in water and PBS (for at least 1 month) [62] 
rGO C18-PMH-PEG Non-covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium (for at least 7 days) 
[23] 
rGO C18-PMH-PEG Non-covalent Stable in water, 9 % NaCl, PBS, FBS and cell culture 
medium (for at least 1 week) 
[40] 
rGO Pluronic® F-127 Non-covalent Stable in water and cell culture medium [92] 
rGO BSA Non-covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium (for at least 7 days) 
[23] 
rGO BSA Non-covalent Stable in water, 9 % NaCl, PBS, 10 % FBS solution and 
cell culture medium (for at least 1 month) 
[50] 
rGO Hematin-terminated Dextran Non-covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium 
[41] 
rGO Cholesteryl HA Non-covalent Stable in water, PBS and 10 % FBS supplemented cell 
culture medium (for at least 7 days) 
[42] 
rGO Low molecular weight heparin-taurocholate conjugate Non-covalent Stable in PBS (up to 3 days) and 10, 50 and 90 % FBS 
supplemented cell culture medium (up to 4 h). 
[93] 
rGO Poly(glycerol)-naphthol conjugate Non-covalent Stable in PBS (up to several weeks) [94] 




Stable in water, PBS, FBS and cell culture medium [14] 
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Adipic dihydrazide (ADH), poly(acrylamide) (PAM), poly(acrylic acid) (PAA), poly(allylamine hydrochloride) (PAH), poly(ethyleneimine) (PEI), poly(N-isopropylacrylamide) 
(PNIPAM), poly(methacrylic acid) (PMAA). 
  
rGO Gelatin Non-covalent Stable in water, PBS, FBS and cell culture medium  




TPGS Non-covalent Stable in water, NaCl and 10 % FBS supplemented cell 




Starch Non-covalent Stable in water (for at least 2 months, 4 ⁰C) [96] 
rGO (reduced by 
dopamine) 
Poly(dopamine), BSA Covalent Stable in water (for at least 2 weeks) and PBS (2 weeks) [37] 
rGO (reduced by 
dopamine) 
Poly(dopamine), Heparin Covalent Stable in water (for at least 1 month) and PBS  
(2 weeks) 
[37] 




Non-covalent Stable in water [97] 
rGO (octadeylamine 
modified) 
Lactoferrin Non-covalent Stable in PBS and FBS supplemented cell culture 
medium (for at least 1 month) 
[98] 
rGO-PEI mPEG Covalent Stable in water (for at least 6 h) [39] 
rGO-Alkynyl PNIPAM-N3 Covalent Stable in water and PBS [99] 
rGO nanoplatelets Dextran Non-covalent Stable in water and biological fluids [65] 
Graphene Pluronic® F38, F68, F77, F87, F88, F98, F108, F127, 
L62, L64 P84, P103, P104 or P123 
Non-covalent Pluronic® F68, F77 and F87 are the most effective in the 
production of aqueous graphene suspensions 
[100] 
Graphene Tetronic® 304, 904, 908, 1107 or 1307 Non-covalent Tetronic® 1107 and 1307 are the most effective in the 




Table 3.2. Different functionalizations used to improve the biocompatibility and hemocompatibility of GFN. 
GFN Material Type of 
functionalization 
Observations Ref. 
GO Branched amine terminated PEG Covalent PEG-GO (20 mg kg-1; i.v. injection) did not induce abnormalities on the major 
organs of tumor bearing mice after 40 days p.i.; 
Blood related parameters of healthy mice injected with PEG-GO (20 mg kg-1) 
after 3 months were similar to those of the control. 
[21] 
GO Branched amine terminated PEG Covalent PEG-GO is eliminated from mice body through feces and urine; 
PEG-GO (20 mg kg-1; i.v. injection) did not induce appreciable toxic effects on 
mice after 90 days p.i.; 
PEG-GO did not change mice’s hepatic and kidney functions nor blood 
biochemistry and hematological related parameters. 
[55] 
GO Branched amine terminated PEG Covalent PEG-GO (50 mg kg-1; i.p. injection) did not induce appreciable toxic effects on 
mice after 90 days p.i.; 
PEG-GO did not induce physiologically significant changes on mice’s hepatic and 
kidney functions nor on blood biochemistry and hematological related 
parameters. 
[56] 
GO Branched amine terminated PEG Covalent Coating GO with PEG improves the cytocompatibility of the materials in 7792, 
MRC-5 and U937 cell lines. 
[23] 
GO Amine terminated PEG with a  
bio-reducible linkage 
Covalent PEG-SS-GO has an improved cytocompatibility in U937 cells when compared to 
GO; 
After the detachment of the reducible coating, materials can be oxidized by 
horseradish peroxidase, leading to their degradation. 
[23] 
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GO Amine modified Dextran Covalent Dextran-GO has a lower effect on the HeLa cells proliferation than GO; 
Dextran-GO (20 mg kg-1; i.v. injection) did not induce abnormalities in mice after 
1 and 7 days p.i. (histological analysis). 
[57] 
GO Amine terminated PEG 
(conjugation), or PAA 
(polymerization) or PAM 
(polymerization) 
Covalent The protein corona formed on the surface of GO-PEG and GO-PAA is lower than 
that present on GO and GO-PAM surfaces; 
GO-PEG and GO-PAA adsorb less IgG than GO and GO-PAM; 
GO-PEG and GO-PAA do not induce meaningful cytotoxicity to J774.A1 cells up 
to 10 µg mL-1 (24 h of incubation) when incubated in serum-free and  
serum-supplemented medium; 
GO-PAA presents the lowest uptake by macrophages; 
The survival rate of mice injected with GO-PEG and GO-PAA (1 mg kg-1;  
i.v. injection) was 100 %; 
Mice injected with GO and GO-PAM (1 mg kg-1) had a survival rate of 80 and  
90 %, respectively; 
GO-PAA has the best in vivo biocompatibility profile since it had the lowest effect 
on mice’s liver and lungs (histological analysis) and all the assessed blood 
biochemistry markers were non-significantly different from those of the control 
(at 1 mg kg-1 for 14 days). 
[11] 
GO Heparin modified with dopamine Covalent At 200 µg mL-1, Heparin-GO induces ≈ 1.2 % of hemolysis while GO induces  
78.5 %; 
Heparin-GO has a better cytocompatible profile in HUVECs than GO (viability of 




GO PEG Non-covalent PEG-GO reduces the invasion and migration of breast cancer cells (in vitro and 
in vivo); 
PEG-GO can disturb the assembly of cytoskeletal F-actin through the 
downregulation of the expression of energy metabolism-related genes, reduction 
of mitochondrial oxidative phosphorylation, and inhibition of the synthesis of 
ATP.  
[101] 
GO BSA Non-covalent Coating GO with BSA improves the cytocompatibility of the materials in 7792, 
MRC-5 and U937 cell lines. 
[23] 
GO BSA, transferrin, fibrinogen, 
immunoglobulin or FBS proteins 
Non-covalent A549 cells incubated with GO (in FBS free medium) display a viability of about  
55 % (at 200 µg mL-1); 
GO coated with several proteins does not induce considerable cytotoxicity to 
A549 cells (at 200 µg mL-1). 
[102] 
GO PEG, DOC or Pluronic® P123 Non-covalent PEG coated GO has a better cytocompatible profile in L929 cells than DOC coated 
GO and Pluronic® P123 coated GO (48 h incubation period). 
[103] 




GO induces a hemolysis of about 27 % at the concentration of 30 µg mL-1; 
Bovine α-lactalbumin/GO induces a hemolysis of about 3 % at the concentration 
of 333.33 µg mL-1. 
[63] 
GO (modified with 
amines)  
HA Covalent HA-GO does not induce considerable alterations in HeLa and L929 cells’ viability 
up to 200 µg mL-1 (24 h of incubation; viability > 80 %); 
At 400 µg mL-1, HA-GO induces 0.7 % of hemolysis while GO induces 1.5 %; 
No toxicity at the tested dose of HA-GO (10 mg kg-1; i.v. injection) was found  
in vivo 10 days p.i. (blood biochemistry and histological analysis). 
[91] 




Cysteine-GO does not induce considerable tissue abnormalities, malformations 
or death in the embryos at the tested doses (up to 10 µg mL-1). 
rGO Chitosan Covalent Chitosan-rGO does not induce meaningful alterations on CEM cells viability up to 
400 µg mL-1 (5 days of incubation). 
[105] 
rGO C18-PMH-PEG Non-covalent Coating rGO with PEG-based amphiphile improves the cytocompatibility of the 
materials in 7792, MRC-5 and U937 cell lines. 
[23] 
rGO a) C18-PMH-PEG Non-covalent PEG-rGO (50 mg kg-1; i.p. injection) did not induce appreciable toxic effects on 
mice after 90 days p.i.; 
PEG-rGO did not induce physiologically significant changes on mice’s hepatic and 
kidney functions nor on blood biochemistry and hematological related 
parameters. 
[56] 
rGO b) C18-PMH-PEG Non-covalent PEG-rGO (50 mg kg-1; i.p. injection) did not induce appreciable toxic effects on 
mice after 90 days p.i.; 
PEG-rGO did not induce physiologically significant changes on mice’s hepatic and 
kidney functions nor on blood biochemistry and hematological related 
parameters. 
[56] 
rGO C18-PMH-PEG Non-covalent Mice injected with PEG-rGO (10 mg kg-1; i.v. injection) did not display signs of 
toxicity after 50 days p.i. (histological, blood and biochemistry analysis). 
[40] 
rGO DSPE-PEG-NH2 Non-covalent DSPE-PEG-NH2 coated rGO induces cytotoxic effects on glioblastoma cells at 
concentrations above 10 µg mL-1. 
[45] 
rGO BSA Non-covalent Coating rGO with BSA improves the cytocompatibility of the materials in 7792, 
MRC-5 and U937 cell lines. 
[23] 
rGO BSA Non-covalent BSA-rGO (20 mg kg-1) did not induce appreciable alterations on mice’s major 




rGO Cholesteryl HA Non-covalent HA-rGO and rGO have a similar cytocompatibility in vitro (24 h of incubation); 
1 day p.i., rGO reduces mice survival rate to 40 % (dose of 20 mg kg-1;  
i.v. injection); 
1 day p.i., HA-rGO treated mice have a 100 % survival rate (40 mg kg-1).  
[42] 
rGO Hematin terminated Dextran Non-covalent Dextran-rGO has a better cytocompatible profile in MCF-7/ADR cells than GO 
(viability of ≈ 85 vs. ≈ 53 %; at 100 µg mL-1; 48 h of incubation). 
[41] 
rGO Poly(glycerol)-naphthol conjugate Non-covalent Poly(glycerol)-rGO does not induce considerable cytotoxicity to MCF-7 cells  
(at 100 µg mL-1; 48 h of incubation)  
[94] 
rGO (reduced by 
dopamine) 
Heparin modified with dopamine Covalent At 200 µg mL-1, Heparin-rGO induces ≈ 0.6 % of hemolysis while GO induces  
78.5 %; 
Heparin-rGO has a better cytocompatible profile in HUVECs than GO (viability of 
≈ 100 vs. ≈ 68 %; at 100 µg mL-1; 24 h of incubation). 
[62] 




Covalent BSA-poly(dopamine)-rGO induces an insignificant hemolysis ( 1.8 %;  
at 200 µg mL-1); 
At 100 µg mL-1, BSA-poly(dopamine)-rGO has a better cytocompatibility than rGO 
( 73 vs.  39 %). 
[37] 




Covalent Heparin-poly(dopamine)-rGO induces an insignificant hemolysis ( 0.2 %;  
at 200 µg mL-1); 
At 100 µg mL-1, Heparin-poly(dopamine)-rGO has a better cytocompatibility than 
rGO ( 95 vs.  39 %; HUVECs; 24 h of incubation).  
[37] 
rGO (ascorbic acid 
treated) 
PVP Covalent PVP-rGO is less immunogenic than GO (induces less maturation of dendritic cells); 
PVP-rGO only induces IL-6 secretion by dendritic cells while GO induces higher 
IL-6 secretion as well as IL-1β and TNF-α secretions; 
PVP-rGO induces less apoptosis of T lymphocytes than GO; 
[12] 
 96 
a) after PEGylation the size was estimated to be 50 nm; b) after PEGylation the size was estimated to be 27 nm; chondroitin sulfate potassium (CON), D-glucosamine sulfate 
potassium (GLU), hydroxyethyl cellulose (HEC), poly(lactide) (PLA), sodium deoxycholate (DOC).  
PVP-rGO suffered no appreciable phagocytosis by macrophages and enhanced 
their activity (GO was susceptible to phagocytosis).  
rGO (glucose 
reduced) 
PEG, DOC or Pluronic® P123 Non-covalent PEG coated rGO has a better cytocompatible profile in L929 cells than DOC 




Starch Non-covalent Starch-rGO does not induce meaningful alterations on SW-620 cells’ viability up 
to 200 µg mL-1 (viability > 90 %; 48 h of incubation). 
[96] 
rGONR DSPE-PEG-NH2 Non-covalent DSPE-PEG-NH2 coated rGONR induce cytotoxic and genotoxic effects on 
glioblastoma cells at concentrations above 1 µg mL-1. 
[45] 
rGO nanoplatelets Dextran Non-covalent Dextran-rGO nanoplatelets do not adsorb human serum albumin. [66] 
rGO nanoplatelets Dextran Non-covalent The maximum tolerable dose of Dextran-rGO nanoplatelets is between 50 and 
125 mg kg-1 (i.v. injection); 
30 days p.i., Dextran-rGO nanoplatelets demonstrate an excellent 
biocompatibility at injected doses of 50 mg kg-1 and bellow (histology, 
respiratory, cardiovascular and hematological factors analysis);  
Materials are excreted mostly through feces; 




PVA, HEC, PEG, PVP, CON, GLU or 
HA 
Non-covalent Graphene nanoplatelets coated with PVA or HEC present the lowest hemolytic 
effect (hemolysis ≤ 0.05 % at 500 µg mL-1); 
PVA coated graphene nanoplatelets are cytocompatible towards HFF-1 cells at 







Covalent PEG-PLA-graphene has a better cytocompatibility than graphene. [106] 
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Table 3.3. Different functionalizations used to improve the blood circulation time and tumor accumulation of GFN. 
GFN Material Type of 
functionalization 
Observations Ref. 
GO Branched amine terminated PEG Covalent PEG-GO has a t1/2 of about 1.5 h; 
PEG-GO achieves a high tumor uptake in 4T1, KB and U87 tumor bearing mice; 
Photothermal effect mediated by PEG-GO leads to tumor eradication (20 mg kg-1,  
808 nm, 2 W cm-2, 5 min). 
[21] 
GO Branched amine terminated PEG Covalent PEG-GO displays a t1/2 = 0.29 h (t’1/2 = 5.8 h) but achieves a tumor accumulation 
lower than 1 % ID g-1; 
PTT mediated by PEG-GO induces a slight reduction of the tumor growth (20 mg  
kg-1, 808 nm, 0.15 W cm-2, 5 min). 
[10] 
GO Branched amine terminated PEG-
Oxoplatin-COOH conjugate 
Covalent Accumulation of platinum in 4T1 tumors is enhanced when delivered by  
Platin-PEG-GO ( 4 vs. 9.6 µg g-1); 
Platinum tumor uptake of mice treated with Platin-PEG-GO and NIR radiation was  
 13.3 µg g-1, presumably due to hyperthermia enhanced EPR effect; 
The chemo-photothermal effect mediated by Platin-PEG-GO led to tumor 
eradication (twice: 10 mg kg-1, 785 nm, 1.5 W cm-2, 3 min); 
No obvious signs of toxicity were found on the off-target organs of mice treated with 
Platin-PEG-GO + NIR; 
Accumulation of platinum in the liver of mice treated with cisplatin, Platin-PEG-GO 
and Platin-PEG-GO in combination with NIR radiation were  9.0, 7.2 and  
6.6 µg g-1, respectively. 
[22] 
GO Amine modified Dextran Covalent Dextran-GO has t1/2 = 0.19 h (t’1/2 = 1.81 h); [57] 
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a) after PEGylation the size was estimated to be 65 nm; b) after PEGylation the size was estimated to be 27 nm.  
The liver and spleen accumulations reduce from about 16 and 10 % ID g-1 (at 4 h p.i.) 
to lower than 2 % ID g-1 at 7 days p.i.; 
Dextran-GO is mainly excreted in feces. 
GO (base 
treated) 
Amine terminated mPEG  Covalent Accumulation of Photochlor® in 4T1 tumors is enhanced when delivered by PEG-GO 
( 1.3 vs. 3.1 % ID g-1); 
The liver accumulation of Photochlor® is also reduced when delivered by PEG-GO  
( 37 vs. 27 % ID g-1). 
[27] 
rGO C18-PMH-PEG Non-covalent PEG-rGO has a t1/2 = 0.65 h (t’1/2  18 h), achieving a tumor accumulation of  
 4 % ID g-1 (at 48 h p.i.); 
The liver and spleen accumulations are about 15 and 21 % ID g-1, respectively. 
[40] 
rGO a) C18-PMH-PEG Non-covalent C18-PMH-PEG coated rGO displays a t1/2 = 0.22 h (t’1/2 = 17.5 h) and achieves a tumor 
accumulation of ≈ 5 % ID g-1. 
[10] 
rGO b) C18-PMH-PEG Non-covalent C18-PMH-PEG coated rGO displays a t1/2 = 0.51 h (t’1/2 = 16.7 h) and achieves a tumor 
accumulation of ≈ 6 % ID g-1; 
PTT mediated by C18-PMH-PEG coated rGO leads to tumor eradication (20 mg kg-1, 
808 nm, 0.15 W cm-2, 5 min). 
[10] 
rGO C18-PMH-PEG-NH2; Succinimidyl 
carboxyl methyl ester-PEG-Maleimide 
Non-covalent;  
Covalent 
Conjugation of additional PEG to C18-PMH-PEG coated rGO improves materials’ blood 
circulation time from t1/2 = 0.19 h (t’1/2 = 18.8 h) to t1/2 = 0.35 h (t’1/2 = 27.7 h); 
This modification also improves materials’ tumor accumulation from 8.8 to  




Table 3.4. Different functionalizations used to improve the cellular uptake and selectivity of GFN. 
GFN Material Type of 
functionalization 
Observations Ref. 
GO Branched amine terminated 
PEG, 
PAH modified with 2,3-
Dimethylmaleic anhydride 
Covalent Delivery of DOX to MCF-7/ADR cells by the polymer functionalized GO produces a 
stronger therapeutic effect than that achieved using free DOX; 
The chemo-photothermal effect mediated by the polymer functionalized GO produces 
an even higher reduction on cancer cells’ viability. 
[73] 
GO Branched amine terminated 
PEG-Oxoplatin-COOH 
conjugate 
Covalent Delivery of platinum to 4T1 cancer cells by Platin-PEG-GO can produce a stronger 
therapeutic effect than that achieved using free cisplatin. 
[22] 
GO Branched amine and 
maleimide terminated PEG, 
TRC105-SH 
Covalent TRC105-PEG-GO targets tumor vasculature by binding to CD105; 
TRC105-PEG-GO can achieve a 2.9-fold higher accumulation in the tumor zone than 
PEG-GO (5.8 vs. 2.0 % ID g-1; at 0.5 h p.i.). 
[76] 
GO Branched amine and 
maleimide terminated PEG, 
TRC105-SH 
Covalent TRC105-PEG-GO targets tumor vasculature by binding to CD105; 
TRC105-PEG-GO can achieve a  1.6-fold higher accumulation in the tumor zone than 
PEG-GO (5.8 vs. 3.6 % ID g-1; at 7 h p.i.). 
[77] 
GO FA-PEG-NH2 Covalent Camptothecin loaded FA-PEG-GO produces a slightly higher reduction on HeLa  
cells’ viability than free Camptothecin; 
Drug loaded FA-PEG-GO therapeutic effect appears to be selective for folate receptor 
expressing cell lines; 
The homing capacity of camptothecin loaded FA-PEG-GO to HeLa tumors is superior 
to that of Camptothecin loaded PEG-GO. 
[13] 
GO Anti-MUC1 Antibody, 
PEG 
Covalent Antibody-PEG-GO achieves a higher uptake by MUC1+ cancer cells than PEG-GO; [107] 
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Antibody-PEG-GO internalization by MUC1- cancer cells is inferior to that occurring in 
MUC1+ cells.  
GO HA-ADH Covalent Delivery of Ce6 by HA-GO to HeLa cells is faster than the diffusion of free Ce6; 
HA-GO delivers its payload more effectively to CD44 overexpressing cells. 
[83] 
GO Carboxymethyl chitosan, HA Covalent HA-Carboxymethyl chitosan-GO delivers a higher DOX dose to CD44 overexpressing 
cancer cells (HeLa) than to normal cells (L929). 
[108] 
GO A1 aptamer Covalent A1-GO achieves a higher binding to A549 cells’ membrane than GO; 
Binding of A1-GO seems to be highly selective for A549 cells; 
Decitabine loaded A1-GO produces a stronger therapeutic effect than decitabine 
loaded GO and free decitabine. 
[109] 
GO Amine terminated Dextran, 
AS1411 aptamer 
Covalent Curcumin loaded AS1411-Dextran-GO delivers a higher drug dose to MCF-7 and 4T1 
cells than curcumin loaded Dextran-GO and free curcumin, leading to an improved 
therapeutic effect. 
[81] 
GO Carboxymethyl chitosan, 
Lactobionic acid 
Covalent DOX loaded Lactobionic acid functionalized GO produces a stronger therapeutic effect 
on cancer cells that express asialoglycoprotein receptors. 
[110] 
GO HA-ADH, APMA, RGD Covalent RGD-HA-GO delivers a higher DOX dose to SKOV-3 cancer cells than HA-GO and GO, 
thus producing a superior therapeutic effect; 
Nanomaterials deliver an inferior DOX dose to normal cells. 
[79] 




Pluronic® F68/HA-GO mediates the delivery of a higher mitoxantrone dose to MCF-7 
and MCF-7/ADR cells than Pluronic® F68/GO and free mitoxantrone; 
The uptake of mitoxantrone in MCF-7 and MCF-7/ADR tumors is higher in the group 
treated with mitoxantrone loaded Pluronic® F68/HA-GO than in those treated with 









GO induces cytotoxic effects at low concentrations on normal and breast cancer cells; 
Bovine α-lactalbumin/GO induces cytotoxicity to breast cancer cells and it is 






Platinum loaded Transferrin-PEI functionalized GO can enhance the cytotoxicity of 
platinum towards cancer cells, while maintaining its low cytotoxicity towards normal 
cells. 
[112] 
GO cRGD-chitosan conjugate Non-covalent cRGD-chitosan functionalized GO internalization by αvβ3 overexpressing cells is higher 
than that of chitosan functionalized GO; 
DOX loaded cRGD-chitosan functionalized GO produces a stronger reduction on cancer 
cells’ viability than DOX loaded chitosan/GO and free DOX. 
[113] 
GO Transferrin-PAH conjugate Non-covalent Docetaxel loaded transferrin-PAH coated GO can induce a stronger reduction of  
MCF-7 cells’ viability than Docetaxel loaded PAH coated GO and free Docetaxel.  
[75] 
GO Pluronic® F-127-FA 
conjugate 
Non-covalent Increasing the FA density on GO from 0 to 100 % augments the internalization of these 
materials by KB cells; 
In vivo, GO functionalized with FA densities of 50 and 100 % have a similar and the 
highest tumor-homing capacity; 
GO decorated with 0, 10 and 25 % of FA have a similar tumor accumulation; 
The photothermal effect mediated by GO with 50 % folate decoration led to the 
eradication of tumors in 2 out of 3 mice (10 mg kg-1, 808 nm, 2 W cm-2, 10 min). 
[80] 
GO Pluronic® F-127-FA, 
Pluronic® F-127-cRGD 
Non-covalent GO dual-functionalized with cRGD and FA has a tumor accumulation superior to that 
of their equivalents only functionalized with one ligand (cRGD or FA); 
Photothermal effect mediated by dual-ligand functionalized GO induces tumor 
eradication, while that mediated by single-ligand functionalized GO only promotes a 
reduction of the tumor growth (7.5 mg kg-1, 808 nm, 2 W cm-2, 10 min). 
[78] 
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GO (base treated) Amine terminated mPEG  Covalent Delivery of Photochlor® by PEG-GO to 4T1 cells is more efficient than the diffusion of 
free Photochlor®. 
[27] 
GO (base treated) TPGS Non-covalent TPGS functionalized GO induces a strong reduction on MCF-7 cells’ viability but has a 
very low effect on fibroblasts’ viability. 
[28] 
GO (modified with 
amines)  
HA Covalent HA-GO delivers a high DOX dose to cancer cells overexpressing CD44 receptors and 
has an unappreciable internalization in normal cells (low CD44 expression). 
[91] 
GO-COOH Chlorotoxin Covalent Chlorotoxin-GO delivers a higher DOX dose to C6 glioma cells than GO; 
DOX loaded Chlorotoxin-GO can produce a higher reduction on cancer cells’ viability 
than DOX loaded GO and free DOX. 
[114] 
GO-COOH HMDA-HA Covalent HA-GO achieves a higher uptake in melanoma cells than in fibroblasts, and thus its 
photothermal effect only affects the melanoma cells; 
HA-GO applied on normal skin remains in the top of the skin; 
HA-GO can diffuse through cancerous skin, reaching the tumor mass; 
Photothermal effect mediated by HA-GO leads to tumor eradication. 
[29] 
GO-COOH FA Covalent FA functionalized GO achieves a higher internalization in cancer cells overexpressing 
FA receptors; 
DOX loaded FA functionalized GO and free DOX can produce a similar reduction of 
MCF-7 cells’ viability. 
[34] 
GO-COOH PEI, Anti-integrin αvβ3 
Antibody; 
DOX-(PAH-Cit) conjugate  
Covalent; 
Non-covalent 
Delivery of DOX to U87 MG cancer cells by antibody functionalized GO produces a 
more potent therapeutic effect than that obtained using non-targeted GO and free 
DOX; 
Antibody functionalized GO promotes a DOX tumor accumulation of  3 % ID g-1 while 








FA functionalized GO achieves a higher internalization in cancer cells overexpressing 
FA receptors; 
Chemo-photothermal therapy mediated by DOX loaded FA functionalized GO leads to 
an improved therapeutic effect. 
[116] 
rGO Hematin terminated Dextran Non-covalent Delivery of DOX by Dextran-rGO to MCF-7/ADR cells is more efficient than the 
diffusion of free DOX, leading to an improved therapeutic effect. 
[41] 





TRC105-PEG-rGO can achieve  2.1-fold higher accumulation in the tumor zone than 
PEG-rGO (5.6 vs. 2.7 % ID g-1; at 3 h p.i.). 
[117] 
rGO Cholesteryl HA Non-covalent HA-rGO can deliver a higher DOX dose to CD44 overexpressing cells than rGO. [42] 
rGO Cholesteryl HA, DSPE-PEG Non-covalent Dox loaded PEG-HA-rGO tumor and liver accumulations are superior to that of DOX 
loaded PEG-rGO. 
[42] 
rGO DSPE-PEG-RGD Non-covalent rGO coated with DSPE-PEG-RGD has a higher tumor accumulation than DSPE-PEG 
coated rGO (≈ 22.7 vs. ≈ 7.3 % ID g-1); 
Target functionalization also reduces nanomaterials’ liver and spleen uptakes from 
about 26 and 22 to 7 and 6 % ID g-1, respectively. 
[74] 
rGO DSPE-PEG-RGD, C18-PMH-PEG Non-covalent DSPE-PEG-RGD/C18-PMH-PEG functionalized rGO achieves a higher internalization in 
U87MG cells than its equivalent functionalized with DSPE-PEG-RAD/C18-PMH-PEG. 
[118] 
rGO Low molecular weight 
heparin-taurocholate 
conjugate 
Non-covalent DOX loaded heparin functionalized rGO produces a stronger in vitro and in vivo 
therapeutic effect than free DOX (the heparin conjugate has also anticancer activity). 
[93] 




FA-polymer functionalized rGO achieves a selective and higher internalization in HeLa 
cells than polymer-rGO; 
[14] 
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N-(3-aminopropyl)methacrylamide hydrochloride (APMA), arginine-alanine-aspartate (RAD), chlorin e6 (Ce6), doxorubicin (DOX), PAH functionalized with citraconic anhydride 
(PAH-Cit). 
DOX loaded FA-polymer-rGO produces a stronger reduction on HeLa cells’ viability 
than free DOX. 
rGO (hydrothermal 
treated) 
TPGS Non-covalent TPGS functionalized rGO induces a strong reduction on MCF-7 cells’ viability but has 
a very low effect on fibroblasts’ viability. 
[28] 
rGO (reduced by 
dopamine) 
AAP10 Covalent The photothermal effect mediated by AAP10 functionalized rGO leads to tumor 
eradication, while that mediated by rGO only induces tumor regression (intratumoral 





Lactoferrin Non-covalent Lactoferrin-rGO capsules display a greater internalization in lactoferrin receptor 
overexpressing cells than PVA-rGO capsules; 
Lactoferrin-rGO capsules display an improved tumor accumulation when compared to 
their PVA coated equivalents. 
[98] 
rGO nanomesh DSPE-PEG-RGD Non-covalent rGO nanomesh coated with DSPE-PEG-RGD has a higher tumor accumulation than 
DSPE-PEG coated rGO nanomesh (≈ 31 vs. ≈ 8.9 % ID g-1); 
Target functionalization also reduces nanomaterials’ liver and spleen uptakes from 
about 17 and 12 to 5 and 3 % ID g-1, respectively; 
Photothermal effect mediated by DSPE-PEG-RGD coated rGO nanomesh leads to tumor 
eradication (2 µg, 808 nm, 0.1 W cm-2, 7 min). 
[74] 
rGONR DSPE-PEG-RGD Non-covalent DSPE-PEG-RGD functionalized rGONR achieve a higher internalization in glioblastoma 
cells than their equivalents functionalized with DSPE-PEG-RAD, leading to an 
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Aim: Evaluate the therapeutic capacity of TPGS functionalized nGO in breast cancer cells. 
Methods: TPGS functionalized nGO-based materials were obtained through two different 
approaches: a simple sonication method and a one-pot hydrothermal treatment. Results: TPGS 
coating successfully improved the stability of the nGO-based materials. The nanomaterials that 
underwent the hydrothermal procedure generated a 1.4 – 1.6 fold higher temperature variation 
under NIR laser irradiation than those prepared only by sonication. In vitro, the TPGS/nGO 
derivatives reduced breast cancer cells’ viability and had an insignificant effect on healthy 
cells. Furthermore, the combined application of TPGS/nGO derivatives and NIR light generated 
an improved therapeutic effect. Conclusion: TPGS/nGO derivatives are promising materials for 
breast cancer phototherapy. 
 




Cancer ablation mediated by nanosized photothermal agents is currently showing promising 
results in in vitro and in vivo assays [1]. This therapeutic approach takes advantage of the 
ability of nanomaterials to accumulate at the tumor site, through passive (using the EPR effect) 
or active (involving the grafting of targeting ligands) transport, and from the capacity of some 
nanostructures to mediate a hyperthermic effect by converting optical energy, like NIR light 
(750-1000 nm), into heat [1]. For therapeutic applications, NIR light is fundamental since it has 
a good tissue penetration and major biological components (e.g. collagen, melanin or water) 
have minimal absorption within this wavelength range [2], thus assuring limited off-target 
interactions with this type of radiation [3, 4]. Therefore, nanomaterials designed to be applied 
in PTT must produce a photothermal effect upon NIR light irradiation. So far, different types 
of nanostructures such as GNR, CNT, tungsten-based nanomaterials, copper sulfide nanocrystals 
or GO have revealed this ability [5-10].  
nGO is a 2D carbon nanomaterial with oxygen functional groups (carboxyl, hydroxyl and epoxy 
groups) that possesses NIR absorption [11, 12]. Due to this fact, nGO has been investigated for 
application in cancer PTT [13, 14]. Moreover, the high versatility of nGO, that is associated 
with its ability to adsorb different molecules through hydrophobic interactions or π-π stacking, 
has instigated its use in other cancer-related applications such as drug or protein delivery [15-
17]. Independently of the type of biomedical application, nGO must be functionalized with 
hydrophilic polymers since it has a low colloidal stability, especially in solutions with a high 
concentration of salts like biological fluids [18]. To overcome such drawback, nGO is often 
functionalized with PEG through covalent bonds, that are established between the amine 
groups of amine-terminated PEG and the carboxyl groups of GO [13, 18]. This type of 
functionalization improves the stability of nGO and is also fundamental to extend the blood 
circulation time of this nanomaterial, which in turn favors its tumor accumulation [18, 19]. 
Alternatively, nGO can also be non-covalently PEGylated using amphiphilic molecules such as 
Pluronic® F-127 [20]. This type of functionalization exploits the hydrophobic interactions that 
are established between the hydrophobic blocks of the amphiphilic molecules and the aromatic 
regions of nGO. In the particular case of reduced nGO (usually obtained by treating GO with 
hydrazine hydrate) and graphene-based materials (e.g. obtained through the oxidation and 
chemical reduction of MWCNT), due to their lack of oxygen functional groups available for 
conjugation, they have been mostly functionalized with amphiphilic molecules such as  
C18-PMH-PEG or DSPE-PEG [18, 21, 22]. Moreover, the PEGylation of these two types of materials 
is also pursued for improving their biocompatibility [22-24]. The application of reduced nGO 
derivatives and graphene-based materials for cancer PTT is appealing since these materials 
have a higher NIR absorption than nGO, and consequently produce a higher hyperthermia and 
an improved therapeutic effect when irradiated with NIR light [18, 22, 24, 25]. 
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From the different and unexplored amphiphilic molecules that can be used to non-covalently 
functionalize nGO and its reduced derivatives, TPGS (PEGylated Vitamin E) appears to be a 
promising candidate for heightening the colloidal stability of these nanomaterials. TPGS is a 
FDA and EMA approved molecule with a broad application in cancer-related topics [26-31]. Due 
to its amphiphilic character, TPGS has been used in the formulation of amphiphilic micelles or 
for coating polymeric and inorganic nanomaterials [32-36]. Moreover, TPGS has intrinsic 
anticancer activity, which renders it with very appealing features for improving the stability of 
nGO derivatives and to endow them with anticancer activity similar to that of a 
chemotherapeutic drug [37, 38].  
In this work, TPGS was employed to functionalize nGO-based materials using two different 
approaches: a simple sonication method and a one-pot hydrothermal treatment. The results 
revealed that the TPGS coating successfully improved the stability of nGO-based materials. 
Moreover, the nGO materials that underwent the hydrothermal procedure demonstrated an 
improved NIR absorption, which in turn enhanced their capacity to generate heat under NIR 
laser irradiation. In vitro, the TPGS/nGO derivatives diminished breast cancer cells’ viability 
and had an insignificant effect on healthy cells. This preferential effect towards breast cancer 
cells can be attributed to TPGS intrinsic anticancer activity. Furthermore, the combined 
application of TPGS/nGO derivatives and NIR light produced an enhanced therapeutic effect, 
thereby confirming the potential of these materials for breast cancer phototherapy. 
 
4.3. Materials and Methods 
 
4.3.1. Materials 
Dulbecco’s Modified Eagle’s Medium F-12 (DMEM-F12), ethylenediaminetetraacetate (EDTA), 
graphite, resazurin, TPGS, and trypsin were acquired from Sigma–Aldrich (Sintra, Portugal). 
Potassium permanganate was obtained from Acros Organics (Geel, Belgium). Sulfuric acid 
(H2SO4, 96 %) was purchased from Panreac (Darmstadt, Germany). Phosphoric acid (H3PO4,  
85 %) was acquired from VWR (Carnaxide, Portugal). Michigan Cancer Foundation-7 (MCF-7) cell 
line was purchased from ATCC (Middlesex, UK). Normal Human Dermal Fibroblasts (NHDF) were 
obtained from PromoCell (Heidelberg, Germany). FBS was obtained from Biochrom AG (Berlin, 
Germany). Cell culture plates and T-flasks were acquired from Thermo Fisher Scientific (Porto, 





4.3.2.1. Synthesis of bwGO 
Graphite oxide (GrO) was synthesized using a modified version of the improved Hummer’s 
method [39]. In brief, a solution of H2SO4/H3PO4 (9:1 v/v, 67 mL) was slowly added to a mixture 
of KMnO4 (3.10 g) and graphite (0.51 g) in an ice bath. This solution was then left to react for 
4 days at room temperature (RT) under stirring. Afterward, the reaction was poured into 67 mL 
of frozen water followed by the addition of H2O2 until a yellow colored solution was attained. 
The product was purified by performing several centrifugations with HCl (3.7 %) and then with 
water. The gathered material was finally dialyzed against water for 5 days, yielding GrO. 
Afterward, nanosized base-washed graphene oxide (bwGO) was obtained by washing GrO with 
a NaOH solution, following a protocol described by Thomas et al. [40], and by subjecting the 
materials to ultrasonication (Vibra-Cell VC600-2, Sonics & Materials, Newtown, USA). 
 
4.3.2.2. Synthesis of TPGS/bwGO 
bwGO was non-covalently functionalized with TPGS by sonication, according to methodologies 
previously described in the literature [18, 41]. In brief, an aqueous solution of bwGO (0.2 mg 
mL-1; 1 mL) was mixed with TPGS (3 mg) and sonicated for 1 h (Branson 5800, Branson 
Ultrasonics, Danbury, USA). Afterward, the solution was dialyzed using a dialysis membrane  
(14 kDa molecular weight cut-off) against water for 3.5 h to remove non-bound TPGS. The 
solution was then centrifuged and the supernatant was recovered to remove any aggregates, 
yielding TPGS functionalized bwGO (TPGS/bwGO). The concentration of bwGO in TPGS/bwGO 
was determined by using a mass extinction coefficient of 3.01 L g-1 cm-1 at 808 nm. The amount 
of TPGS incorporated in TPGS/bwGO was calculated by analyzing the UV-Vis-NIR absorption 
spectrum of this compound and by using the following equation: 
AbsTPGS/bwGO at 285 nm = AbsbwGO at 285 nm + AbsTPGS at 285 nm 
First, the concentration of bwGO in the TPGS/bwGO solution was determined by performing a 
standard curve of bwGO at 808 nm (please note that TPGS does not absorb at this wavelength). 
Afterwards, the determined concentration of bwGO and the standard curve of bwGO at 285 nm 
were employed to find the absorbance of bwGO at this wavelength. Subsequently, the 
determined absorbance of bwGO was subtracted to that of TPGS/bwGO, yielding the 
absorbance of TPGS (at 285 nm). Finally, the absorbance of TPGS at 285 nm was used to 
determine its concentration using a standard curve of TPGS (at 285 nm). The gathered data 
revealed that 15.8 ± 1.0 µg of TPGS were incorporated per each µg of bwGO. 
 
121 
4.3.2.3. Synthesis of TPGS/htGO 
bwGO was also reduced and functionalized with TPGS through a one-pot hydrothermal 
treatment according to a methodology previously described in the literature [42]. In brief, an 
aqueous solution of bwGO (0.2 mg mL-1; 1 mL) was mixed with TPGS (3 mg) and placed in an 
oil-bath at 80 °C, for 24 h. Afterward, the solution was left to cool at RT and then dialyzed and 
centrifuged using the procedure described above for TPGS/bwGO. The supernatant was then 
recovered yielding TPGS functionalized hydrothermal treated GO (TPGS/htGO). The 
concentration of htGO in TPGS/htGO was determined by using a mass extinction coefficient of 
5.64 L g-1 cm-1 at 808 nm. Non-coated htGO was produced using a similar procedure, but without 
adding TPGS. 
The presence of TPGS in the hydrothermal procedure affects the extent of the reduction of 
htGO. Due to that, a standard curve of htGO can not be used for determining the concentration 
of TPGS in TPGS/htGO since the obtained values would be underestimated. To accomplish that, 
solutions of as-prepared TPGS/htGO (i.e., that were not subject to dialysis or centrifugation) 
at different concentrations were used to obtain the standard curve of this material at 285 nm 
(please note that in this case the exact amount of TPGS and htGO are known since the samples 
were not purified). Afterwards, the absorbance of TPGS at 285 nm was subtracted to that of 
as-prepared TPGS/htGO (at 285 nm), yielding the absorbance of htGO. Subsequently, the 
standard curve of htGO (referred from now on as htGO*) at this wavelength was performed. 
The amount of TPGS incorporated in TPGS/htGO was then calculated by analyzing the  
UV-Vis-NIR absorption spectrum of this compound and through the following equation: 
AbsTPGS/htGO at 285 nm = AbshtGO at 285 nm + AbsTPGS at 285 nm 
To do so, the concentration of htGO in the TPGS/htGO solution was determined by using a 
standard curve of as-prepared TPGS/htGO at 808 nm (please note that TPGS does not have 
absorption at this wavelength). The determined concentration of htGO and the standard curve 
of htGO* at 285 nm were employed to find the absorbance of htGO at 285 nm. Subsequently, 
the determined absorbance of htGO at 285 nm was subtracted to that of TPGS/htGO, yielding 
the absorbance of TPGS. Finally, the absorbance of TPGS at 285 nm was used to determine its 
concentration using a standard curve of TPGS. The gathered data revealed that 26.8 ± 0.7 µg 
of TPGS were incorporated per each µg of htGO. 
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4.3.2.4. Characterization of GrO and nGO-based materials 
The interlayer spacing of GrO and graphite was characterized by X-ray Diffraction (XRD) analysis 
in a Rigaku Geigger Flex D-max III/c diffractometer (Rigaku Americas Corporations, Woodlands, 
USA), equipped with a copper tube, over the range of 2θ from 5 to 90 °. The carbon to oxygen 
ratio of GrO, bwGO and htGO was characterized by Energy-dispersive X-ray spectroscopy (EDS) 
using a XFlash Detector 5010 (Bruker, Karlsruhe, Germany). The different chemical bonds 
present in GrO, bwGO and htGO were identified by Fourier transform infrared spectroscopy 
(FTIR) using a Nicolet iS10 spectrometer (Thermo Scientific Inc., Waltham, USA) with a spectral 
width ranging from 4000 to 600 cm−1. FTIR characterization was also employed to confirm the 
TPGS functionalization through the analysis of the chemical bonds present in the spectra of 
TPGS/nGO derivatives. The suitability and efficacy of the TPGS functionalization were also 
confirmed by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK) at a scattering angle of 173 °. The nanosized dimensions of TPGS/nGO 
derivatives were assessed by transmission electron microscopy (TEM, HT7700, Hitachi, Japan) 
using an accelerating voltage of 100 kV, after staining the samples with phosphotungstic acid 
(2 %, w/v). To determine the potential of the different nGO-derivatives to be applied in cancer 
PTT, their UV-Vis-NIR absorption spectra were acquired on an Evolution 201 spectrophotometer 
(Thermo Scientific Inc., Waltham, USA) over the wavelength range from 200 to 1000 nm. 
Moreover, the photothermal efficiency of TPGS/bwGO and TPGS/htGO derivatives was 
determined by exposing these nanomaterials to NIR laser irradiation (808 nm, 1.7 W cm-2) over 
5 min and recording the temperature variations using a thermocouple thermometer. 
 
4.3.2.5. Evaluation of the cytotoxic profile of non-functionalized nGO 
derivatives 
The biocompatibility of the non-functionalized nGO derivatives was evaluated by the resazurin 
assay as previously described [43]. To do so, NHDF or MCF-7 cells (1 x 104 cells/well) were 
seeded on 96-well plates and cultured in DMEM-F12 medium supplemented with 10 % of FBS and 
1 % of penicillin/streptomycin in a humidified incubator (37 °C, 5 % CO2) [44]. After 24 h, the 
medium was removed and cells were incubated with medium containing bwGO or htGO at 
different concentrations (1 – 100 µg mL-1 of GO equivalents) for 24 and 48 h. After incubation, 
the medium was replaced with fresh medium containing resazurin (10 % v/v) and then cells 
were incubated for 4 h in the dark (37 °C, 5 % CO2). Cells incubated only with medium (without 
nGO derivatives) and cells treated with ethanol (70 %) were used as negative (K-) and positive 
(K+) controls, respectively. Cells’ viability was determined by analyzing the fluorescence of 
resorufin (λex = 560 nm; λem = 590 nm) in a Spectramax Gemini EM spectrofluorometer (Molecular 




4.3.2.6. Evaluation of the cytotoxic effect of TPGS/nGO derivatives 
The cytotoxic effect of TPGS and TPGS/nGO derivatives to NHDF and MCF-7 cells was evaluated 
using the resazurin assay [44]. In brief, NHDF or MCF-7 cells were seeded in 96-well plates at a 
density of 1 x 104 cells/well. After 24 h, the medium was exchanged and cells were incubated 
with fresh medium containing TPGS, TPGS/bwGO or TPGS/htGO at different concentrations 
(TPGS: 0.1 – 40 µM; TPGS/bwGO and TPGS/htGO: 0.1 – 10 µg mL-1 of GO equivalents) for 24 and 
48 h. Cells’ viability was then determined by the resazurin assay as described above. 
 
4.3.2.7. Evaluation of the phototherapeutic effect mediated by TPGS/nGO 
derivatives 
The phototherapeutic capacity of TPGS/nGO derivatives was determined as previously 
described in the literature [45]. In brief, MCF-7 cells were sub-cultured in 96-well plates at a 
density of 1 x 104 cells/well. After 24 h, the medium was exchanged and cells were incubated 
with fresh medium containing bwGO, htGO, TPGS/bwGO or TPGS/htGO at different 
concentrations (6.25 and 10 µg mL-1 of GO equivalents) for 24 h. Afterward, cells were 
irradiated with NIR light (808 nm, 1.7 W cm-2) during 5 min. Cancer cells’ viability was 
determined by following the resazurin protocol described above.  
 
4.3.2.8. Calcein-AM and trypan blue stainings 
Calcein-AM (labels live cells) staining was performed to confirm the phototherapeutic efficacy 
of TPGS/nGO derivatives. In brief, 3 x 104 MCF-7 cells/well were seeded in µ-slide 8-well 
imaging plates (Ibidi GmbH, Munich, Germany). On the following day, the medium was 
exchanged and cells were incubated with fresh medium containing bwGO, htGO, TPGS/bwGO 
or TPGS/htGO for 24 h. Afterward, cells were irradiated with NIR light (808 nm, 1.7 W cm-2) 
during 5 min. Then, the medium was removed, cells were rinsed with PBS and incubated with 
Calcein-AM (2 µM). Subsequently, cells were rinsed with PBS and fixed in paraformaldehyde  
4 % (15 min, RT). Imaging experiments were performed in a Zeiss Axio Observer Z1 (Carl Zeiss 
AG, Oberkochen, Germany) under a 10x objective using an excitation λ of 470 ± 20 nm and an 
emission λ of 525 ± 25 nm. 
Trypan blue (labels dead cells) staining was also performed to assess the phototherapeutic 
capacity of TPGS/nGO derivatives. Briefly, after the laser irradiation step, cells were rinsed 
with PBS and then incubated with trypan blue (0.2 % (w/v)). Afterward, cells were rinsed, fixed 
and images were collected in an Olympus CX41 inverted optical microscope equipped with an 
Olympus SP-500 UZ digital camera. 
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4.3.2.9. Statistical analysis 
One-way analysis of variance (ANOVA) with the Student-Newman-Keuls test was used for 
multiple groups comparison. A p value lower than 0.05 (p < 0.05) was considered statistically 
significant. GraphPad Prism v6.0 (Trial version, GraphPad Software, San Diego, USA) was used 
for data analysis. 
 
4.4. Results and discussion 
 
4.4.1. Preparation and characterization of GrO 
The successful synthesis of GrO was confirmed by XRD, FTIR, UV-Vis and EDS  
analysis (Figure 4.1).  
 
 
Figure 4.1. Characterization of GrO. XRD (A) and FTIR (B) spectra of GrO and graphite.  
UV-Vis-NIR absorption spectrum of GrO (C). 
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XRD spectrum of graphite (GrO precursor) showed its characteristic peak at 2Θ = 26.5 ° (Figure 
4.1A). After the chemical oxidation, a product with a diffraction peak of 2Θ = 9.55 ° was 
obtained (Figure 4.1A). This result demonstrates the introduction of oxygen groups in graphite 
since the interlayer space increased to approx. 9.3 Å. As importantly, the absence of graphite 
diffraction peaks in GrO spectrum indicates that the final product does not have un-oxidized 
graphite. FTIR analysis demonstrated that GrO has different types of oxygen functional groups 
(hydroxyl, carboxyl and epoxy), further corroborating the successful oxidation of graphite 
(Figure 4.1B). EDS analysis of GrO revealed that this material has a carbon:oxygen (C:O) ratio 
of 61:39. Finally, the characteristic absorbance peak of GrO was also present in the absorption 
spectrum of GrO (λmax= 229 nm) (Figure 4.1C). These results are in agreement with literature 
reports and together these confirm the successful synthesis of GrO [39]. 
 
4.4.2. Preparation and characterization of TPGS/nGO derivatives 
Subsequently, GrO was base-washed in order to remove the oxidation debris since it can 
improve the adsorption of molecules, like TPGS, on the surface of GO [40, 46, 47]. Then, the 
obtained material was subjected to ultrasonication, yielding nanosized bwGO.  
Two different approaches were used to produce bwGO derivatives functionalized with TPGS 
(Figure 4.2A). In the first approach, bwGO was functionalized with TPGS using a simple 
sonication method (TPGS/bwGO) (Figure 4.2A). The binding of TPGS to bwGO was confirmed 
through FTIR analysis. Prior to functionalization, the bwGO FTIR spectrum shows various peaks 
at ≈ 3270 cm-1 (O-H stretch), 1730 cm-1 (C=O stretch), and 1041 cm-1 (C-O stretch) that belong 
to the different oxygen functional groups present on this material (see Figure 4.2B for further 
details). In turn, the FTIR spectrum of TPGS/bwGO displayed peaks with an increased intensity 
at 2884 cm-1 (C-H stretch), 1737 cm-1 (C=O stretch) and 1105 cm-1 (C-O stretch) (Figure 4.2B). 
Such peaks can be attributed to the chemical bonds present in TPGS (Figure 4.3A) and also 
confirm that bwGO was functionalized with TPGS.  
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Figure 4.2. Preparation and characterization of TPGS/nGO derivatives. Schematic illustration of the 
method used for preparing TPGS/bwGO and TPGS/htGO (A). FTIR spectra of bwGO and TPGS/bwGO (B). 
DLS size distribution of bwGO, TPGS/bwGO, and TPGS/bwGO in saline solution (NaCl 0.9 %) (C). FTIR 
spectra of htGO and TPGS/htGO (D). DLS size distribution of htGO, TPGS/htGO, and TPGS/htGO in saline 




Figure 4.3. TPGS characterization. FTIR spectra of TPGS (A). Peaks observed at 2884, 1737 and  
1105 cm-1 are attributed to C-H, C=O and C-O stretches, respectively. Absorption spectra of TPGS (B). An 
absorption peak at 260 – 300 nm is observed (inset). 
 
DLS results indicate that the TPGS functionalization did not affect the size of the nanostructures 
since bwGO and TPGS/bwGO reveal a similar size distribution (Figure 4.2C). To further assess 
the suitability of the TPGS coating, DLS analysis of bwGO and TPGS/bwGO in NaCl 0.9 % (that 
was used as a model saline solution) was also performed. As expected, bwGO promptly 
precipitated in NaCl 0.9 % (Figure 4.4), which is in agreement with the poor colloidal stability 
of nGO derivatives in saline solutions [18].  
 
Figure 4.4. Macroscopic images of bwGO, htGO, TPGS/bwGO, and TPGS/htGO in water, NaCl 0.9 % and 
serum supplemented medium (DMEM-F12 supplemented with FBS (10 %, (v/v)) taken over the course of  
5 days (end-point of the study). bwGO and htGO promptly precipitated in NaCl 0.9 %. TPGS/bwGO 
precipitated in NaCl 0.9 % after an incubation period of 12 h. 
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In contrast, TPGS/bwGO demonstrated a similar size distribution, without any signs of 
aggregation, when immersed in NaCl 0.9 % or in water (Figures 4.2C and 4.4). TPGS/bwGO 
remained stable in NaCl 0.9 % during 12 h and maintained its stability in water and in serum 
supplemented medium up to 5 days (Figure 4.4). Such findings also attest the successful 
functionalization of bwGO with TPGS and ensure the applicability of TPGS/bwGO in subsequent 
experiments. TEM characterization was then performed to confirm the lateral dimensions of 
TPGS/bwGO since DLS analysis cannot be used to estimate with confidence the precise 
dimensions of non-spherical materials. The results revealed that TPGS/bwGO has an average 
lateral size of 53 nm, which is crucial for its application in cancer-related  
topics (Figure 4.5A-5B). Moreover, bwGO and TPGS/bwGO displayed a zeta potential of  
-56.2 ± 1.1 and -22.5 ± 1.1 mV, respectively. The zeta potential value obtained for TPGS/bwGO 
is in agreement with those previously published in the literature for TPGS-based nanomedicines 
[32, 48].  
 
 
Figure 4.5. Size distribution of TPGS/nGO derivatives. TEM images of TPGS/bwGO (A) and  
TPGS/htGO (C). Prior to the analysis samples were stained with phosphotungstic acid  
(2 %, w/v). More than 500 nanostructures were measured for each sample in TEM images. Lateral size 




Finally, the 260 – 300 nm peak observed in the UV-Vis-NIR spectrum of TPGS/bwGO also supports 
the presence of TPGS in this material (Figures 4.6A and 4.3B). Moreover, the UV-Vis-NIR 
absorption spectra of TPGS/bwGO and bwGO were similar for higher wavelengths (Figure 4.6A), 
indicating that bwGO functionalization with TPGS did not affect its NIR absorption, which is 
crucial for its application in cancer PTT. 
To improve the NIR absorption of bwGO, this nanomaterial was reduced by a hydrothermal 
treatment (24 h at 80 °C), yielding hydrothermal treated GO (htGO). The hydrothermal 
treatment produced a prominent decrease in the intensity of the oxygen functional groups of 
htGO when compared to bwGO (Figure 4.2D) and also increased the zeta potential of the 
nanosheets to -44.7 ± 2.1 mV. The EDS analysis revealed that bwGO and htGO have a carbon to 
oxygen ratio of 65:35 and 68:32, respectively. Together these results confirm the reductive 
capacity of the hydrothermal treatment. Moreover, htGO displayed a higher UV-Vis-NIR 
absorption than bwGO (on average a 2.4-fold higher absorption at 808 nm), thus confirming the 
suitability of this method to improve the NIR absorption of bwGO (Figures 4.6A), as previously 
described by Chen and co-workers [42]. 
Furthermore, the hydrothermal treatment was also applied to reduce bwGO and non-covalently 
functionalize it with TPGS (TPGS/htGO) by a one-pot approach (Figure 4.2A). Similar to 
TPGS/bwGO, the FTIR (Figures 4.2D and 4.3A), DLS (Figure 4.2E), and UV-Vis-NIR (Figures 4.6A 
and 4.3B) analysis of TPGS/htGO also confirmed the suitability and the efficacy of the TPGS 
functionalization. Interestingly, TPGS/htGO maintained its stability in water, NaCl 0.9 % and 
serum supplemented medium during 5 days, which may be correlated with the higher capacity 
of htGO to adsorb TPGS (Figure 4.4). Moreover, the TEM characterization revealed that 
TPGS/htGO has an average lateral size of 74 nm, rendering it suitable to be applied in cancer 
therapy (Figure 4.5C-5D). The zeta potential of TPGS/htGO (-23.0 ± 2.7 mV) was also similar to 
that of TPGS/bwGO. However, the NIR absorption displayed by TPGS/htGO was lower than that 
of htGO, which implies that the inclusion of TPGS in the hydrothermal treatment affects the 
reduction process of bwGO (Figure 4.6A). Nevertheless, TPGS/htGO demonstrated on average 
a 1.9-fold higher absorption at 808 nm than TPGS/bwGO (Figure 4.6B). Since a  
808 nm laser light will be employed in photothermal studies to irradiate the TPGS/nGO 
derivatives, TPGS/htGO may produce an enhanced temperature variation under NIR irradiation 




Figure 4.6. Photothermal capacity of TPGS/nGO derivatives. UV-Vis-NIR absorption spectra of bwGO, 
htGO, TPGS/bwGO, and TPGS/htGO at a concentration of 10 µg mL-1 (of GO equivalents) (A). Absorbance 
of TPGS/htGO at 808 nm normalized to that of TPGS/bwGO at the same wavelength (data represent mean 
± SD, n = 4) (B). Temperature variation curves of TPGS/bwGO solutions at different concentrations  
(of bwGO) during 5 min of NIR irradiation (808 nm, 1.7 W cm-2) (n = 1) (C). Temperature variation curves 
of TPGS/htGO solutions at different concentrations (of htGO) during 5 min of NIR irradiation (808 nm,  
1.7 W cm-2) (n = 1) (D). 
 
4.4.3. Evaluation of the photothermal capacity of TPGS/nGO 
derivatives 
After confirming the NIR absorption of TPGS/bwGO and TPGS/htGO, the photothermal ability 
of these materials was investigated by recording the temperature changes upon NIR laser 
irradiation. Both TPGS/nGO derivatives produced a dose-dependent temperature variation 
under NIR laser irradiation (Figures 4.6C-6D). At the highest concentration tested (75 µg mL-1 
of GO equivalents) and after 5 min of laser irradiation, TPGS/bwGO and TPGS/htGO produced 
a temperature variation of about 18 and 27 °C, respectively (Figures 4.6C-6D). Such 
temperature increase can lead to cancer cells death through diverse mechanisms including 
dysfunction of mitochondrial and enzymatic functions, protein denaturation and disruption of 
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cells’ membrane [49]. In turn, at the lowest concentration (6.25 µg mL-1 of GO equivalents) the 
photoinduced heat produced by both TPGS/nGO derivatives (ΔT ≈ 4 – 6 °C) can still damage 
cancer cells by compromising DNA repair mechanisms, altering cellular metabolism and 
increasing the sensitivity of cancer cells to anticancer agents (Figures 4.6C-6D) [49]. In these 
experiments, water was used as the control and it demonstrated a negligible response to NIR 
light during the irradiation period (Figures 4.6C-6D). Such findings attest the photothermal 
potential of the TPGS/nGO derivatives. 
In general, TPGS/htGO generated a photoinduced heat 1.4 – 1.6 times higher than TPGS/bwGO 
(Figure 4.7). The enhanced photothermal conversion of TPGS/htGO is correlated with its higher 
NIR absorption and proves the utility of the hydrothermal treatment to improve the PTT 
capacity of nGO derivatives.  
 
 
Figure 4.7. Temperature variation induced by different concentrations of TPGS/bwGO and TPGS/htGO, 
after 5 min of laser irradiation (808 nm, 1.7 W cm-2).  
 
Even though the applied hydrothermal treatment is not as effective as hydrazine hydrate-based 
treatments for obtaining nGO derivatives with an improved photothermal capacity, this method 
is a greener route since it does not employ hazardous and highly toxic chemicals [18]. Moreover, 
reductions based on hydrazine hydrate generally do not support one-pot approaches. As a 
consequence, first the nGO derivatives must be reduced and purified, followed by 
functionalization and new purification steps [18]. These facts emphasize the simplicity and 
convenience of the one-pot hydrothermal functionalization and reduction herein applied. 
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4.4.4. Evaluation of nGO derivatives’ biocompatibility  
Before assessing the biological performance of TPGS/nGO derivatives, the biocompatibility of 
the non-coated materials was evaluated by using NHDF and MCF-7 cells as healthy and breast 
cancer models, respectively. The results revealed that NHDF treated with bwGO and htGO up 
to 100 µg mL-1 display a viability superior to 92 % (Figures 4.8A-8B), which suggests the excellent 
biocompatibility of these materials within the tested concentration range (1 – 100 µg mL-1) in 
healthy cells.  
 
 
Figure 4.8. Evaluation of the biocompatible profile of bwGO (A) and htGO (B) at different concentrations 
and incubation periods in NHDF. The biocompatibility of bwGO (C) and htGO (D) in MCF-7 cells was also 
determined in the same experimental conditions. Data represent mean ± SD, n = 5. K- and K+ represent 
the negative and positive controls, respectively. 
 
A dose-dependent variation in the viability of MCF-7 cells was noticed (Figures 4.8C-8D). 
Nevertheless, MCF-7 cells incubated with both materials up to 100 µg mL-1 demonstrated a 
viability above 78 %, which also indicates that these nanomaterials are biocompatible within 
the tested dose (Figures 4.8C-8D). Moreover, both materials did not induce modifications on 
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cells’ morphology during the tested periods, thereby corroborating the cell viability results 
(Figure 4.9).  
 
 
Figure 4.9. Optical microscopic images of NHDF and MCF-7 cells after different incubation periods (24 
and 48 h) with bwGO and htGO (100 µg mL-1). Non-treated cells were denoted as the control. 
 
The potential biocompatibility or toxicity of GO-based materials depends strongly on the lateral 
dimensions, chemical composition and surface chemistry of the nanosheets [50-52]. Akhavan 
and co-workers demonstrated that ultra-small rGO-based materials (average lateral dimension 
of 11 nm) prepared using hydrazine hydrate induce a higher toxicity to human mesenchymal 
stem cells (hMSCs) than their equivalents with bigger dimensions [52]. In a different work, 
Zhang and co-workers verified that small sized GO (average lateral size of 34 nm and 147 nm), 
which has a similar size to that of bwGO and htGO, induces few alterations to human cervical 
cancer cells (HeLa) when compared to 206 nm sized GO [53]. Chang et al. demonstrated the 
biocompatible profile of GO with different lateral sizes in non-small cell lung cancer cells (A549) 
up to 100 µg mL-1 [54]. Recently, Pattammattel et al. reported that human embryonic kidney 
cells (HEK 293T) incubated with 75 and 100 µg mL-1 of bwGO for 24 h, display a viability of 
about 90 and 68 %, respectively, which is also in line with our results considering that the 
biocompatibility of GO-based materials depends on multiple factors [50, 55]. The slightly lower 
biocompatibility determined for htGO (in MCF-7 cells) is also in agreement with the results 
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available in literature since rGO-based materials (particularly those prepared using hydrazine 
hydrate) may display a weaker biocompatible profile [51, 56, 57].  
 
4.4.5. Evaluation of TPGS/nGO derivatives’ anticancer activity 
After confirming the biocompatibility of the non-coated materials, the possible anticancer 
potential of the TPGS/nGO derivatives mediated by TPGS activity was also evaluated in NHDF 
and MCF-7 cells. As can be observed in Figures 4.10A-10B and 4.11, TPGS/bwGO and 
TPGS/htGO, at the tested concentrations (0.1 – 10 µg mL-1 of GO equivalents), did not induce 
any significant alterations in NHDF cellular viability and morphology after an incubation period 
of 24 or 48 h (viability > 88 %). 
 
 
Figure 4.10. Evaluation of the cytotoxic profile of TPGS/bwGO (A) and TPGS/htGO (B) at different 
concentrations and incubation periods in NHDF. The cytotoxicity of TPGS/bwGO (C) and TPGS/htGO (D) 
in MCF-7 cells was also determined in the same experimental conditions. Data represent mean ± SD,  




Interestingly, a reduction in MCF-7 cells’ viability and modifications on cells’ morphology were 
noticed for low concentrations of the produced materials (Figures 4.10C-10D and 4.11). After 
an incubation period of 24 h, TPGS/nGO derivatives induced cytotoxic effects for 
concentrations above 7.5 µg mL-1 (of GO equivalents). Moreover, after an incubation of  
48 h these materials produced meaningful alterations in MCF-7 cells’ viability for concentrations 
above 6.25 µg mL-1 (of GO equivalents) (Figures 4.10C-10D). In fact, after this period, 
TPGS/bwGO and TPGS/htGO at the concentration of 7.5 µg mL-1 (of GO equivalents) were able 
to reduce MCF-7 cells’ viability up to 34 and 32 %, respectively.  
 
 
Figure 4.11. Optical microscopic images of NHDF and MCF-7 cells after different incubation periods (24 
and 48 h) with TPGS/bwGO and TPGS/htGO (6.25 and 10 µg mL-1 of GO equivalents). Non-treated cells 
were denoted as control. 
 
The differential effect of TPGS/nGO derivatives in NHDF and MCF-7 cells can be explained by 
the distinct sensitivity displayed by these cells to TPGS (Figure 4.12). In fact, TPGS produced a 
dose-dependent cytotoxic effect on MCF-7 cells, while NHDF incubated with this compound only 
display a decrease in their viability for higher concentrations and for long incubation periods 
(Figure 4.12). These results are in agreement with the findings previously reported by 
Neophytou et al., which investigated the molecular mechanism of action of TPGS in different 
cell lines and also verified that breast cancer cells are sensitive to TPGS while healthy cells are 
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resistant to its effect [38]. In particular, authors verified that TPGS exerts its anticancer activity 
through inhibition of Protein Kinase B (PKB or Akt) phosphorylation [38]. In MCF-7 cells, this 
inhibition produces a decrease in the levels of BcL-2 and Survivin (which are overexpressed), 
leading to cell cycle arrest and caspase-dependent and -independent cell death [38]. In normal 
cells, authors verified that TPGS does not induce a cytotoxic effect since the targeted/affected 
signaling-cascade is not upregulated [38]. Due to these properties, TPGS was also combined 
with other materials and pro-drugs in order to explore and enhance its anticancer activity [58-
61]. Therefore, the TPGS functionalization improves the stability of TPGS/bwGO and 




Figure 4.12. Evaluation of the cytotoxic profile of TPGS at different concentrations (0.1 – 40 µM) and 
incubation periods (24 and 48 h) in NHDF (A) and MCF-7 (B) cells. Data represent mean ± SD, n = 5. K- and 
K+ represent the negative and positive controls, respectively. 
 
4.4.6. Evaluation of the phototherapeutic effect mediated by 
TPGS/nGO derivatives 
After confirming the preferential therapeutic effect of TPGS/nGO derivatives in MCF-7 cells, 
the capacity of these materials to mediate an enhanced cytotoxic effect by combining their 
anticancer activity with photothermal capability was also evaluated. For this purpose, MCF-7 
cells were incubated with TPGS/nGO derivatives for 24 h followed by their irradiation with NIR 
light (Figure 4.13A).  
The combined application of TPGS/nGO derivatives and NIR light during 5 min produced a 
prominent reduction in MCF-7 cells viability (Figure 4.13B), which was superior to that mediated 
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by non-irradiated nanomaterials in the same experimental conditions (Figures 4.10C-10D). For 
instance, TPGS/bwGO, at the concentration of 6.25 µg mL-1 (of GO equivalents) and with an 
incubation time of 24 h, did not affect MCF-7 cells while its irradiation with NIR light decreased 
cells viability to about 35 % (Figures 4.10C and 4.13B). In equivalent experimental conditions 
(same concentration and incubation period), TPGS/htGO reduced slightly the viability of cancer 
cells (to approximately 91 %) and its combined application with NIR irradiation produced a 
decrease in cells viability to about 31 % (Figures 4.10D and 4.13B). The slightly better 
therapeutic effect mediated by TPGS/htGO under NIR laser irradiation may be a consequence 
of its improved photothermal capacity (Figure 4.6D) and slightly better anticancer activity 
(Figure 4.10D). Moreover, the sole application of the NIR light and its combination with  
non-coated materials (bwGO and htGO) did not induce any toxicity towards cancer cells (Figure 
4.13B). These results imply that the temperature variation produced by TPGS/nGO derivatives 
under NIR laser irradiation sensitizes cancer cells to TPGS action, resulting in a synergistic 
therapeutic effect (Figure 4.13B).  
 
 
Figure 4.13. In vitro phototherapy using TPGS/nGO derivatives. Schematic representation of the 
phototherapy (A). Therapeutic effect mediated by bwGO, htGO, TPGS/bwGO and TPGS/htGO under NIR 
irradiation (808 nm, 1.7 W cm-2, 5 min) towards MCF-7 cells (B). NIR represents cells solely irradiated with 
NIR light. K- and K+ represent the negative and positive controls, respectively. Data represent mean ± SD, 
n = 5, n.s. = non significant, ∗p < 0.05. 
 
Trypan blue (stains cells that have a compromised membrane with blue color) and Calcein-AM 
(non-fluorescent dye that is converted to a fluorescent molecule by live cells) stainings were 
also used to provide a visual confirmation of TPGS/nGO derivatives phototherapeutic efficacy 
(Figure 4.14).  
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Figure 4.14. Trypan blue and Calcein-AM staining of MCF-7 cells after cells being incubated with different 
concentrations of nGO and TPGS/nGO derivatives (6.25 and 10 µg mL-1 of GO equivalents) during 24 h 
without (- NIR) or with (+ NIR) laser irradiation (808 nm, 1.7 W cm-2, 5 min). Cells not treated with 
nanomaterials were used as controls. 
 
Consistent with the previous findings, the sole application of non-functionalized nGO 
derivatives (bwGO and htGO) or their combination with NIR light did not affect MCF-7 cells 
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integrity (Figure 4.14). As expected, similar results were obtained for cells treated with 
TPGS/bwGO or TPGS/htGO at the concentration of 6.25 µg mL-1 (of GO equivalents) (Figure 
4.14). However, the same materials in conjugation with NIR light produced a strong therapeutic 
effect since, after the treatment and staining protocol (comprises staining, fixing and washing 
steps), no intact cells remained in the well, thereby confirming that under these conditions 
MCF-7 cells are severely affected (Figure 4.14). TPGS/nGO derivatives at the concentration of 
10 µg mL-1 (of GO equivalents) or in combination with NIR light produced a similar result, which 
is also in agreement with the previous results (Figure 4.10, 4.13 and 4.14). 
So far, nGO derivatives have been: (i) functionalized with hydrophilic polymers to improve their 
stability and biocompatibility, (ii) reduced to enhance their photothermal capacity and  
(iii) decorated with targeting ligands to improve their selectivity. By combining these 
approaches, some materials were able to photoablate cancer cells/tumors, by using low 
concentrations and/or power density [18, 22, 24, 25]. In this work, TPGS/bwGO and TPGS/htGO 
preferentially diminished breast cancer cells’ viability, displaying an insignificant effect on 
normal cells, an effect that can be attributed to TPGS intrinsic anticancer activity. This type 
of selectivity mediated by TPGS molecular action is advantageous since it may not be hindered 
by the formation of a protein corona on nanomaterials’ surface as it has been reported for 
targeted nanomaterials [62]. Moreover, TPGS/nGO derivatives under NIR laser irradiation 
produced a synergistic therapeutic effect whose efficacy is comparable and, in some cases, 
superior to previously described materials by mediating cancer cells destruction at a relatively 
low concentration and power density [21, 22, 25, 42, 57, 63-69] (Table S.4.1 – supplementary 




In the present study, TPGS/bwGO and TPGS/htGO nanomaterials were prepared through a 
simple sonication method and a one-pot hydrothermal treatment, respectively. The application 
of TPGS to coat nGO derivatives is herein reported for the first time and the results revealed 
that it was able to improve the stability of these nanomaterials. TPGS/htGO possessed about 
1.9-fold higher NIR absorption than TPGS/bwGO, thus producing a 1.4 – 1.6 times superior 
temperature variation under NIR laser irradiation. In vitro, TPGS/bwGO and TPGS/htGO 
diminished breast cancer cells’ viability and had an insignificant effect on healthy cells. This 
preferential effect towards breast cancer cells can be attributed to TPGS intrinsic anticancer 
activity. Moreover, at low doses, both TPGS/nGO derivatives mediated under NIR laser 
irradiation an improved cytotoxic effect towards cancer cells, and it was found that TPGS/htGO 
produced a slightly better therapeutic outcome. Overall, the results reveal that TPGS/bwGO 
and TPGS/htGO are promising agents for breast cancer therapy.   
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to ≤ 10 %? 
Ref. 
Polyglicerol-reduced 
nGO loaded with 
Curcumin 
30a,b) 1 2 MCF-7 No [1] 
PEGylated and HA 
functionalized rGO 
loaded with IR825 





loaded with DOXc) and 
Irinotecan 












1 – 100 7.5 8 U87MG Yes [5] 
ZnFe2O4–rGO hybrid 
nanostructures 
10 7.5 4-12 LNCaP Yes [6] 
Glucose rGO 
(prepared in the 
presence of Fe 
catalyst) 
10-1000 7.5 0.5-12 LNCaP Yes [7] 
PVP-graphene 5-10 2 5 U251 Yes [8] 
FA-PVP-nGO loaded 
with DOX 
20a) 2 5 HeLa Yes [9] 
PEGylated nGO loaded 
with DOX 
30a) 2 3 EMT6 Yes [10] 
Cetuximab conjugated 
PEGylated nGO loaded 
with Epirubicin 
5-25a) 2 2 U87 Yes [11] 
PEGylated reduced 
nGO 
6 0.6 5 A549 Yes [12] 
TPGS/nGO derivatives 10 1.7 5 MCF-7 Yes This 
work 
a) Drug concentration; b) value in µM; c) Doxorubicin.  
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This chapter is based on a manuscript submitted for publication entitled: POxylated 
Graphene Oxide Nanomaterials for Combination Chemo-Phototherapy of Breast Cancer 






PEGylated GO nanomaterials have been showing promising results in cancer therapy, due to 
their drug loading and photothermal capacities. However, the recent reports regarding the 
immunogenicity of PEG based coatings highlight the importance of investigating alternative 
materials to functionalize GO. Herein, GO derivatives were functionalized for the first time 
with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with 
doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of 
breast cancer cells. The results revealed that POxylated GO displays the required properties 
for application in cancer therapy. Moreover, the screening of different DOX:TOS combination 
ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic 
effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal 
cells. POxylated GO was then loaded with this drug combination in order to assess its  
chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells 
induced a stronger therapeutic effect than that attained with the free drug combination. 
Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing 
DOX:TOS loaded POxylated GO to NIR radiation. Overall, POxylated GO is a promising drug 
delivery and phototherapeutic agent. 
 




Combination chemotherapy is commonly applied to treat several types of cancers, including 
breast cancer. In this therapeutic approach, drug combinations (e.g. DOX + cyclophosphamide) 
are used to tackle cancer cells through different pathways, aiming to achieve additive or 
synergistic therapeutic effects, being the latter the most advantageous [1, 2]. However, the 
administration of multiple chemotherapeutics is challenging since an escalation of drugs’  
side-effects may occur [3, 4]. Furthermore, the distinct biodistribution and clearance profiles 
of the drugs may hamper the uptake of precise drug:drug combination ratios by cancer cells [5, 
6].  
To surpass these limitations, drug combinations can be loaded in nano-sized materials, allowing 
a ratiometric drug delivery to cancer cells [6]. In addition, the encapsulation of drugs in 
nanocarriers also improves their solubility and protects them from degradation or rapid 
clearance [7]. Among the different types of nanomaterials that have been explored for  
co-encapsulating drugs, nGO is a promising material since it has an excellent loading capacity 
and has the ability to encapsulate a wide variety of compounds through hydrophobic 
interactions and/or π-π stacking [8-10]. Moreover, the NIR absorption of GO based materials 
enables their application in cancer photothermal therapy [11, 12]. In this therapeutic approach, 
GO absorbs NIR radiation and converts it into heat, thus inducing cancer cells death and/or 
sensitization to the action of chemotherapeutics [13]. 
Despite the potential of GO based nanomaterials for use in combination chemo-photothermal 
therapy, these materials precipitate rapidly when in contact with biological fluids [14]. To 
overcome this limitation, GO is generally functionalized with PEG derivatives through covalent 
linkages or non-covalent interactions [11, 14]. The PEGylation of GO can also improve its blood 
circulation time, favoring its accumulation on the tumor zone [11, 14]. However, recently it 
was unveiled that PEGylated GO derivatives suffer from the accelerated blood clearance 
phenomenon [15], which may limit the repeated administration of these nanomaterials for 
cancer-related applications and highlights the importance of investigating PEG alternatives to 
functionalize GO. 
In this work, GO derivatives were functionalized for the first time with an amphiphilic polymer 
based on poly(2-ethyl-2-oxazoline) (PEtOx) and were explored for combination  
chemo-phototherapy of breast cancer cells. PEtOx was selected due to its hydrophilic character 
and possible application as a PEG alternative [16-18]. PEtOx was grafted onto  
poly(maleic anhydride-alt-1-octadecene) (PMAO) since the hydrophobic blocks of the latter can 
efficiently adsorb to GO surface [14]. Furthermore, the DOX and TOS drug combination was 
selected to be loaded into GO since it was recently used with success in the treatment of gastric 
cancer cells [19]. Our results revealed that POxylated GO displays suitable physicochemical, 
colloidal, optical and biological properties for cancer therapy. Additionally, the screening of 
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different DOX:TOS combination ratios revealed that the 1:3 DOX:TOS molar ratio has an 
improved therapeutic potential since it has an optimal synergistic cytotoxic effect (low 
combination index across multiple fractions affected) towards breast cancer cells, while on 
normal cells it has a weaker effect. Therefore, POxylated GO was efficiently loaded with this 
drug combination in order to investigate its chemo-phototherapeutic performance. The delivery 
of DOX:TOS by POxylated GO to cancer cells produced a stronger therapeutic effect than that 
attained using the free drug combination. Furthermore, DOX:TOS loaded POxylated GO under 
NIR laser irradiation produced an even greater cytotoxicity towards cancer cells, thus 
confirming the therapeutic capacity of the ratiometric drug delivery and phototherapy 
mediated by POxylated GO. 
 
5.3. Materials and Methods 
 
5.3.1. Materials 
DMEM-F-12, EDTA, PMAO (30000-50000 Da), resazurin, TOS and trypsin were purchased from 
Sigma–Aldrich (Sintra, Portugal). DOX was acquired from Carbosynth (Berkshire, UK). PEtOx 
(5000 Da) was obtained from Polysciences (Bergstrasse, Germany). MCF-7 cell line was acquired 
from ATCC (Middlesex, UK). NHDF were purchased from PromoCell (Heidelberg, Germany). FBS 
was obtained from Biochrom AG (Berlin, Germany). Cell culture plates and T-flasks were 
obtained from Thermo Fisher Scientific (Porto, Portugal). Water used in all assays was double 




5.3.2.1. Synthesis of POx-g-PMAO 
POx-g-PMAO was prepared according to a method previously described in the literature with 
slight modifications [20]. Briefly, PMAO (105 mg), PEtOx (510 mg) and a catalytic amount of 
concentrated H2SO4 (i.e., several drops) were refluxed in chloroform at 70 °C for 12 h. 
Afterward, the solvent was removed through rotary-evaporation (Rotavap® R-215, Büchi, 
Switzerland). The obtained material was then dialyzed (14 kDa molecular-weight cutoff 
membrane) against water for 3 days and freeze-dried (ScanVac CoolSafe, LaboGene ApS, 
Denmark), yielding POx-g-PMAO. 
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5.3.2.2. Functionalization of GO derivatives 
bwGO was produced as described in a previous publication of our group [21]. bwGO was then 
functionalized with POx-g-PMAO using a simple sonication method [21]. In brief, a mixture of 
bwGO (200 µg mL-1; 1 mL) and POx-g-PMAO (500 µg) was sonicated for 60 min (Branson 5800, 
Branson Ultrasonics, CT, USA). Afterward, the solution was centrifuged (to remove any possible 
aggregates) and the supernatant was recovered, yielding POx-g-PMAO functionalized bwGO 
(POx-GO).  
The absorption spectrum of POx-GO was used to determine the content of POx-g-PMAO 
incorporated on this nanomaterial, using the following equation: 
AbsPOx-GO at 206 nm = AbsbwGO at 206 nm + AbsPOx-g-PMAO at 206 nm 
To accomplish that, the absorption spectrum of POx-GO in water:methanol (1:1 (v/v)) was 
initially acquired. Afterward, the concentration of bwGO in the POx-GO solution was 
determined using a standard curve of bwGO at 808 nm (POx-g-PMAO does not display any 
absorbance at 808 nm in the concentration range used herein). Subsequently, AbsbwGO at 206 nm 
(determined using a standard curve) was subtracted to the AbsPOx-GO at 206 nm, rendering the 
AbsPOx-g-PMAO at 206 nm. Finally, the concentration of POx-g-PMAO was determined using the  
AbsPOx-g-PMAO at 206 nm and a standard curve of POx-g-PMAO (at 206 nm). All the standard curves 
were prepared with the analytes dissolved in water:methanol (1:1 (v/v)). 
 
5.3.2.3. Physicochemical characterization of POx-GO derivatives 
The successful functionalization of bwGO with POx-g-PMAO was confirmed through FTIR using 
a Nicolet iS10 spectrometer (Thermo Scientific Inc., MA, USA) with a spectral width ranging 
from 4000 to 600 cm-1. POx-GO size distribution and colloidal stability were confirmed by DLS 
using a Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) at a scattering angle of 
173°. UV-Vis absorption spectroscopy (Evolution 201 spectrophotometer, Thermo Scientific 
Inc.) was employed to confirm the NIR absorption of POx-GO. The photothermal capacity of 
POx-GO was confirmed by monitoring the temperature variations, using a thermocouple 
thermometer, upon irradiation of the nanostructures with NIR laser light over a period of 5 min 




5.3.2.4. Evaluation of POx-GO cytocompatibility  
The cytocompatibility of POx-GO to MCF-7 cells and NHDF was characterized using the resazurin 
method, as previously described by our group [22]. All cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium-F12 supplemented with 10 % (v/v) of FBS and 1 % (v/v) of 
penicillin/streptomycin in a humidified incubator (37 °C, 5 % CO2). For the assay, MCF-7 cells 
and NHDF were seeded at a density of 1 x 104 cells/well in 96-well plates. After 24 h, the 
medium was removed, and cells were incubated with culture medium containing different doses 
of POx-GO (1 – 100 µg mL-1 of bwGO equivalents) for 24 or 48 h. Then, cells were incubated 
with culture medium containing resazurin (10 % (v/v)) in the dark for 4 h (37 °C, 5 % CO2). Cells’ 
viability was then determined by analyzing the fluorescence of resorufin (λex = 560 nm;  
λem = 590 nm) in a Spectramax Gemini EM spectrofluorometer (Molecular Devices LLC, CA, USA). 
Negative (K-) and positive (K+) controls correspond to cells incubated solely with culture 
medium (without nanomaterials) and to cells treated with ethanol (70 % (v/v)), respectively. 
 
5.3.2.5. Screening of DOX:TOS combinations 
The concentration of DOX, TOS and DOX:TOS combinations (at different molar ratios ranging 
from 5:1 to 1:5) required to inhibit MCF-7 cells’ viability by 20, 50 and 80 % (IC20, IC50 and IC80) 
were determined through the resazurin assay, as described above. In brief, MCF-7 cells were 
seeded at a density of 1 x 104 cells/well in 96-well plates. After 24 h, the medium was removed, 
and cells were incubated with culture medium containing different drug doses for 24 h. Then, 
cells were incubated with resazurin (10 % (v/v)) for 4 h in the dark (37 °C, 5 % CO2) and their 
viability was determined as described in section 5.3.2.4. Subsequently, drugs’ dose-response 
curves were traced to determine their IC20, IC50 and IC80 (OriginPro, trial version, OriginLab 
Corporation, MA, USA). Finally, the Chou-Talalay method was employed to disclose the 
Combination Index (CI) of the different DOX:TOS combination ratios at inhibition levels of  
20 (Fraction affected (Fa)=0.2), 50 (Fa=0.5) and 80 % (Fa=0.8) [23]. CI < 1 was considered to be 
a synergistic effect whereas CI > 1 was considered to be an antagonistic effect. 
 
5.3.2.6. Preparation of DOX:TOS loaded POx-GO 
DOX and TOS loaded POx-GO was prepared by using a simple sonication method. In brief, a 
solution containing bwGO and POx-g-PMAO was sonicated as described in section 5.3.2.2. Then, 
this solution was mixed with 20 µL of the dual drug combination mixture (DOX:TOS at 1:3 molar 
ratio in methanol), followed by sonication for 30 min. Subsequently, the solution was dialyzed 
(1000 Da molecular-weight cutoff membrane) against water for 90 min to remove non-loaded 
drugs and the methanol. Finally, the solution was centrifuged (to remove any possible 
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aggregates) and the supernatant was recovered, yielding DOX and TOS loaded POx-GO  
(DT loaded POx-GO).  
The UV-Vis-NIR absorption spectrum of DT loaded POx-GO was used to determine the content 
of DOX and TOS on this nanomaterial, using the following equations: 
AbsDT loaded POx-GO at 498 nm = AbsbwGO at 498 nm + AbsDOX at 498 nm 
AbsDT loaded POx-GO at 284 nm = AbsbwGO at 284 nm + AbsDOX at 284 nm+ AbsTOS at 284 nm 
(please note that POx-g-PMAO does not display any absorbance at the above wavelengths in 
the concentration range used herein) 
First, the absorption spectrum of DT loaded POx-GO in water:methanol (1:1 (v/v)) was 
acquired. Afterward, the concentration of bwGO in the DT loaded POx-GO solution was 
determined using a standard curve of bwGO at 808 nm (DOX and TOS do not display any 
absorbance at 808 nm in the concentration range used herein). Subsequently, AbsbwGO at 498 nm 
(determined using a standard curve) was subtracted to the AbsDT loaded POx-GO at 498 nm, rendering 
the AbsDOX at 498 nm (TOS does not display any absorbance at 498 nm in the concentration range 
used herein). The concentration of DOX was then determined using the AbsDOX at 498 nm and a 
standard curve of DOX (at 498 nm).  
Then, AbsbwGO at 284 nm and AbsDOX at 284 nm (determined using standard curves) were subtracted to 
the AbsDT loaded POx-GO at 284 nm, rendering the AbsTOS at 284 nm. The concentration of TOS was then 
determined using the AbsTOS at 284 nm and a standard curve of TOS (at 284 nm). All the standard 
curves were prepared with the analytes dissolved in water:methanol (1:1 (v/v)). 
 
5.3.2.7. Evaluation of DOX and TOS loaded POx-GO combination  
chemo-phototherapeutic effect  
The combination chemo-phototherapeutic effect mediated by DT loaded POx-GO was 
determined as we previously described [21]. For such, MCF-7 cells were seeded in 96  
well-plates as described above. After 24 h, cells were incubated with DT loaded POx-GO (20.5 
µM of 1:3 DOX:TOS combination; 34.7 µg mL-1 of bwGO equivalents) or POx-GO (34.7 µg mL-1 of 
bwGO equivalents). After 4 h of incubation, cells were irradiated with NIR light (808 nm,  
1.7 W cm-2) during 5 min. Upon 24 h of incubation, cells were incubated with resazurin  
(10 % (v/v)) for 4 h in the dark (37 °C, 5 % CO2) and their viability was determined as described 
in section 5.3.2.4.   
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5.3.2.8. Statistical analysis 
ANOVA with the Student-Newman-Keuls test was applied for the comparison of multiple groups. 
A value of p lower than 0.05 (p < 0.05) was considered statistically significant. Data analysis 
was performed in GraphPad Prism v6.0 (Trial version, GraphPad Software, CA, USA). 
 
5.4. Results and Discussion 
 
5.4.1. Preparation and characterization of POx-GO 
GrO was produced according to a previous publication of our group using a modified version of 
the improved Hummer’s method [21]. Afterwards, this material was treated with sodium 
hydroxide and sonicated, yielding bwGO, whose characterization is reported elsewhere [21]. 
To prepare PEtOx-functionalized bwGO, we first conjugated bwGO with amine-terminated 
PEtOx using the EDC chemistry (data not shown). However, this material displayed an unsuitable 
colloidal stability since it promptly precipitated in saline solutions (data not shown). 
Considering that this type of functionalization relies on the carboxyl groups of bwGO that are 
available for conjugation, we hypothesized that the weak colloidal stability could be related 
with a scarce amount of PEtOx covalently bonded to bwGO.  
In this way, we prepared a PEtOx-based amphiphilic polymer by grafting PEtOx into PMAO  
(POx-g-PMAO) by adapting a protocol described elsewhere [20]. In this case, the amount of 
PEtOx in the functionalized bwGO may be increased since the multiple PEtOx chains in  
POx-g-PMAO are used to functionalize bwGO through hydrophobic-hydrophobic interactions 
established between the nanomaterial and the hydrophobic regions of the amphiphilic polymer. 
The successful synthesis of POx-g-PMAO was confirmed by FTIR (Figure 5.1). In the FTIR 
spectrum of POx-g-PMAO, several peaks at 2853 cm-1 (C-H stretch) and 1779 cm-1 (C=O stretch 
from anhydrides) can be observed, which are also present in PMAO spectrum. Furthermore, the 
absence of the peak at 1856 cm-1 (C=O stretch from anhydrides) and the weak intensity of the 
one at 1779 cm-1 (C=O stretch from anhydrides) in POx-g-PMAO spectrum also corroborate the 
opening of the maleic anhydride ring and suggest the grafting of PEtOx into PMAO. Additionally, 
the peaks at 2976 cm-1 (C-H stretch), 1733 cm-1 (C=O stretch from carbonyls) and 1632 cm-1 
(C=O stretch from amides) present in PEtOx spectrum are also present in POx-g-PMAO spectrum, 




Figure 5.1. FTIR spectra of POx-g-PMAO, PEtOx and PMAO. 
 
POx-g-PMAO was then employed to functionalized bwGO using a simple sonication method (for 
the sake of simplicity, POx-g-PMAO functionalized bwGO will be termed as POx-GO from here 
on) – Figure 5.2A [21]. The presence of POx-g-PMAO in POx-GO was confirmed by FTIR analysis 
(Figure 5.2B), which displays several peaks belonging to the amphiphilic polymer. POx-GO 
incorporated 1.76 ± 0.02 µg of POx-g-PMAO per µg of bwGO, which is fundamental to attain 
materials with improved colloidal stability. Furthermore, the DLS results confirmed that  
POx-GO maintained its size distribution upon incubation with PBS solution (Figure 5.2C). In fact, 
POx-GO remained stable as a colloid in saline solutions (Figure 5.2C), while bwGO precipitates 
in this type of solutions as we previously reported [21]. In this way, the functionalization of 
bwGO with POx-g-PMAO can address a major limitation of this GO derivative, thus ensuring its 





Figure 5.2. Preparation and characterization of POx-GO. Schematic illustration of the POx-GO preparation 
method (A). FTIR characterization of POx-GO (B). DLS size distribution of POx-GO and POx-GO in PBS (C). 
Macroscopic images of POx-GO in water, PBS and serum supplemented medium (DMEM-F12 supplemented 
with FBS (10 % (v/v)) (C inset). Temperature variation curves of POx-GO at different concentrations  
(of bwGO) during a 5 min NIR laser irradiation period (808 nm, 1.7 W cm-2) (D). 
 
Subsequently, we analyzed the UV-Vis-NIR absorption of POx-GO, which revealed that this 
nanomaterial possesses NIR absorption (Figure 5.3). The NIR absorption of POx-GO indicates 
that this material may be applied as a NIR-responsive photothermal agent. To confirm this 
hypothesis, the photothermal capacity of POx-GO was evaluated by exposing the nanomaterials 
to 808 nm laser radiation and recording the temperature variations attained (Figure 5.2D). After 
5 min of NIR laser irradiation, POx-GO produced, at the highest concentration tested  
(75 µg mL-1 of bwGO equivalents), a temperature increase of ≈ 24 °C, which is sufficiently high 
to induce the death of cancer cells [13]. In turn, at the lower concentrations, a temperature 
variation of 13-17 °C was achieved upon irradiation of POx-GO (Figure 5.2D). Such raise in the 
temperature may still induce damage to cancer cells and/or sensitize them to the action of 
chemotherapeutic drugs (chemosensitization) [13]. As importantly, water irradiated with NIR 
light (control) only suffered a temperature variation of ≈ 2 °C (Figure 5.2D). These results 
 158 
confirm that POx-GO can be employed in phototherapy applications since it elicits minimal  
off-target heating. When compared to a previous report, the photoinduced heat produced by  
POx-GO is superior to that of bwGO functionalized with PEGylated vitamin E [21], which can 




Figure 5.3. UV-Vis-NIR absorption spectrum of POx-GO. 
 
Finally, the cytocompatibility of POx-GO towards MCF-7 cells (breast cancer cell model) and 
NHDF (normal cell model) was determined (Figure 5.4). At the highest concentration of  
POx-GO tested (100 µg mL-1 of bwGO equivalents), the functionalized materials did not affect 
meaningfully the viability of both cell lines (cellular viability > 88 %), which is fundamental for 
their use in biomedical applications (Figure 5.4). This data is in line with the good 
cytocompatibility reported for PEtOx-based nanomedicines [18, 24-26]. In fact, POx-GO 
revealed a similar cytocompatible profile to that of GO covalently conjugated with  
amine-terminated PEtOx reported by Wang et al. [26]. Moreover, when compared to PEGylated 
GO, POx-GO displayed an improved cytocompatibility towards MCF-7 cells, which is also a good 
indication of the safety profile of this nanomaterial [27].  
Taken together, these results confirmed that POx-GO presents suitable physicochemical, 
colloidal, optical and biological properties to be explored as a nanoplatform for the delivery of 





Figure 5.4. Evaluation of the cytocompatibility of POx-GO at different concentrations (of bwGO) and 
incubation times (24 and 48 h) towards MCF-7 cells (A) and NHDF (B). Data represent mean ± SD (n = 5). 
 
5.4.2. Combinatorial drug screening  
The administration of drug combination with synergistic activity to cancer cells can produce 
improved therapeutic outcomes. However, different drug:drug ratios may have distinct types 
of combinatorial effects depending on the Fa that is analyzed. Therefore, prior to the 
encapsulation of the DOX-TOS combination in POx-GO, we first determined the DOX:TOS molar 
ratio that presents optimal synergy across several Fa (Figure 5.5A). For this purpose, MCF-7 
cells were incubated with DOX:TOS at different molar ratios (ranging from 5:1 to 1:5) and their 
IC20, IC50 and IC80 were determined (Figure 5.5B and 5.6). Then, the CI at each Fa was calculated 
(Figure 5.5C).  
In general, with the exception of the 1:2 DOX:TOS ratio (at Fa=0.2), all the tested combinations 
synergistically reduced MCF-7 cells’ viability (Figure 5.5C). The DOX:TOS synergism is likely 
correlated to the fact that TOS, besides having the capacity to inhibit the proliferation and 
induce the apoptosis of MCF-7 cells [28], it can also increase the DOX influx and suppress its 
efflux from cancer cells [19], leading to an enhanced therapeutic effect. 
Although the DOX:TOS ratios containing a higher DOX dose (5:1, 4:1, 3:1, 2:1) displayed a 
greater synergism (lower CI value) at Fa of 0.2 and 0.5 (i.e., at inhibition levels of 20 and  
50 %, respectively), those did not present the lowest CI value (i.e., the highest synergism) at 
Fa=0.8 (at a inhibition level of 80 %). In this way, these drug ratios are not the most suited for 
breast cancer therapy since their synergy is weaker at higher inhibition levels. On the other 
hand, the 1:3 DOX:TOS ratio presented a CI  0.56 at all the Fa tested, and had a very low CI 
at Fa=0.8 (Figure 5.5C), thus displaying an optimal synergy. Furthermore, the use of DOX:TOS 
combinations with a greater content of TOS is appealing since this drug has a low effect on the 
viability of healthy cells [28, 29]. Therefore, the cytotoxicity of the 1:3 DOX:TOS combination 
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towards NHDF was also determined (Figure 5.5D). The IC20, IC50 and IC80 of the 1:3 DOX:TOS 
combination towards NHDF were 39, 80 and 163 µM, respectively. Comparing the effect of this 
drug combination on NHDF and on MCF-7 cells, the 1:3 DOX:TOS combination displayed a  
2 times weaker effect towards NHDF (Figure 5.5D). 
 
 
Figure 5.5. In vitro screening of the therapeutic potential of the DOX:TOS combinations. Schematic 
illustration of the parameters used to disclose the optimal DOX:TOS combination for MCF-7 cells  
treatment (A). IC20, IC50 and IC80 of the different DOX:TOS combinations in MCF-7 cells (B). CI of the 
different DOX:TOS combinations at Fa=0.2, 0.5 and 0.8 in MCF-7 cells (C). Cell viability curves of MCF-7 
cells and NHDF incubated with the 1:3 DOX:TOS combination (D). The points represent the mean of the 
experimental data (n = 5). The lines represent the determined dose-response curves. 
 
Additionally, the therapeutic potential of the 1:3 DOX:TOS combination is also attested by the 
fact that this drug cocktail has a similar or greater synergy (CI  0.56) than other DOX-based 
drug combinations reported in the literature to treat MCF-7 cells (DOX:Resveratrol CI = 0.691 
[30], DOX:Dihydroartemisinin CI = 0.50 [31], DOX:Fulvestrant CI = 0.71 [32], DOX:Tamoxifen  
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CI = 1.60 [32], DOX:4-Hydroxytamoxifen CI = 1.01 [32]). Therefore, the 1:3 DOX:TOS ratio was 
selected to be encapsulated in the POx-GO due to its optimal synergy in MCF-7 cells and weaker 
effect towards NHDF. 
 
 
Figure 5.6. Cell viability curves of MCF-7 cells treated with different concentrations of DOX, TOS and 
DOX:TOS combinations (at different molar ratios). The points represent the mean of the experimental 
data (n = 5). The lines represent the determined dose-response curves. 
 
5.4.3. Phototherapeutic capacity of DOX and TOS loaded POx-GO 
The selected DOX:TOS combination ratio was encapsulated in POx-GO (termed DT loaded  
POx-GO from here on) through a simple sonication method since both drugs can be adsorbed on 
 162 
GO based materials’ surface through non-covalent interactions (Figure 5.7A). DT loaded  
POx-GO encapsulated 0.070 ± 0.012 µg of DOX per µg of bwGO and 0.205 ± 0.030 µg of TOS per 
µg of bwGO (n = 3). Besides showing a high loading capacity (a total of 0.275 ± 0.042 µg of drug 
per µg of bwGO), DT loaded POx-GO was able to encapsulate the DOX:TOS combination at the 
desired molar ratio, which is crucial for attaining an optimal synergistic effect. Furthermore, 
DT loaded POx-GO reveled a size distribution similar to that of POx-GO (Figure 5.7B), indicating 
that the loading of the drug combination is not detrimental to the nanomaterials’ size. The 
zeta potential of DT loaded POx-GO (-34.2 ± 0.6 mV) and POx-GO (-37.2 ± 2.5 mV) were also 
similar, which also corroborates that the loading of the DOX:TOS combination occurs onto the 
aromatic matrix of POx-GO.  
 
 
Figure 5.7. Preparation and characterization of DT loaded POx-GO. Schematic illustration of the 
phototherapy (A). DLS size distribution of POx-GO and DT loaded POx-GO (B). Macroscopic images of DT 
loaded POx-GO in water, PBS and serum supplemented medium (DMEM-F12 supplemented with FBS (10 % 
(v/v)) (B inset). Evaluation of the therapeutic capacity of POx-GO and DT loaded POx-GO without and 
with NIR irradiation (+ NIR; 808 nm, 1.7 W cm-2, 5 min) towards MCF-7 cells (C). K- and NIR represent the 
negative control and cells solely treated with NIR light, respectively. Data represent mean ± SD (n = 5), 




Having confirmed the ability of POx-GO to load the DOX:TOS combination at its optimal molar 
ratio, then the efficacy of this formulation in decreasing MCF-7 cells’ viability was assessed 
(Figure 5.7A). To clearly perceive the therapeutic potential of the DT loaded POx-GO, this 
nanomaterial was administered to cancer cells at a concentration that contains only half of the 
IC50 dose of the 1:3 DOX:TOS combination (20.5 µM) (Figure 5.7C). The results showed that the 
delivery of the DOX:TOS through POx-GO is efficient since cancer cells’ viability was reduced 
to about 61 % (Figure 5.7C). In fact, drug loaded nanomaterials do not always outperform in 
vitro the therapeutic effect mediated by free drugs [33-35]. For instance, the delivery of 
Camptothecin+Methotrexate and DOX+Irinotecan combinations by GO based nanostructures to 
cancer cells did not result in a more effective therapy in comparison to the free drug 
combinations [33, 35]. Such may be related to the fact that, in in vitro assays, free drugs are 
not strongly impaired by clearance mechanisms or may present faster diffusion to the cells’ 
cytoplasm. In this way, the improved therapeutic effect mediated by DT loaded POx-GO attests 
the drug delivery efficacy of this nanoformulation. 
Furthermore, the combined application of DT loaded POx-GO and NIR radiation resulted in an 
even greater therapeutic effect, since it was able to further reduce MCF-7 cells’ viability to  
 39 % (Figure 5.7C). As importantly, the sole application of NIR light did not induce a decrease 
on cancer cells’ viability, which is in agreement with the low interaction of 808 nm radiation 
with biological components [13]. Moreover, POx-GO irradiated with NIR light did not induce 
cancer cells’ death (Figure 5.7C). In this way, the enhanced chemo-phototherapeutic effect 
mediated by DT loaded POx-GO is likely to result from a chemosensitization effect induced by 
a local temperature increase produced by the nanomaterials under irradiation.  
In the literature it is reported that Folate receptor targeted rGO loaded with Docetaxel and 
Irinotecan can produce a similar phototherapeutic effect towards MCF-7 cells, to that induced 
by DT loaded POx-GO, but requires a higher drug dose (50 vs. 20.5 µM) and a higher power 
density (3 vs. 1.7 W cm-2) [36]. In another work, the exposure of PEGylated GO loaded with 
DOX+Irinotecan to NIR light (3 W cm-2, 5 min) improved  1.13-times its therapeutic effect 
towards MCF-7 cells [35]. Herein, the NIR irradiation (1.7 W cm-2, 5 min) of DT loaded POx-GO 
enhanced its therapeutic capacity by  1.56-fold. In this way, DT loaded POx-GO are promising 
materials for breast cancer therapy. 
 
5.5. Conclusion 
In the present study, the suitability of PEtOx based amphiphilic coatings to functionalize GO 
derivatives and the DOX:TOS combination ratio with optimal anticancer activity were 
investigated for the first time. POx-GO revealed suitable physicochemical, colloidal, optical 
and biological properties for application in cancer therapy. Furthermore, the 1:3 DOX:TOS 
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combination presented an optimal synergy for MCF-7 cells, and thus was efficiently loaded in 
POx-GO. The in vitro data revealed that the delivery of DOX:TOS by POx-GO to cancer cells 
produced a stronger therapeutic effect than that attained using the free drug combination. 
Furthermore, DT loaded POx-GO produced, under NIR laser irradiation, an even greater 
cytotoxicity towards cancer cells. Overall, POx-GO is a promising drug delivery and 
phototherapeutic agent. This study also paves the way for investigating PEtOx-based coatings 
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Concluding Remarks and Future Trends 
 
Nowadays, cancer continues to have a tremendous impact on the society. Despite all the 
efforts, cancer mortality rates remain very high. In fact, according to the World Health 
Organization, approximately 1 in 6 deaths are caused by cancer. The heterogenicity of this 
disease together with the core problems of the classic treatments (chemotherapy and 
radiotherapy) contribute for this scenario. The problems of the conventional therapies comprise 
a low therapeutic efficacy, that is further decreased by resistance mechanisms, and off-target 
toxicity, that can pose a threat to patients’ life. Even though during the last decade new types 
of therapies have reached the clinic (targeted chemotherapy and immunotherapy), these are 
also overwhelmed by resistance mechanisms, and a have a remarkable higher cost to the health 
service providers.  
To overcome these problems, PTT mediated by nanomaterials is currently under investigation. 
In particular, those based on GO have a tremendous potential for improving cancer treatment. 
In fact, the pre-clinical investigation performed so far highlights the excellent photothermal 
and drug delivery capacities of this nanomaterial. However, the direct use of GO in  
cancer-related applications is severely hindered by its weak colloidal stability, low tumor 
uptake and non-selectivity towards cancer cells.  
The present research work aimed to address these problems and to implement novel strategies 
to improve cancer PTT mediated by GO-based materials. Such was pursued by i) employing 
coatings that can improve the biological performance of GO-based materials, ii) exploring 
preparation methods that can enhance GO photothermal capacity, and iii) encapsulating drug 
combinations with optimal synergistic anticancer activity on GO. 
In the first experimental work presented here, GO derivatives were functionalized for the first 
time with TPGS, an FDA- and EMA-approved amphiphilic polymer. The TPGS functionalization 
successfully improved the colloidal stability of the GO-based nanomaterials. Particularly, the 
materials functionalized through the hydrothermal treatment revealed an enhanced stability 
and photothermal capacity. As importantly, the TPGS/GO derivatives retained the intrinsic 
anticancer activity of TPGS. Thus, in the in vitro studies, these nanodevices were able to induce 
cytotoxicity to breast cancer cells and minimal effects to healthy cells. Furthermore, the 
irradiation of TPGS/GO derivatives with NIR light induced an even greater reduction on the 
viability of breast cancer cells, thereby confirming their phototherapeutic potential. 
The classic approach used in the literature to develop nanoformulations with a preferential 
effect towards cancer cells is the functionalization of nanomedicines’ surface with targeting 
ligands [1]. Although some authors have applied this approach with success, the design of 
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targeting ligand-functionalized nanomaterials is challenging since i) the protein corona formed 
on nanomaterials’ surface can cover the ligand, rendering an ineffective targeting, and  
ii) requires a fine-tuning of the ligand-density, which is problematic due to the disparities in 
nanomaterials’ uptake found both in in vitro and in vivo assays [2, 3]. Furthermore, targeted 
nanomaterials have been showing disappointing results on clinical trials (e.g. BIND 
Therapeutics, Inc. Bind-014 – PSMA-targeted Nanoparticles loaded with Docetaxel) [4]. Due to 
these facts, nanostructures without surface passivation (e.g. DaunoXome® - Liposome loaded 
with Daunorubicin) or with PEG-passivation (e.g. DOXIL® – PEGylated Liposome loaded with DOX) 
are those that are still in use in the clinic [5]. In this way, achieving a preferential effect on 
cancer cells by coating GO derivatives with TPGS is promising since this type of selectivity is 
mediated by the TPGS molecular action (inhibition of Akt phosphorylation, leading to a 
decrease in the levels of BcL-2 and Survivin, which are overexpressed on breast cancer cells), 
and thus it is not likely to be affected by the problems described for targeting  
ligand-functionalized nanostructures. 
In the second experimental study, GO-based materials aimed for cancer-therapy were 
functionalized for the first time with a POx-based amphiphilic polymer. The POxylated GO 
derivatives demonstrated suitable physicochemical, colloidal, optical and biological properties 
for application in cancer therapy. Parallelly, the therapeutic potential of the DOX:TOS 
combination was screened, demonstrating that the 1:3 DOX:TOS molar ratio produces an 
optimal synergistic therapeutic effect towards breast cancer cells (combination index of about 
0.56 at different inhibition levels) and that it has a 2-times weaker effect on normal cells. 
POxylated GO derivatives were then loaded with the 1:3 DOX:TOS combination in order to 
evaluate its chemo-phototherapeutic potential. The in vitro studies revealed that the delivery 
of DOX:TOS by POxylated GO-based materials to cancer cells induced a stronger therapeutic 
effect than that attained with the free drug combination. Furthermore, an even greater 
cytotoxic effect towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO 
derivatives to NIR radiation, confirming the chemo-phototherapeutic potential of this 
nanoformulation. 
During the course of this PhD thesis, it was revealed by Kataoka’s research group that 
nanomaterials can accumulate in the tumor by extravasating through the dynamic vents that 
occur spontaneously in the tumor vasculature (also termed as eruptions) [6]. This finding 
completely shifts the paradigm by putting a high emphasis on enhancing the nanomaterials’ 
blood circulation in order to improve their tumor uptake (prior to this study, the modulation of 
nanomaterials’ size was excessively pursued with the intent of enhancing the tumor-homing 
capacity) [6]. Furthermore, the first case on the accelerated blood clearance of PEGylated  
GO-based materials was also reported [7]. In this regard, Cai’s research group found that 
PEGylated GO derivatives can experience a rapid blood clearance mediated by anti-PEG 
antibodies, which will ultimately compromise their ability to reach the tumor [7]. Based on this 
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body of information, the POxylation of GO gives a major contribution to the pursuit of  
PEG-alternatives for coating GO-based nanomaterials. Furthermore, the discovery of the 
optimal DOX:TOS combination ratios for breast cancer treatment was also an important 
breakthrough. Besides having a greater synergism than other DOX-based combinatorial 
therapies reported in the literature, the selected DOX:TOS combination demonstrated a lower 
effect on healthy cells. In this way, the POxylation of GO derivatives and their ratiometric 
loading with the optimal DOX:TOS combination is an appealing strategy to produce 
nanoformulations that may achieve a high blood circulation time (and tumor uptake) and may 
induce a substantially higher therapeutic effect on the cancer cells. 
Overall, the results obtained demonstrate that the applicability of GO-based materials in 
cancer therapy can be augmented by functionalizing them with amphiphilic polymers. 
Furthermore, the PTT potential of GO derivatives can be further enhanced by using coatings 
with intrinsic anticancer activity or by co-encapsulating drugs that display a higher effect on 
cancer cells. These novel strategies will further contribute for the translation of GO-based 
materials from the bench to the bedside. 
In the future, three major topics should be investigated in order to further accelerate the 
translation of GO-based phototherapies: 
 
1. In vivo validation of POx-based and zwitterionic-based amphiphilic coatings 
In a near future, the validation of the in vivo biodistribution and biocompatibility of the 
POxylated GO materials will be crucial to fully disclose the potential of this coating as a  
PEG-alternative. Moreover, synthesizing a PEtOx-TOS conjugate (an analog of TPGS but with 
PEtOx instead of PEG as the hydrophilic segment) and exploring it in the functionalization of 
GO derivatives is also an appealing approach since such material may retain the long blood 
circulation properties of PEtOx and the intrinsic anticancer activity of Vitamin E derivatives. 
Furthermore, zwitterionic-based amphiphilic polymers also hold a great potential for improving 
the blood circulation time of GO-based materials, and hence their tumor accumulation. In this 
way, validating such materials in in vitro and in vivo assays can be of great interest. 
 
2. Acceleration of GO biodegradation  
The long-term body accumulation of inorganic nanomaterials constitutes a barrier for their 
clinical translation. In this regard, the body-clearance of functionalized GO can be accelerated 
by using detachable coatings (the detachment of the coating allows the degradation of GO 
through oxidative-biodegradation). This research topic is still poorly investigated, and the 
applicability of such phenomenon to rGO-based materials was not yet unveiled. In this way, the 
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evaluation of the in vivo behavior of GO/rGO functionalized with amphiphilic materials that 
are detached from nanomaterials’ surface in response to tumor microenvironment (e.g. acidic 
pH or enzymatic degradation by MMP-2) or intracellular (e.g. reductive conditions) stimuli 
should be pursued.  
 
3. Environmentally-friendly reduction of GO 
As demonstrated herein, the hydrothermal-treatment improved the NIR absorption of GO (mass 
extinction coefficient = 5.64 L g-1 cm-1, at 808 nm) and yield nanomaterials with good 
cytocompatibility. Nevertheless, rGO attained using hydrazine hydrate still has a higher NIR 
absorption (mass extinction coefficient = 24.6 L g-1 cm-1, at 808 nm) than htGO. However, the 
latter is highly cytotoxic to cells, which is in part related to the toxicity of the hydrazine 
hydrate. Thus, evaluating the applicability of natural compounds in the reduction of GO is an 
area of great interest. In this regard, ongoing investigation has shown that Vitamin C can be 
used for the reduction of GO, yielding rGO with a high NIR absorption (mass extinction 
coefficient = 12.67 L g-1 cm-1, at 808 nm), acceptable cytocompatibility and appropriate 
physicochemical properties for cancer-related applications. Further optimizations in the 
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